WO2009076337A1

WO2009076337A1 - Gamma secretase modulators

Info

Publication number: WO2009076337A1
Application number: PCT/US2008/086030
Authority: WO
Inventors: Xianhai Huang; Robert G. Aslanian; Anandan Palani
Original assignee: Schering Corporation
Priority date: 2007-12-11
Filing date: 2008-12-09
Publication date: 2009-06-18
Also published as: MX2010006379A; CN101970433A; CA2708151A1; EP2268636A1; JP2011506460A; US20100298372A1

Abstract

This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).

Description

GAMMA SECRETASE MODULATORS

Reference To Related Application

This application claims the benefit of U.S. Provisional Application Serial No. 61/012863 filed December 11 , 2007.

Field of the Invention

The present invention relates to certain heterocyclic compounds useful as gamma secretase modulators (including inhibitors, antagonists and the like), pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat various diseases including central nervous system disorders such as, for example, neurodegenerative diseases such as Alzheimer's disease and other diseases relating to the deposition of amyloid protein. They are especially useful for reducing Amyloid beta (hereinafter referred to as Aβ) production which is effective in the treatment of diseases caused by A/? such as, for example, Alzheimers and Down Syndrome.

Background of the Invention Alzheimer's disease is a disease characterized by degeneration and loss of neurons and also by the formation of senile plaques and neurofibrillary change. Presently, treatment of Alzheimer's disease is fimited to symptomatic therapies with a symptom-improving agent represented by an acetylcholinesterase inhibitor, and the basic remedy which prevents progress of the disease has not been developed. A method of controlling the cause of onset of pathologic conditions needs to be developed for creation of the basic remedy of Alzheimer's disease.

Aβ protein, which is a metabolite of amyloid precursor protein (hereinafter referred to as APP), is considered to be greatly involved in degeneration and loss of neurons as well as onset of demential conditions (for example, see Kiein W L, et al Proceeding National Academy of Science USA_t Sep. 2, 2003, 100(18), p. 10417-22, suggest a molecular basis for reversible memory loss.

Nitsch R M, and 16 others, Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease, Neuron, May 22, 2003, 38(4), p. 547-554) suggest that the main components of kβ protein are A/?40 consisting of 40 amino acids and A/?42 having two additional amino acids at the C-terminal. The AjS40 and PκβA2 tend to aggregate (for example, see Jarreli J T et ai, The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease, Biochemistry, May 11 ,1993, 32(18), p. 4693- 4697) and constitute the main components of senile plaques (for example, (Glenner GG, et at, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochemical and Biophysical Research Communications, May 16, 1984, 120(3), p. 885-90. See also Masters C L, et al, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proceeding National Academy of Science USA, June 1985, 82(12), p. 4245-4249.).

Furthermore, it is known that mutations of APP and presenelin genes, which Is are observed in familial Alzheimer's disease, increase production of A/?4G and A/?42 (for example, see Gouras G K, et al, tntraneuronal Aβ142 accumulation in human brain, American Journal of Pathology, January 2000, 156(1), p. 15-20, Also, see Scheuner D, et al, Nature Medicine, August 1996, 2(8), p. 864-870; and Forman M S, et al, Differential effects of the Swedish mutant amyloid precursor protein on β- amyloid accumulation and secretion in neurons and nonneuronal cells, Journal of Biological Chemistry, Dec. 19, 1997, 272(51), p. 32247-32253.). Therefore, compounds which reduce production of A/?40 and A7?42 are expected to be agents for controlling progress of Alzheimer's disease or for preventing the disease. These A^s are produced when APP is cleaved by beta secretase and subsequently cleaved by gamma secretase. Jn consideration of this, creation of inhibitors of κ-secretase and β-secretase has been attempted for the purpose of reducing production of A/?s. Many of these known secretase inhibitors are peptides or peptidomimetics such as L-685,458. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of κ-secretase activity, Biochemistry, Aug. 1, 2000, 39(30), p. 8698-8704).

Also of interest in connection with the present invention are: US 2007/0117798 (Eisai, published May 24, 2007); US 2007/0117839 (Eisai, published May 24, 2007); US 2006/0004013 (Eisai, published January 5, 2006); WO 2005/110422 (Boehringer ingelheim, published November 24, 2005); WO 2006/045554 (CeJIzone AG, published may 4, 2006); WO 2004/110350 (Neurogenetics , pubiished December 23, 2004); WO 2004/071431 (Myriad Genetics, published August 26, 2004); US 2005/0042284 (Myriad Genetics, published February 23, 2005) and WO 2006/001877 (Myriad Genetics, published January 5» 2006).

There is a need for new compounds, formulations, treatments and therapies to treat diseases and disorders associated with A/?. It is, therefore, an object of this invention to provide compounds useful in the treatment or prevention or amelioration of such diseases and disorders.

Summary of the Invention in its many embodiments, the present invention provides a novel cfass of compounds as gamma secretase modulators (including inhibitors, antagonists and the like), methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with the AjS using such compounds or pharmaceutical compositions. This invention provides novel compounds, that are gamma secretase modulators, of the formula:

(3) or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein all substituents are defined below. This invention also provides compounds of formula (I).

This invention also provides compounds of formula (I) in pure and isolated form.

This invention also provides compounds of formula (!) selected from the group consisting of: compounds of formulas IA to IH, 2 to 9, 12 to 18, 20, 21 , 40 to 43, 55, 2A to 9A, 12A to 18A, 20A₍ 21A₁4OA to 43A, 55A, 2B to 9B, 12B to 18B, 208, 21B, 408 to 43B, 55B, 2C to 9C₁12C to 18C₁2OC, 21 C, 4OC to 43C₁55C, 6.2, 9.1, 10,1, 10.2, 10.3, 14.1, 16.1, 16.2, 18.1, 19.1, 20.2, 21.2, 23.2, 25.1, 26.1, 27.1, 28.1, 30.1, 36.1, 37,1, 38.1, 39.1, 41.1, 43.1, 45.1, 46.1, 47.1, 48.1, 49.1, 50.1, 51.1, 52.1, 59.1, 60.1, 61.1, 64.1, 65.1, 68.1, 70.1, E1, E2, and E3.

This invention also provides compounds of formula (!) selected from the group consisting of: compounds of formulas IA to IH.

This invention also provides compounds of formula (I) selected from the group consisting of: compounds of formulas 2 to 9, 12 to 18, 20, 21, 40 to 43, and 55. This invention also provides compounds of formula (!) selected from the group consisting of: compounds of formulas 2A to 9A, 12A to 18A, 2OA, 21 A, 4OA to 43A, and 55A.

This invention also provides compounds of formula (i) selected from the group consisting of: compounds of formulas 2B to 9B, 12B to 18B, 2OB, 21 B, 4OB to 43B₁ and55B.

This invention also provides compounds of formula (I) selected from the group consisting of: compounds of formulas 2C to 9C, 12C to 18C, 2OC, 21 C, 4OC to 43C, and 55C.

This invention also provides compounds of formula (I) selected from the group consisting of: compounds of formulas 6.2, 9.1, 10.1, 10.2, 10.3, 14.1, 16.1, 16.2,

18.1, 19.1, 20.2, 21.2, 23.2, 25.1, 26.1, 27.1, 28.1, 30.1, 36.1, 37.1, 38.1, 39.1, 41.1, 43.1, 45.1, 46.1, 47.1, 48.1, 49,1, 50.1, 51.1, 52.1, 59.1, 60,1, 61.1, 64.1, 65.1, 68.1, and 70.1.

This invention also provides compounds of formula (I) selected from the group consisting of: compounds of formulas E1, E2, and E3.

This invention also provides pharmaceutical compositions comprising an effective amount of one or more (e.g., one) compounds of formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof, and a pharmaceutically acceptable carrier. This invention also provides pharmaceutical compositions comprising an effective amount of one or more (e.g., one) compounds of formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof, and an effective amount of one or more (e.g., one) other pharmaceutically active ingredients (e.g., drugs), and a pharmaceutically acceptable carrier. The compounds of formuta (I) can be useful as gamma secretase modulators and can be useful in the treatment and prevention of diseases such as, for example, centra! nervous system disorders such as Afeheimers disease and Downs Syndrome.

Thus, this invention also provides methods for: (1) method for modulating (including inhibiting, antagonizing and the like) gamma-secretase; (2) treating one or more neurodegenerative diseases; (3) inhibiting the deposition of amyloid protein (e.g., amyfoid beta protein) in, on or around neurological tissue (e.g., the brain); (4) Alzheimer's disease; and (5) treating Downs syndrome; wherein each method comprises administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of such treatment.

This invention also provides combination therapies for (1) modulating gamma- secretase, or (2) treating one or more neurodegenerative diseases, or (3) inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (4) treating Alzheimer's disease. The combination therapies are directed to methods comprising the administration of an effective amount of one or more (e.g. one) compounds of formula (I) and the administration of an effective amount of one or more (e.g., one) other pharmaceutical active ingredients (e.g., drugs).

This invention also provides methods for. (1) treating mild cognitive impairment; (2) treating glaucoma; (3) treating cerebral amyloid angiopathy; (4) treating stroke; (5) treating dementia; (6) treating microgliosis; (7) treating brain inflammation; and (8) treating olfactory function loss; wherein wherein each method comprises administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of such treatment. This invention also provides a kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of formula (f) in a pharmaceutically acceptable carrier, and another container (i.e., a second container) comprises an effective amount of another pharmaceutically active ingredient (as described beiow), the combined quantities of the compound of formula (1) and the other pharmaceutically active ingredient being effective to treat the diseases or conditions mentioned in any of the above methods.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula (I) is selected from the group consisting of: compounds of formulas IA to IH, 6.2, 10,2, 10.3, 20.2, 21.2, 23.2, 2 to 9, 12 to 18, 20, 21. 40 to 43, 55, 2A to 9A₁ 12A to 18A₁ 20A, 21 A, 4OA to 43A, 55A, 2B to 9B, 12B to 18B₁ 2OB, 21 B, 4OB to 43B, 55B₁ 2C to 9C, 12C to 18C, 2OC, 21C₁ 4OC to 43C, 55C, E1, E2_S and E3. This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula (!) is selected from the group consisting of: compounds IA to IH.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula (!) is selected from the group consisting of: compounds 6.2, 10.2, 10.3, 20.2, 21.2, and 23.2.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formuia (() is selected from the group consisting of: compounds 2 to 9, 12 to 18, 20, 21, 40 to 43, and 55.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula (I) is selected from the group consisting of: compounds 2A to 9A₁ 12A to 18A, 2OA, 21A, 40A to 43A, and 55A.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula (I) is selected from the group consisting of: compounds 2B to 9B, 12B to 18B, 2OB, 21 B, 4OB to 43B, and 55B.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula (I) is selected from the group consisting of: compounds 2C to 9C, 12C to 1δC, 2OC, 21 C, 4OC to 43C, and 55C.

This invention also provides any of the above mentioned methods, pharmaceutical compositions or kit wherein the compound of formula (I) is selected from the group consisting of: compounds E1 , E2, and E3.

Detailed Description Of The Invention

This invention provides compounds, useful as gamma secretase modulators, of formula (i):

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

R^1A, G¹, G², G³, G⁴, (B)₅ G₁ R⁹, R¹⁰, and W are independently selected; letters (A) and (B) in formula (I) are reference letters to identify the rings present in formula (I); the numbers (1), (2), (3), (4), and (5) are reference numbers to identify positions of the Ring (A); G⁴ is at position (1), G³ is at position (2), G² is at position (3), G¹ is at position (4) and the N is at position (5); the moiety -G-R¹⁰-R⁹ is bound through G to G⁴ (i.e., position (1)) or G³ (i.e., position (2)), and when G is bound to G⁴ then G⁴ is a -C-, and when G is bound to G³ then G³ is a -C-; the dotted line between G¹ and G² represents an optional bond;

Ring (B) is the ring formed from the N at position (5) and G¹, and G¹ is carbon or N (i.e., -N(R²)_d- wherein d is 0), and when G¹ is N the optional bond between G¹ and G² is absent; said Ring (B) is a 4 to 8 (and in one example 5 to 6) membered heterocycfoalkyl, heteroaryl, or heterocycloalkenyl ring; said heterocycloalkyl, heterocycloalkenyi, or a heteroaryl ring Ring (B), in addition to the nitrogen common to Ring (A) and Ring (B), optionally comprises, at least one (e.g., 1 to 3, or 1 to 2, or 1 ) other heteroatom selected from the group consisting of: -NR²-, -O- , -S-, -S(O)-, and -S(O)₂-; said Ring (B) is optionally substituted with 1 to 6 independently selected R²¹ substituents; d is 0 or 1 (and those skilled in the art will appreciate that when d is 0 in the -N(R²)_d- moiety there is no substituent on the N, thus, the moiety -N(R²)_d- is -H= or -NH- when d is 0, i.e., when d is 0 in a moiety there is the appropriate number of H atoms on the N to fill the required valences); m is 0 to 6; n is 1 to 5; p is 0 to 5; q is 0, 1 or 2, and each q is independently selected (and those skilled in the art will appreciate that when q is 0 in the moiety -C(R^¹ )_q this means that there is no R²¹ substituent on the carbon, and the -C(R²¹ J_q moiety is -CH= Or -CH₂-, i.e., when q is 0 in a moiety there is the appropriate number of H atoms on the carbon to fill the required valences); r is 1 to 3; t is 1 or 2;

W is selected from the group consisting of: -C(O)-, -S(O)₂-, -S(O)-, and -C(=NR²)- (and in one example W is -C(O)-);

G is selected from the group consisting of: a direct bond (i.e., R¹⁰ is bound directly to either G³ or G⁴), -C(O)-, -(C=NR²)-, -(C=C(R⁶J₂J-, -CHR³- (e.g., -CHOH)₅ C(R⁴J₂, -CF₂-, -N(R²)- (and in one example, -NH-), -O-, -S-, -S(O)₁, ~CR⁴(OH)-,

-CR⁴(OR⁴h -C=C-, alkynyl, -(CH₂)_rN(R²)-, -(CHR⁴)_rN(R²)-, -(C(R⁴J₂JrN(R²)-, -N(R²KCH₂V-, -N(R²)(CHR⁴)_r~ ~N(R²XC(R⁴)₂)_r- -(CH₂JrO-, -(CHR⁴)_rO-, ~(C(R⁴)₂)_r- 0-, -O-(CH₂)_r -, -O-(CHRV, -O-(C(R⁴)₂)_r -, -(CH₂)_r-O-C(O)-, -(CHR⁴)_r -O-C(O)-, -(C(R⁴)₂)_r-O-C(O)-, -C(O)-O-(CH₂Jr -, -C(OJ-O-(CHR⁴Jr -, -C(O)-O-(C(R⁴J₂Jr-, -C(OJNR⁵-, -0-C(OJ-, -C(O)-O-, -0-C(OJ-NR⁵-, -NR⁵C(OJ-, -(CH₂)_rNR⁵~C(OJ-, -(CHR⁴)_rNR⁵-C(O}-, ~(C(R⁴J₂)rNR⁵-C(O)-, -C(OJNR⁶(CH₂J_r -, -C(OJNR⁵ (CHR⁴J_n -, -C(O)NR⁵ (C(R⁴J₂Jr -, -NR⁵S(OJ₁ -, -(CH₂)_rNR⁵S(O)_r -, -(CHR⁴JrNR⁵S(O)₄ -, -(C(R⁴)₂)_rNR⁵S(O)_r, -S(O)₁NR⁵-, -S(OJtNR⁵(CH₂)_r -, -S(OJtNR⁵(CHR⁴J_r -,

-S(O)₁NR^C(R⁴J₂Jr -, -NR⁵-C(O)-O~, -NR⁵-C(O)-NR⁵-, -NR⁵-S(OJ_rNR⁵-, -NR⁵-C(=NR²J-NR⁵-, -NR⁵~C(=NR²)-O-, ~O-C(=NR²)-NR⁵-, -C(R⁴J=N-O-, -0-N=C(R⁴J-, -0-C(R⁴J=N-, -N=C(R⁴J-O-, -(CH₂J_2-3- (i.e., 2 to 3 -CH₂- groups J, -(C(R⁴J₂J_2-3- (i.e., there are 2 to 3 -(C(R⁴J₂ groupsj_s and -(CHR⁴J_2-3- (i.e., there are 2 to 3 -(CHR⁴J- groups), cycloalkyl (e.g., C₃ to Ci_D cycloalky!), heterocycloalkyl (comprising 1 to 4 heteroatoms independently selected from the group consisting of: -O-, -NR²-, -S-, -S(OJ-, and -S(OJ₂J;

G¹ is selected from the group consisting of: (1) -C(R^2tJ_q- wherein q is O when the optional bond is present (i.e., G¹ is C), (2) -C(R²¹ )_q- wherein q is 1 when the optional bond is absent,

(3) -CH- when the optional bond is absent, and

(4) -N(R²)_<r wherein d is 0, and the optional bond is absent;

G² is selected from the group consisting of: a direct bond (i.e., G³ is bonded directly to G¹, and Ring A is a five membered ring), -C(R²¹)_Φ -N{R²)_d-,

-C(O)-, S(O), S(O)₂, -C(N(R²)₂h and -C(=NR²)-; and with the provisos that:

(1) when the optional bond between G¹ and G² is not present (i.e., there is a single bond between G¹ and G²) then G² is not -C(N(R²)₂)-, and

(2) when the optional bond between G¹ and G² is present (i.e., there is a double bond between G¹ and G²J₁ then:

(a) q for the -C(R²¹ )_q group is 0 or 1 (and when q is 0 then there is a H on the carbon), and

(b) d for the -N(R²)_d- group is 0 (and there is no H on the N due to the double bond between G¹ and G²), and (C) G² is not a direct bond, -C(O)-, -C(=NR²)- )-, -S(O)₂, or S(O)-;

G³ is selected from the group consisting of: (a) -C(R²¹ )_q wherein q is 0 (i.e., the

is C and there are no valences to fill with a H atom), (b) -CH- (i.e., q is 0 and there is a valence to fill with a H), (c) -C(R²¹)_q wherein q is 1 , and (d) -N(R²)_d wherein d is 0 (and there is no H on the N due to the double bond between G³ and G⁴); and with the proviso that: when moiety G is bound to G³, then G³ is carbon (i.e., the group G³ is the group -C(R²¹)_q wherein q is 0 and there is no valence to fili with a H atom);

G⁴ is selected from the group consisting of: (a) -C(R²¹ )_q wherein q is 0 (i.e., the -C(R²¹)q is C and there are no valences to fili with a H atom), (b) -CH- (i.e., q is 0 and there is a valence to fill with a H), (c) -C(R²¹)_q wherein q is 1, and (d) -N(R²)_d wherein d is 0 (and there is no H on the N due to the double bond between G³ and G⁴); and with the proviso that: when moiety G is bound to G⁴, then G⁴ is carbon (i.e., the group G⁴ is the group -C(R²¹ )_ς wherein q is 0 there is no valence to fill with a H atom); and provided that 0 to 2 of the G¹, G², G³, and G⁴ moieties are -N(R²)_d- and each R² is independently selected and each d is independently selected, and provided that Ring (A) does not have three consecutive ring nitrogen atoms;

R^1A is selected from the group consisting of: alky!-, alkenyh afkynyh aryl-, arylalkyh alkylary!-, cydoaϊkyi, cydoaikenyl, cycloaikylalkyh fused benzocycloalkyl- (Le., benzofusedcycloalkyl-), fused benzoheterocycloalkyl- (i.e., benzofusedπeterocycioalkyl-), fused heteroarylcycloalkyl- (i.e., heteroarylfusedcycloatkyl-), fused heteroaryfheterocycloalkyt- (i.e., heteroaryifusedheterocycloafkyf-), fused cycioalkylaryt (i.e., cycjoalkyfusediaryi-), fused heterocycloalkylaryf- (i.e., heterocycloalkyifusedaryl-), fused cycloaikylheteroaryl- (i.e., cycloalkytfusedheteroaryl-), fused heterocycfoalkyiheteroaryf- (i.e., heterocycloalkylfusedheteroaryl-), fused benzocycloalkylalkyl- (i.e., benzofusedcycfoalkyialkyl-), fused benzoheterocycfoalkylalkyl- (i.e., benzofusedheterocycioalkylalkyl-), fused heteroarylcydoalkyiaikyi- (i.e., heteroarylfusedcycloalkylalkyf-), fused heteroaryfheterocycloalkylalkyl- (i.e., heteroaryifusedheterocycloalkylalkyl-), fused cycloalkylarylafkyJ- (i.e., cyctcafkyfusedlarylaikyl-), fused heterocycfoalkylaryfafkyl- (i.e., heterocycloaikyifusedarylalkyl-), fused cydoalkylheteroarylalkyl- (i.e., cydoalkyifusedheteroarylalkyl-), fused heterocycloalkylheteroarytalkyi- (i.e., heterocycloalkylfusedheteroarylafkyJ-), heteroaryh heteroarylalkyh heterocyclyl-, heterocyclenyh and heterocyclyaikyl-; wherein each of said alky!-, alkenyl-, alkynyi-, aryi-, aryialkyf-, alkylaryh cycloalkyl, cycloaikenyl, cycloalkylalkyl-, fused benzocycloa!kyl» fused benzoheterocycloalky!, fused heteroarylcycloalky!, fused heteroatylheterocycloalkyl, fused cycloafkylaryl, fused heterocycJoalkylaryl, fused cycloaikylheteroaryl, fused heterocycloalkylheteroaryi, fused benzocycioaikylaiky!-, fused benzoheterocydoalkyiaikyl-, fused heteroarylcycloalkylalkyi-, fused heteroarylheterocycloatkylalkyl-, fused cycϊoalkylaryialkyh fused heterocycloalkyfaryialkyl-, fused cyctoalkylheteroarylaikyi-, fused heterocycloalkylheteroarylaikyl-, heteroaryl, heteroarylaikyl-, heterocyclyl, heterocyclenyi and heterocyclyaikyl- R^1Λ groups is optionally substituted with 1 -5 independently selected R²¹ groups; Each R² is independently selected from the group consisting of: H, -OH₁

-O~alkyl (i.e., alkoxy), -O-(ha!o substituted alky) (such as, for example, -O-fluoroalkyl), -NH(R⁴), -N(R⁴}₂ (wherein each R⁴ is independently selected), -NH₂, -S(O)R⁴, -S(O)(OR⁴), -S(O)₂R⁴, -S(O)₂(OR⁴), -S(O)NHR⁴, ~S(O)N(R⁴}₂, -S(O)NH₂, -S(O)₂NHR⁴, -S(O)₂N(R⁴J₂, -S(O)₂NH₂, -CN, -C(O)₂R⁴, -C(O)NHR⁴, -C(O)N(R⁴)₂, -C(O)NH₂, -C(O)R⁴, unsubstituted aryt, substituted aryl, unsubstituted heteroaryl, substituted heteroaryi, unsubstituted atkyl, substituted alkyl, unsubstituted aryialkyl-, substituted arylalkyi-, unsubstituted heteroaryialkyh substituted heteroaryiaikyl-, unsubstituted alkeny!_; substituted alkenyl, unsubstituted alkynyi, substituted alkynyi, unsubstituted cycioalky!, and substituted cycfoafkyl, wherein said substituted aryl, heteroaryl, afkyl, aryialkyh heteroarylaikyh alkenyi, aikynyl and cycloalkyl groups are substituted with 1 to 5 independently selected R²¹ groups;

R³ is selected from the group consisting of: H, -OH, halo, -O-alkyl (i.e., alkoxy), -O-(halo substituted alky) (such as, for example, -O-fluoroalkyl), -NH(R⁴), -N(R⁴)₂ (wherein each R⁴ is independently selected), -NH₂, -S(R⁴), -S(O)R⁴, -S(O)(OR⁴), -S(O)₂R⁴, -S(O)₂(OR⁴), -S(O)NHR⁴, -S(O)N(R⁴)_2> -S(O)NH₂, -S(O)₂NHR⁴, -S(O)₂N(R⁴J₂, -S(O)₂NH₂, -CN₁ -C(O)₂R⁴, -C(O)NHR⁴, -C(O)N(R⁴)₂, -C(O)NH₂, -C(O)R⁴, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryi, unsubstituted alkyl, substituted alkyi, unsubstituted aryialkyh substituted aryialkyh unsubstttuted heteroarylaikyh substituted heteroarylalkyl-, unsubstituted alkenyi, substituted alkenyi, unsubstttuted aikynyl, substituted alkynyl, unsubstituted cycioaikyi, and substituted cycloalkyl, wherein said substituted aryl, heteroaryl, alkyl, aryfalkyh heteroarylalkyl-, alkenyJ, alkynyl and cycfoafkyl groups are substituted with 1 to 5 independently selected R²¹ groups; each R⁴ is independently selected from the group consisting of: unsubstituted ary!, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted alkyl, substituted alkyl, unsubstituted aryialkyh substituted aryialkyh unsubstituted heteroarylaikyh substituted heteroarylalkyl-, unsubstituted alkenyi, substituted alkenyi, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycloalkyl, and substituted cycloalkyl, wherein said substituted aryl, heteroaryl, alkyl, arylafkyh heteroarylaikyh alkenyi, alkynyl and cycloafkyl groups are substituted with 1 to 5 independently selected R²¹ groups; each R⁵ is independently selected from the group consisting of. H, unsubstitued alkyi, substituted alkyl, unsubstitued alkenyi, substituted alkenyi, unsubstitued alkynyl, substituted alkynyl, unsubstitued cycloalkyl, substituted cycioaikyi, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups are substituted with one or more (e.g., 1 to 5) substttuents independently selected from: R²;

Each R⁶ is independently selected from the group consisting of: H, halo, -CF₃, -O-alkyi (i.e., atkoxy), -O-(halo substituted alky) (such as, for example, -O-fiuoroa!kyl), -S(O)R⁴, -S(O)(OR⁴), -S(O)NHR⁴, -S(O)N(R⁴)₂ (wherein each R⁴ is independently selected), -S(O)NH₂, -S(O)₂NHR⁴, -S(O)₂N(R⁴J₂ (wherein each R⁴ is independently selected), -S(O)₂NH₂, ~C(=NOR²⁴)R²⁵, and -S(O)₂R²⁴; -CN, -C(O)₂R⁴, -C(O)NHR⁴, -C(O)N(R⁴)₂ (wherein each R⁴ is independently selected), -C(O)NH₂, -C(O)R⁴, unsubstitυted aryi, substituted aryl, υnsubstituteci heteroaryl, substituted heteroaryj, unsubstituted alkyl, substituted alky), unsubstituted arylaiky!-, substituted arylaJkyh unsubstituted heteroaryialkyl-, substituted heteroarylalkyl-, unsubstituted alkenyl, substituted aSkenyl, unsubstituted afkynyl, substituted alkynyl, unsubstituted cycloaikyl, and substituted cycloalkyf, wherein said substituted aryf, heteroaryi, aikyl, arylalkyh heteroarylalkyl-, afkenyl, alkynyl and cycloalkyl groups are substituted with 1 to 5 independently selected R²¹ groups;

R⁹ is selected from the group consisting of: arylalkoxy-, heteroaryialkoxy-, arylalkylamino-, heteroarylalkylamino-, aryl, aryiaikyh heteroary!, heteroarylalkyl-, heterocycfyi, heterocyclenyl, and heterocyclyafkyh wherein each of said R⁹ arylalkoxy-, heteroarylaSkoxy-, arylalkylamino-, heteroarylalkylamino-, aryl, arylalky!-, heteroaryl, heteroarylalkyl-, heterocyclyl, heterocyclenyl, and heterocyclyalkyl- is optionally substituted with 1-5 independently selected R²¹ groups;

R^1G is selected from the group consisting of: aryi- (e.g., phenyl), heteroaryl- (e.g., pyridyl), cycloalkyl-, cycloalkenyl, cycloalkylalkyl-, heterocyclyl-, heterocyclenyl-, heterocyclylalkyl-, heterocyclyalkenyi-, fused benzocycloalkyl- (i.e., benzofusedcycloalkyl-), fused benzoheterocycloalkyl- (i.e., benzofusedheterocycioalkyl-), fused heteroarylcycloalkyi- (i.e., heteroarylfusedcycloalkyl-), fused heteroarylheterocycloalkyl- (i.e., heteroaryifusedheterocycloalkyl-), fused cycloalkylaryl (i.e., cycloalkyfusedlaryl-), fused heterocycloalkylaryf- (i.e., heterocycloalkyffusedaryf-), fused cycloalkylheteroaryl- (i.e., cycloalkylfusedheteroaryl-), fused heterocycloalkylheteroaryl- (i.e., heterocycloalkylfusedheteroaryl-),

wherein X is selected from the group consisting of: 0, -N(R¹⁴)- and -S-; and wherein each of said R¹⁰ moieties is optionally substituted with 1-5 independently selected R²¹ groups; or

R⁹ and R¹⁰ are linked together to form a fused tricyclic ring system wherein R⁹ and R¹⁰ are as defined above and the ring linking R⁹ and R¹⁰ is an aikyl ring, or a heteroalkyi ring, or an aryl ring, or a heteroaryl ring, or an alkenyi ring, or a heteroalkenyl ring (for example, the tricyclic ring system is formed by linking the atoms adjacent to the atoms by which R⁹ and R¹⁰ are bound together);

R¹⁴ is selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycioalkylalkyl, cycloalkenyi, heterocyciyl, heterocyclenyl, heterocyclylalkyl, heterocyclyalkenyh aryl, arylalkyl, heteroaryl, heteroarylalkyl, -CN, -C(O)R 15 -C(O)OR ,1⁵5⁰,

and -P(O)(OR¹⁵XOR¹⁶);

R^15A and R^16A are independently selected from the group consisting of aikyl, alkenyl, alkynyl, cycloalkyf, cycloalkytalkyl, heterocyciyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyciyl, (R¹⁸)_π-aikyl, 8_V

(R v1 ^l8^β)_n-cycloa!kylalkyl, {R 1^lS^o)v_n-heterocyc!yl_t (R _J1 'Vheterocyclylalkyl,

(R >1^!β⁰)v_n-arylalkyl, (R ,1'8°)_n-heteroaryi and (R 1'8V, heteroarylalkyl; or

R¹⁵, R st¹e^D and R i1"7 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycioaJkylalkyl, heterocyciyl, heterocyciylalkyS, aryl, arylalkyf, heteroaryi, heteroarylalkyi, arylcycloalkyi, arylheterocyciyl, (R¹⁸)_n-alkyl, (R¹ Vcycloalkyf, (R^^-cycloalkylalkyl, (R¹⁸)_n-heterocyclyl, (R¹⁸)_n-heterocyciylaikyi,

(R¹ Varytøtkyl, (R^' Vheteroaryl and (R¹⁸)_n-heteroarylalkyi; each R¹⁸ is independently selected from the group consisting of alkyl, alkenyl, alkynyi, aryj, aryiaikyj, arylaJkenyl, arylaikynyi, -NO₂, halo, heteroaryl, HO-a!kyoxyaJkyl, -CF₃, -CN, alkyi-CN, -C(O)R¹⁹, -C(O)OH, -C(O)OR¹⁹, -C(O)NHR²⁰, -C(O)NH₂, -C(O)NHz-C(O)N(aikyl)_2f -C(O)N(aiky!)(aryl), -C(O)N(alkyl)(heterøaryl), -SR¹⁹, -S(O)₂R²⁰, -S(O)NH₂, -S(O)NH(alkyl), -S(O)N(a!kyl)(alkyl), -S(O)NH(aryl), -S(O)₂NH₂, -S(O)₂NHR¹⁹, -S(O)₂NH(heterocyclyl), -S(O)₂N(alkyl)₂, -S(O)₂N(alkyl)(aryl), -OCF₃, -OH, -OR²⁰, -O-heterocyciyi, -O-cycioatkylalkyl, -O-heterocyclyialkyf, -NH₂, -NHR²⁰, -N(aikyi)_2l -N(ary!alkyl)₂₎ -N(arylalkylHheteroarylalkyl), -NHC(O)R²⁰, -NHC(O)NH₂, -NHC(O)NH(alkyl)₁ -NHC(O)N(alkyl)(alkyl)_! -N(alkyl)C(O)NH(alkyl), -N(alkyl)C(O)N(afkytKalkyI), -NHS(O)₂R²⁰, -NHS(O)₂NH(aikyi),

-NHS(0)₂N(alkyl)(alkyl), -N(alkyl)S(O)₂NH(alkyl) and -N(alkyl)S(O)₂N(alkyl)(aikyl); or two R¹⁸ moieties on adjacent carbons can be linked together to form a

R¹⁹ is selected from the group consisting of: alky!, cydoalkyl, aryl, arylalkyl and heteroaryialky!;

R²⁰ is selected from the group consisting of: alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl and heteroaryialkyl; each R²¹ is independently selected from the group consiting of: alkyl, alkenyl, aikynyl, cycloaikyl, cycloalkylalkyl, cycloalkenyl, heterocycloalkyl, -O, =N-R², heterocycloalkylalkyf, aryl, arylalkyl, heteroaryl, heteroaryialkyl, halo, -CN, -OR¹⁵, -C(O)R¹⁵, -C(O)OR¹⁵, -C(O)N(R¹⁵XR¹⁶), -SR¹⁵, -P(OXCH₃J₂, -SO(=NR¹⁵)R¹⁶-, -SF₅, -OSF₅, -Si(R^15A)₃ wherein each R^15A is independently selected -S(O)N(R¹⁵XR¹⁶), -CH(R¹⁵XR¹⁶), -S(O)₂N(R¹⁵XR¹⁶),~-C(=NOR¹⁵}R¹⁵, -P(O)(OR¹⁵)(OR¹⁶), -N(R¹⁵)(R¹⁶)_S -alkyl-N(R¹⁵)(R¹⁶), -N(R¹⁵)C(O)R¹⁶, -CH₂-N(R¹⁵)C(O)R¹⁶, -CH₂-N(R¹⁵)C(O)N(R¹⁶)(R¹⁷)_t -CH₂-R¹⁵; -CH₂N(R¹⁵XR¹⁶), -N(R¹⁵)S(O)R^1βA, -N(R^1S)S(O)₂R^16A, -CH₂-N(R¹⁵JS(O)₂R¹^, -N(R¹⁵JS(O)₂N(R¹⁶XR¹⁷), -N(R¹⁵)S(O)N(R¹⁶)(R¹⁷), -N(R¹⁵)C(O)N(R¹⁶)(R¹⁷), -CH₂-N(R¹⁵JC(O)N(R¹⁶XR¹⁷J, -N(R¹⁵JC(O)OR¹⁶, -CH₂-N(R¹⁵JC(O)OR¹⁶, -S(O)R^15A, =NOR¹⁵, -N₃, -NO₂, -S(O)₂R^15A, -0-N=C(R⁴J₂ (wherein each R⁴ is independently selected), and -O-N=C(R⁴)₂ wherein R⁴ is taken together with the carbon atom to which they are bound to form a 5 to 10 membered ring, said ring optionally containing 1 to 3 heteroatoms selected from the group consisting of -O-, -S-, -S(OJ-, -S(O)₂-, and -NR²-; wherein each of said alky!, alkenyl, alkynyl, cycloaikyl, cycloalkylalkyl, cycioalkenyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryi, and heteroarylalkyi R²¹ groups is optionally substituted with 1 to 5 independently selected R²² groups; each R²² group is independently selected from the group consisting of alkyl, cycioafkyl, cyctoaikenyl, heterocycloalkyl, aryJ, heteroaryi, halo, -CF₃, -CN, -OR¹⁵, -C(O)R¹⁵, -C(O)OR¹⁵, -alkyf-C(O)OR¹⁵, C(O)N(R¹⁵XR¹⁶), -SR¹⁵, -S(O)N(R¹⁵XR¹⁶), -S(O)₂N(R¹⁵XR¹⁶), -C(=NOR¹⁵)R¹⁶, -P(O)(OR¹⁵)(OR¹⁶), -N(R¹⁵XR¹⁶), -alkyl-N(R^1s)(R¹⁶), ~N(R¹⁵)C(O)R¹⁶, -CH₂-N(R¹⁵)C(O)R¹⁶, -N(R¹⁵)S(O)R^16A, -N(R¹⁵)S(O)₂R^16A, -CH₂-N(R¹⁵)S(O)₂R^16A, -N(R¹⁵)S(O)₂N(R¹⁶)(R¹⁷), -N(R¹⁵)S(O)N(R¹⁶)(R¹⁷), -N(R¹⁵)C(O)N(R¹⁶)(R¹⁷), -CH₂-N(R¹⁵)C(O)N(R¹⁶)(R¹⁷), -N(R¹⁵)C(O)OR¹⁶, -CH₂-N(R¹⁵)C(O)OR¹⁶, -N₃, =NOR¹⁵, -NO₂, -S(O)R^15A and -S(O)₂R^15A; and provided that: when W is -(C=O)-, and G is bound to G⁴, and when G¹, G² _, G³, and G⁴ are the same or different -C(R²¹ )_q- moiety, and G is -CHR³-, then R³ is not H, halo, unsubstituted ary!, substituted aryl, unsubstituted heteroaryi, substituted heteroaryi, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted heteroarylalkyi, substituted heteroarylalkyi, unsubstituted alkyl, substituted alkyl, or -O-aikyl; and when R²¹ is bound to a carbon that has three other filled valences (such as, for example, in the moiety

then R²¹ is not -O, =NR², or =NOR¹⁵; and when G is bound to G⁴, and G¹ is a C(R²¹ )_q group, and the carbon of said G¹ group is bound to a =N- in Ring B (i.e., there is a double bond between the G¹ carbon and a N in Ring B), and the optional bond between G¹ and G² is not present (i.e., there is a single bond between G¹ and G²), and G² is N(R² )_d, and G³ is -C(R²¹ )_q-, then G is not CHR³; and when G is bound to G⁴, and G¹ is a C(R²¹ )_q group, and the carbon of said G¹ group is bound to an -NR²- in Ring B (i.e.,there is a single bond between the G¹ carbon a N in Ring B), and the optional bond between G¹ and G² is present (i.e., there is a double bond between G¹ and G²), and G² is N(R²)_d, and G³ is -C(R²¹V, then G is not CHR³; and when G is bound to G⁴, and G¹ is a C(R²¹ )_q group, and the carbon of said G¹ group is bound to a =N- in Ring B (i.e., there is a double bond between the G¹ carbon and a N in Ring B), and G² is a direct bond (i.e., G¹ is bound directly to G³), and G³ is N₁ then G is not CHR³.

The compounds of this invention are useful for treating central nervous system disorders such as, for example, neurodegenerative diseases such as Alzheimer's disease and other diseases relating to the deposition of amyloid protein. They are especially useful for reducing Amyloid beta (hereinafter referred to as Aβ) production which is effective in the treatment of diseases caused by Aβ such as, for example, Alzheimers and Down Syndrome.

Thus, for example, the compounds of this invention can be used to treat the following diseases or conditions: Alzheimers disease, mild cognitive impairment (MCI), Downs Syndrome, Glaucoma (Guo et.al., Proc. Natl. Acad. Sci. USA 104, 13444- 13449 (2007)), Cerebral amyloid angiopathy, stroke or dementia (Frangione et al., Amyloid: J. Protein folding Disord. 8, suppl. 1 , 36-42 (2001), Mtcrogliosis and brain inflammation (M P Lamber, Proc, Natl. Acad. Sci. USA 95, 6448-53 (1998)), and Olfactory function loss (Getchell, et.al. Neurobiology of Aging, 663-673, 24, 2003). In one embodiment of this invention R^1A is selected from the group consisting of: alky!-, alkenyh alkynyh aryh arylaikyh alkylaryl-, cycioaikyh cycloafkenyl, cycloalkylalkyl-, fused benzocycloalkyS (i.e., benzofusedcycloafkyl), fused benzoheterocycloalkyl (i.e., benzofusedhetero-cycloalkyi), fused heteroarylcycloaikyl (i.e., heteroarylfusedcycloalky!), fused heteroaryiheterocycloafky) (i.e., heteroarylfusedheterocycloalkyl), heteroaryh heteroaryfalkyl-, heterocyciyl-, heterocyclenyl, -and heterocyclyalkyl-; wherein each of said alkyh aikenyl- and alkynyl-, aryl-, aryialkyh aikylaryh cycioaikyh cycloalkenyh cycioalkylalkyh fused benzocycloalkyl, fused benzoheterocycloalkyl, fused heteroarylcycloaikyl, fused heteroarylheterocycloalkyl, heteroaryh heteroarylalkyh heterocyciyl-, heterocyctenyl and heterocyclyalkyl- R^1A groups is optionally substituted with 1 -5 independently selected R²¹ groups; or

Examples of moieties formed when R¹⁰ and R⁹ are linked together to form a fused tricyclic ring system include., but are not limited to:

wherein R¹⁰ and R⁹ are as defined for formula (I), and Ring C is the ring linking R¹⁰ and R⁹, that is Ring C is an aikyt ring, or a heteroalkyl ring, or an aryl ring, or a heteroaryl ring, or an alkenyl ring, or a heteroalkenyl ring. Examples of moieties formed when R¹⁰ and R⁹ are linked together to form a fused tricyclic ring system include, but are not limited to:

wherein R and R are as defined for formula (1), and Ring C is the ring linking R aanndd R⁹, that is Ring C is a heteroalkyl ring, or a heteroaryi ring, or a heteroalkenyl ring.

In one example, the fused tricyclic ring system formed when R^1Q and R⁹ are linked together is

wherein Ring C is a heteroalkyi ring, or a heteroaryi ring, or a heteroalkenyl ring, thus, for example, the tricyclic ring system is formed by linking the atoms adjacent to the atoms by which R¹⁰ and R⁹ are bound together), and wherein said fused tricyclic ring system is optionally substituted with 1 to 5 independently selected R²¹ groups.

Other examples of moieties formed when R¹⁰ and R⁹ are linked together to form a fused tricyclic ring system include, but are not limited to:

Another embodiment of this is directed to compounds of formula (0 wherein at least one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ is present, and wherein each R^15A is independently selected, anά wherein when there is more than one group, each group is independently selected.

Another embodiment of this is directed to compounds of formula (I) wherein at ieast one (e.g., 1 to 3, or 1-2, or 1) group selected from the group consisting of: -SF₅ and -OSF₅ is present, and wherein when there is more than one group, each group is independently selected. In one embodiment of this invention one group selected from the group consisting of: -SF₅, -OSFs, and -Si(R^15A)₃ (wherein each R^15A is independently selected} is present in the compounds of formula ((}. In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are present in the compounds of formula (I).

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^16A is independently selected) are present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)₃.

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are present in the compounds of formula (J), wherein at least one group is other than -Si(R^15A)₃. In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of alky! (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula (I).

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of aikyl (e.g., methyl and ethyl) and aryi (e.g., phenyl)) are present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)s (wherein each R^15A is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)₃.

In another embodiment of this invention three groups selected from the group consisting of: -SF₅.. -OSF₅., and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)₃. in another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si{R^1SA}₃ (wherein each R^15A is independently selected from the group consisting of rnethyf, ethyl and phenyl) is present in the compounds of formula (I). in another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula (I). in another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula (I). In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^1SA)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula (i), wherein at least one group is other than -Si(R^1SA)₃.

Jn another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)₃.

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula (I).

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula (I). In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, anύ -Si{R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula (i), wherein at least one group is other than -Si(R^1SA}₃. In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)₃.

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ is present in the compounds of formula (I), and said -Si(R^15A)₃ group is selected from the group consisting of. -Si(CHa)₃, -Si(CH₃)₂phenyl, and -Si(CH₂CHa)₂CH₃,

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ are present in the compounds of formula (I), and said -Si(R^1SA)₃ group is selected from the group consisting of: -Si(CHs)₃, -Si(CH₃)₂phenyl, and -Si(CH₂CHg)₂CH₃.

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ are present in the compounds of formula (I), and said -Si(R^16A)₃ group is selected from the group consisting of: -Si(CHs)₃, - Si(CH₃)₂ρhenyi, and ~Si(CH₂CH₃)₂CH₃.

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)3, and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CH₃)₃, ~Si(CH₃)₂phenyl, and -Si(CH₂CH₃)₂CH₃.

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSFg, and -Si(R^15Λ)₃ are present in the compounds of formula (!), wherein at least one group is other than -Si(R^1SA)₃, and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CH₃)₃, -Si(CH₃)₂phenyl, and -Si(CH₂CHs)₂CH₃,

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^1SA)₃ is present in the compounds of formula (I)₁ and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CHs)₃ and -Si(CH₂CHa)₂CH₃, In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and ~Si(R^15A)₃ are present in the compounds of formuia (!}, and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CH₃)₃ and -Si(CH₂CHs)₂CH₃, in another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ are present in the compounds of formula (I)₅ and said -Si(R^15Λ)3 group is selected from the group consisting of: -Si(CH₃)₃ and -Si(CH₂CHa)₂CH₃..

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)s, and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CHs)₃ and -Si(CH₂CH₃)₂CH₃,

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSFg, and -Si(R^15A)₃ are present in the compounds of formula (I), wherein at least one group is other than -Si(R^15A)₃, and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CH₃J₃, -Sι(CH₃)₂phenyl, and -Si(CH₂CHs)₂CH_3.

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(CH₃)₃ is present. In another embodiment of this invention two groups selected from the group consisting of: -SFs, -OSFs, and -Si(CH₃)₃ are present in the compounds of formuia (I)..

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(CH₃)₃ are present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSFs, and -Si(CH₃)₃ are present in the compounds of formula (I), wherein at feast one group is other than -Si(CHa)₃,

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and ~Si(R²⁴)₃ are present in the compounds of formula (I), wherein at least one group is other than -Si(CH₃)₃. In another embodiment of this invention one group selected from the group consisting of: -SF₅ and -OSF₅ is present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₅ and -OSF₅ are present in the compounds of formula (I). In another embodiment of this invention three groups selected from the group consisting of: -SF₅ and -OSF₅ are present in the compounds of formula (I)

In another embodiment of this invention one -SF₅ group is present in the compounds of formula (I). in another embodiment of this invention two -SFg groups are present in the compounds of formula (I).

In another embodiment of this invention three -SF₅ groups are present in the compounds of formula (J).

In another embodiment of this invention one -OSF₅ group is present in the compounds of formula (I).

In another embodiment of this invention two -OSF₅ groups are present in the compounds of formula (I).

In another embodiment of this invention three -OSF₅ groups are present in the compounds of formula (f). In another embodiment of this invention one -Si(R^15a)₃ (wherein each R^15A is independently selected) group is present in the compounds of formula (!).

In another embodiment of this invention two -Si(R^15A)3 (wherein each R^15A is independently selected) groups are present in the compounds of formula (I),

!n another embodiment of this invention three -Si(R^15A)₃ (wherein each R^15A is independently selected) groups are present in the compounds of formula (I). in another embodiment of this invention one -Si(R^15A)3 (wherein each R^15A is independently selected from the group consisting of aikyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula (I).

In another embodiment of this invention two -Si(R^15A}3 (wherein each R^15A is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and ary! (e.g., phenyl)) is present in the compounds of formula (I).

Jn another embodiment of this invention three -Si(R^15A)a (wherein each R^15A is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula (I). In another embodiment of this invention one -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula (I). In another embodiment of this invention two -Si{R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula (I).

In another embodiment of this invention three -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula (I).

In another embodiment of this invention one -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula (f). in another embodiment of this invention two -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula (I).

In another embodiment of this invention three -Sι(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula (I).

In another embodiment of this invention one -Si(R^15A)₃ group is present m the compounds of formula (I), and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CHa)₃, -Si(CH₃)₂phenyl, and ~Si(CH₂CH₃)₂CH₃.

In another embodiment of this invention two -Si(R^15A)₃ groups are present in the compounds of formula (I), and said -Si(R^15A)₃ groups are independently selected from the group consisting of: -Si(CH₃)₃, -Si(CH₃)₂phenyf, and -Si(CH₂CH₃)₂CH₃,.

In another embodiment of this invention three -Si(R^15Λ)₃ groups are present in the compounds of formula (i), and said -Si(R^i5A)₃ groups are independently selected from the group consisting of: -Si(CH₃)₃, -Si(CH₃)₂pheny!, and ~-Si(CH₂CH₃)₂CH₃.. In another embodiment of this invention one -Si(R^15A)₃ group is present in the compounds of formula (I), and said -Si(R^15A)₃ group is selected from the group consisting of: -Si(CH₃)₃ and -Si(CH₂CHs)₂CH_3.

In another embodiment of this invention two -St(R^15A)₃ groups are present in the compounds of formula (I), and said -Si(R^15A)₃ groups are independently selected from the group consisting of: -Si(CH₃)₃ and

In another embodiment of this invention three -Si(R^15A)₃ groups are present in the compounds of formula (I), and said -Si(R^15A)₃ groups are independently selected from the group consisting of: -Si(CHa)₃ and -Si(CH₂CH₃)₂CH_3.. In another embodiment of this invention one -S!(R^15A)s group is present in the compounds of formula (I), and said -Si(R^1SA)₃ group is -Si(CH₃)₃.

In another embodiment of this invention two -Si(R^15A)3 groups are present in the compounds of formula (!), and said -Si(R^15Λ)₃ groups are -Si(CHs)₃,. fn another embodiment of this invention three -Si(R^15A)₃ groups are present in the compounds of formula (i), and said -Si(R^15A)3 groups are -Si(CH₃J₃,. in another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, -Si(CH₃)₃, -Si(CH₃)₂phenyi, and -Si(CH₂CHs)₂CH₃) is present in the compounds of formula (I). In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, -Si(CH₃)₃, and ~Si(CH₂CH₃)₂CH₃) is present in the compounds of formula (I).

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(CHa)₃, is present in the compounds of formula (I). In another embodiment of this invention one -SF₅ group is present in the compounds of formula (I), and one or two additional groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are also present in the compounds of formula (I).

In another embodiment of this invention one -SF₅ group is present in the compounds of formula (I)₁ and one or two additional groups selected from the group consisting of: -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are also present in the compounds of formula (I).

In another embodiment of this invention one -OSF₅ group is present in the compounds of formula (I), and one or two additional groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are also present in the compounds of formula (I).

In another embodiment of this invention one -OSF₅ group is present in the compounds of formula (I), and one or two additional groups selected from the group consisting of: -SF₅ and -Si(R^15A)₃ (wherein each R^15A is independently selected) are also present in the compounds of formula (I). in another embodiment of this invention one -SF₅ group is present in the compounds of formula (I), and one or two additional groups selected from the group consisting of: -SF₅ and -OSF₅ are also present in the compounds of formula (I). (n another embodiment of this invention one -OSF₅ group is present in the compounds of formula (f ), and one or two additional groups selected from the group consisting of: -SF₅ and -OSF₅ are also present in the compounds of formula (I). in another embodiment of this invention one -Si(R^15A)a (wherein each R^15A is independentfy selected) group is present in the compounds of formula (i), and one or two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are also present in the compounds of formula (I). in another embodiment of this invention one ~Si(R^15A)3 (wherein each R^15A is independently selected) group is present in the compounds of formula (I), and one or two groups selected from the group consisting of: -SF₅ and -OSF₅ are also present in the compounds of formula (I).

In another embodiment of this invention at ieast one group selected from the group consisting of: -SFs, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and aryl (e.g., phenyl)) is present in the compounds of formula (I),

In another embodiment of this invention at least one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of alkyi (e.g., methyl and ethyl) and phenyl) is present in the compounds of formula (I).

In another embodiment of this invention at least one group selected from the group consisting of: -SF₅, -OSF₅, and ~Sϊ(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formuia (I). In another embodiment of this invention at least one group selected from the group consisting of: -SF₅, -OSF₅, -Si(CH₃)₃, -Si(CH₃)₂phenyi, and -Si(CH₂CH₃)₂CH₃) is present in the compounds of formula (I).

In another embodiment of this invention at least one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(CH₃)₃ is present in the compounds of formula (I).

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently seiected) Is present in the compounds of formula (I). In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15Λ)₃ (wherein each R^15A is independently selected from the group consisting of aikyi (e.g., methyl and ethyi) and aryl (e.g., phenyl)) is present in the compounds of formula (I). Sn another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of alkyl (e.g., methyl and ethyl) and phenyl) is present in the compounds of formula (I).

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of methyl, ethyl and phenyl) is present in the compounds of formula (I). in another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, -Si(CH₃)₃, -Si(CH₃)₂phenyl, and -Si(CH₂CHs)₂CH₃) is present in the compounds of formula (I). in another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, -Si(CH₃)_3> and -Si(CH₂CH₃)₂CH₃) is present in the compounds of formula (I).

In another embodiment of this invention one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(CHa)₃, is present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are present in the compounds of formula (I).

In another embodiment of this invention two groups independently selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected from the group consisting of alkyf (e.g., methyl and ethyl) and aryi (e.g., phenyl)) are present in the compounds of formula (I). in another embodiment of this invention two groups independently selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^1SA)₃ (wherein each R^15A is independently selected from the group consisting of alky! (e.g., methyl and ethyl) and phenyl) are present in the compounds of formula (I).

In another embodiment of this invention two groups selected from the group consisting of: -SF₆, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently seiected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula (I).

In another embodiment of this invention two groups independently selected from the group consisting of: -SF₅, -OSFs, -Si(CHa)₃, -Si(CH₃)₂phenyl, and -Sϊ(CH₂CHb)₂CH₃) is present in the compounds of formula (I).

In another embodiment of this invention two groups independently selected from the group consisting of: -SF₅, -OSF₅, -Si(CH₃)₃, and -Si(CH₂CHa)₂CH₃) are present in the compounds of formula (i).

In another embodiment of this invention two groups independently selected from the group consisting of: -SF₅, -OSF₅, and -Si(CH₃)_S are present in the compounds of formula (I). in another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^15A is independently selected) are present in the compounds of formula (i)i. In another embodiment of this invention three groups independently selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)₃ (wherein each R^1SA is independently selected from the group consisting of alky! (e.g., methyl and ethyl) and aryl (e.g., phenyl)) are present in the compounds of formula (I).

In another embodiment of this invention three groups independently selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15Λ)₃ (wherein each R^15A is independently selected from the group consisting of aikyl (e.g., methyl and ethyl) and phenyl) are present in the compounds of formula (I).

In another embodiment of this invention three groups selected from the group consisting of: -SF₅, -OSF₅, and -Sι(R^1SA)₃ (wherein each R^15A ts independentiy selected from the group consisting of methyl, ethyl and phenyl) are present in the compounds of formula (I), in another embodiment of this invention three groups independently selected from the group consisting of: -SF₅, -OSF₅, -Si(CH₃)₃, ~Si(CH₃)2phenyl, and -Si(CH₂CHs)₂CH₃) is present in the compounds of formula (f). In another embodiment of this invention three groups independently selected from the group consisting of: -SF_5s -OSF₅, -Si(CH₃)₃, and "Si(CH₂CHs)₂CH₃) are present in the compounds of formula (I). in another embodiment of this invention three groups independently selected from the group consisting of; -SF₅, -OSF₅₁ and -Si(CH₃)3 are present in the compounds of formula (I). in another embodiment of this invention at (east one group selected from the group consisting of: -SFs, -OSF₅, and -Sϊ{R^15A)₃ (wherein each R^15A is the same or different alkyi group) is present in the compounds of formula (I).

In another embodiment of this invention at least one group selected from the group consisting of: -SF₅, -OSF₅, and -Si(R^15A)3 (wherein each R^i5A is independently selected from the group consisting of methyl and ethyl) is present in the compounds of formula (I). fn another embodiment of this invention one -SF₅ group is present in the compounds of formula (I)₁ and one or two groups selected from the group consisting of: -SF₅ and -OSF5 are also present In the compounds of formula (I).

In another embodiment of this invention one -OSF₅ group is present in the compounds of formula (I), and one or two groups selected from the group consisting of: -SFs and -OSF5 are also present in the compounds of formula (I).

Those skilfed in the art will appreciate that the G moiety -(C=NR²)- represents

NR²

.,„„. f π» „. and the G moiety -(C=C(R⁶)₂)- represents

I l — C— _.

In one embodiment of this invention, the cycloaikyl G moiety is unsubstitued In another embodiment of this invention, the cycloaikyl G moiety is substituted with 1 to 6 independently seiected R²¹ groups.

(n another embodiment of this invention, the cycloaikyl G moiety is a C3 to C10 cycloaikyl substituted with 1 to 6 independently selected R²¹ groups. In one example G is a cyclobutanone ring.

In one embodiment of this invention, the cycloalky! G moiety is a C3 to C-io cycloalkyi. In one example, said cycloalky! is selected from the group consisting of: cyclopropyj, cyciobutyϊ, cyclopentyl and cyclohexyl. In another example of said cycloaSkyl G moiety the cycloaikyi ring carbon by which said cycioalkyl moiety is bound to position (1 ) or (2) is different from the cycfoafkyl ring carbon by which said cycloalky! moiety is bound to moiety R¹⁰. In another example of said cycloalkyl G moiety the cycloalky! ring is bound to position (1 ) or (2) and the R¹⁰ moiety by the same cycloalkyl ring carbon. in another embodiment of this invention, the heterocycloalkyl G moiety is unsubstitued.

In another embodiment of this invention, the heterocycloalkyl G moiety is unsubstitued and said heterocycioalkyi G moiety comprises 1 to 4 heteroatoms independently setected from the group consisting of: -O-, -NR²-, -S-, -S(O)-, and -S(O)₂. Jn another embodiment of this invention, the heterocycioaikyi G moiety is substituted with 1 to 6 independently selected R²¹ groups, and said heterocycloalkyl G moiety comprises 1 to 4 ring heteroatoms independently selected from the group consisting of: -O-, -NR²-, -S-, -S(Oh and -S(O)₂.

In one embodiment of this invention, the heterocycioaikyi G moiety comprises 1 to 4 heteroatoms. In one example, said heterocycloalkyl G moiety comprises 1 to 4 heteroatoms. In another example, said heterocycloalkyl G moiety comprises 1 to 3 heteoatoms. In another example, said heterocycioaikyi G moiety comprises 1 to 2 heteroatoms. In another example, said heterocycloalkyl G moiety comprises 1 heteroatom. The heteroatoms in said heterocycloalkyl G moiety are independently selected from the group consisting of -O- , -NR²-, -S-, -S(O)-, and

-S(O)₂- In one example, said heterocycloalkyl G moiety is bound to the R¹⁰ moiety and position (1 ) or (2) by the same heterocycfoalky! ring atom. In another example, said heterocycloalkyl moiety is bound to the R¹⁰ moiety and position (1 ) or (2) by different heterocycioaikyi ring atoms, and wherein the heterocycloalkyl ring atoms that bind the heterocycloalkyl moiety to R¹⁰ and position (1 ) or (2) are selected from the group consisting of carbon and nitrogen.

An example of said alkynyf G moiety is:

Those skilled in the art will appreciate that when W is -S(O)-, the -S(O)- moiety can be:

or the -S(O)- moiety can be;

The compounds of formufa (I) do not have three consecutive nitrogen atoms in the ring. Thus, in addition to the nitrogen at position (5) in formula (i), there are 0 to 2 additional nitrogens in the ring (i.e., 0 to 2 -N(R²)_d- groups in the ring) provided that the nitrogens are not in consecutive ring positions. Thus, (a) when G¹ is -N(R²)d- then G² is not -N(RV, and (b) when G³ is -N(RV and G² is -N(R²)_d- then G¹ is not -N(RV, and (c) when G³ is -N(R²)_d- and G¹ is -N(FtV then G² is not -N(RV). In formula (I)₁ 0 to 2 of the G¹, G², G³, and G⁴ moieties are -N(R²)_d- wherein each d and each R² is independently selected. Thus Ring (A) in formula (I) comprises a total of 1 to 3 nitrogen atoms (the N at position (5) and 0 to 2 -N(R²Jd- moieties) in the ring such that the Ring (A) does not comprise three consecutive ring nitrogens, and each d and each R² is independently selected. In one embodiment of this invention the moiety -G-R¹⁰-R⁹ is bound through G to position (1).

In another embodiment of this invention the moiety — G-R¹⁰-R⁹ is bound through G to position (2).

In another embodiment of this invention G is selected from the group consisting of: G is selected from the group consisting of: a direct bond (i.e., R¹⁰ is bound directly to either G³ or G⁴), cycloaikyl (e.g., C₃ to Cto, and also for example, cyclopropyl, cyclobutyl, cyclopentyi and cyclohexyl, and wherein in one example the cycloalkyi ring carbon by which said cycloaikyl moiety is bound to positions (1) or (2) is different from the cycfoafky! ring carbon by which said cyctoalkyf moiety is bound to moiety R¹⁰, and wherein in another example said cycloaikyl ring is bound to positions (1) or (2} and the R¹⁰ moiety by the same cycloaikyl ring carbon), heterocycloalkyl (wherein said heterocycloalkyl comprises 1 to 4 heteroatoms, and in one example, 1 to 4 heteroatoms, and in another example 1 to 3 heteoatoms, and in another example 1 to 2 heteroatoms, and in another example 1 heteroatom, and wherein said heteroatoms are selected from the group consisting of -O-, -NR²-, -S-, -S(O)-, and -S(O)z, and wherein in one example said heterocycloalky! moiety is bound to the R¹⁰ moiety and positions (1 ) or (2) by the same heterocycloalkyl ring atom, and in another example said heterocycioalkyl moiety is bound to the R¹⁰ moiety and positions (1) or (2) by different heterocycloalkyl ring atoms, and wherein the heterocycloalkyl ring atoms that bind the heterocycloalkyl moiety toR¹⁰ and positions (1) or (2) are selected from the group consisting of carbon and nitrogen), -C=C-, -CF₂- atkynyl (e.g., -CsC-), -NH-, -N(R²)- (and in one example, -NH-), -O-, -CR⁴(0H)-, -CR⁴(OR⁴)-, -(CH₂)rN(R²)~, -N(R²)(CH₂)_r -, -(CH₂)₂-3 -, ~(C(R⁴)₂)_r - (wherein each R⁴ is independently selected), -(CHR⁴)₂-₃ - (wherein each R⁴ is independently selected),

-S-, -S(O)-, and -S(O)₂.

IInn oonnee e embodiment of this invention the moiety -G-R¹⁰-R⁹ is bound through G to position (1).

In another embodiment of this invention the moiety -G-R¹⁰-R⁹ is bound through G to position (2).

In another embodiment of this invention t is 1.

In another embodiment of this invention t is 2.

In another embodiment of this invention r is 1.

In another embodiment of this invention r is 2. In another embodiment of this invention r is 3.

In another embodiment of this invention G is selected from the group consisting of: a direct bond, and -N(R²)- (e.g., -NH-).

In another embodiment of this invention G is a direct bond.

In another embodiment of this invention G is -N(R²)- (e.g., -NH-). In another embodiment of this invention G is a cycloalkyl.

In another embodiment of this invention G is a heterocycloalkyl.

In another embodiment of this invention G is -C=C-.

In another embodiment of this invention G is -CF₂-. in another embodiment of this invention G is alkynyt In another embodiment of this invention G is -O-.

In another embodiment of this invention G is -CR⁴(OH)-. fn another embodiment of this invention G is -CR⁴(OR⁴)-.

In another embodiment of this invention G is -(CH₂)_rN(R )-. In another embodiment of this invention G is -N(R²)(CH₂)r -. in another embodiment of this invention G is -{CH₂)2-5 -. in another embodiment of this invention G is -(C(R⁴)z)_r~ (wherein each R⁴ is independently selected). In another embodiment of this invention G is ~(CHR⁴)₂.5 - (wherein each R⁴ is independent^ selected).

In another embodiment of this invention G is -S-.

In another embodiment of this invention G is -S(O)-.

In another embodiment of this invention G is -S(O)₂. In another embodiment of this invention G is -C(O)-.

In another embodiment of this invention G is -(C=NR²)-.

In another embodiment of this invention G is -(C=C(R⁶)2)-.

In another embodiment of this invention G is -(CHR³)-. in another embodiment of this invention G¹ is -C(R²¹)_q-. in another embodiment of this invention G¹ is -N(R²)_d~ . in another embodiment of this invention G² is a direct bond.

In another embodiment of this invention G² is -C(R²¹ )_q-.

In another embodiment of this invention G² is -N(R²)_d-.

In another embodiment of this invention G² is -C(O)-. In another embodiment of this invention G² is -C(=NR²)-.

Sn another embodiment of this invention G² is -S(O)₂.

In another embodiment of this invention G² is-S(O)-.

In another embodiment of this invention G² is -C(N(R²)a)-.

In another embodiment of this invention G³ is -C(R²¹ )_q-. In another embodiment of this invention G³ is -N(R²)_d-.

In another embodiment of this invention W is -C(O)-. in another embodiment of this invention W is -S(O)-.

!n another embodiment of this invention W is -S(O)₂-. in another embodiment of this invention W is -C(=NR²)-. In another embodiment of this invention G is -C(O)-, and W is -C(O)-.

In another embodiment of this invention G is -(C=NR²)-, and W is -C(O)-.

In another embodiment of this invention G is --(C-G(R⁶^)- wherein each R⁶ is independently selected, and W is -C(O)-. In another embodiment of this invention G is -(CHR³)-, and W is -C(O)-. in another embodiment of this invention G is -(CHR )-. and R is H (i.e., G is -CH₂-), and W is -C(O)-.

In another embodiment of this invention G is -(CHR³)-. and R³ is -OH (i.e., G is -(CHOH)-), and W is -C(O)-.

In another embodiment of this invention G is -(CHR³)-. and R³ is -O-a!kyl (i.e., aikoxy, such as, for example, -OCH₃), and W is -C(O)-.

In another embodiment of this invention G¹ is -C(R²¹Jq-, and W is -C(O)-. In another embodiment of this invention G¹ is -N(R²Jd-, and W is -C(O)-. (n another embodiment of this invention G² is -C(R²¹ )_q-, and W is -C(O)-. in another embodiment of this invention G is -N(R )_<j-, and W is -C(O)-. In another embodiment of this invention G² is -C(O)-, and W is -C(O)-. In another embodiment of this invention G² is -S(O)- ,and W is -C(O)-. In another embodiment of this invention G² is -S(O)₂-, and W is -C(O)-. In another embodiment of this invention G² is -C(=NR²)-, and W is -C(O)-. iInn aannootthheerr eemmbbooddiimmeenntt ooff tthhiiss iinnvveention G² is -C(N(R²J₂)- wherein each R² is independently selected, and W is -C(O)-.

In another embodiment of this invention G³ is -C(R²¹)_q~, and W is -C(O)-. In another embodiment of this invention G³ is -N(R²)_d-, and W is -C(O)-. In another embodiment of this invention R²¹ is selected from the group consisting of: atkyf, -OR¹⁵, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, and alky! substituted with 1 to 5 independently selected R²² groups (e.g., haio, such as, for example, F, Cl, and Br).

In another embodiment of this invention R is selected from the group consisting of: aikyl, -OR¹⁵, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, and alkyf substituted with t to 5 independently selected R²² groups (e.g., halo, such as, for example, F, CJ, and Br₅ and wherein in one example the alkyl substituted R²¹ group is -CF₃), wherein R¹⁵ and R¹⁶ are independently selected from the group consisting of: H, alkyl, (R^1s)_n-arylafkyl- (wherein, for example, n is 1 , and R^1S is -OR²⁰, and R²⁰ is alkyl (e.g., methyl), cycloalkyl (e.g., cyclobutyl), and (R¹⁸)_π-alkyi (e.g, n is 1, R¹⁸ is -OR²⁰, and R²⁰ is alkyl (e.g., methyl).

In another embodiment of this invention R²¹ is selected from the group consisting of: (a) alkyl, -OR^1S (wherein R¹⁵ is alkyl, e.g., methyl and ethyl), (b) -C(O)OR¹⁵ (wherein R¹⁵ is aikyi.e.g., methyl), (c) -C(O)NR¹⁵R¹⁶ (wherein R¹⁵ and R¹⁶ are independently selected from the group consisting of: H, alkyl, (R¹⁸)_n-aryla!kyl- (wherein, for example, π is 1 , and R^1δ is -OR²⁰, and R²⁰ is alkyl (e.g., methyl), cycioaikyi (e.g., cyciobutyi), and (R¹⁸)_n-alkyf (e.g. n is 1 , R¹⁸ is ~OR²⁰ _S and R²⁰ is alky! (e.g., methyt), and in one example, only one of R¹⁵ and R¹⁶ is H), and (d) atkyl substituted with 1 to 5 independently selected R²² groups (e.g., halo, such as, for example, F, Cf, and Br, and wherein in one example the afkyl substituted R²¹ group is -CF₃). in one embodiment of this invention R¹⁰ is selected from the group consisting of: aryl- (e.g., phenyl), heteroaryl- (e.g., pyridyl), cycloafkyl-, cycloalkenyl, cycloalkylalkyh heterocyclyh heterocyclenyh heterocyclylalkyl-, heterocyciyalkeny!-, fused benzocycloalkyl- (i.e., benzofusedcycioaikyl-), fused benzoheterocycloalkyi- (i.e., benzofusedheterocycioaikyi-), fused heteroarylcycioalkyl- (i.e., heteroaryifusedcycloaikyl-), fused heteroarylheterocycloalkyl- (i.e., heteroarylfusedheterocycloalkyl-), fused cycloalkylaryl (i.e., cycJoaikyfusedfary!-), fused heterocycloalkyfaryl- (i.e., heterocycioa(kyifusedaryl-), fused cycloalkylheteroaryl- (i.e., cycloalkyifusedheteroaryl-), and fused heterocycloafkylheteroaryl- (i.e., heterocycioatky(fusedheteroaryl-), and wherein each of said R¹⁰ moieties is optionally substituted with 1-5 independently selected R²¹ groups.

In another embodiment of this invention R¹⁰ is selected from the group consisting of:

wherein X is selected from the group consisting of: O, -N(R¹⁴)- and -S-; and wherein each of said R¹⁰ moieties is optionally substituted with 1-5 independently selected R²¹ groups.

ISn another embodiment of this invention R¹⁰ is selected from the group consisting of:

ΛΛΛΛ

wherein each of said R ,10 moieties is optionally substituted with 1-5 independently selected R²¹ groups.

In another embodiment of this invention R¹⁰ in formula (!) is selected from the group consisting of:

10AA 11AA 12AA 13AA 14AA

15AA 16AA 17AA 18AA

24AA 25AA 26AA 27AA 28AA

ΛΛΛΛ vΛΛΛΛ ΛΛΛΛ

33AA 34AA 35AA 36AA

37AA 38AA 39AA 40AA

JVWV vAΛAΛ

41AA 42AA in another embodiment of this invention R 10 ^■ is group 1AA, In another embodiment of this invention R¹⁰ is group 2AA. in another embodiment of this invention R¹⁰ is group 3AA. In another embodiment of this invention R¹⁰ is group 4AA. In another embodiment of this invention R¹⁰ is group 5AA, In another embodiment of this invention R¹⁰ is group 6AA. In another embodiment of this invention R¹⁰ is group 7AA. !n another embodiment of this invention R¹⁰ is group 8AA. In another embodiment of this invention R¹⁰ is group 9AA. in another embodiment of this invention R¹⁰ is group 10AA. In another embodiment of this invention R¹⁰ is group 11AA. In another embodiment of this invention R¹⁰ is group 12AA. in another embodiment of this invention R¹⁰ is group 13AA. Sn another embodiment of this invention R¹⁰ is group 14AA. In another embodiment of this invention R¹⁰ is group 15AA. in another embodiment of this invention R¹⁰ is group 16AA. tn another embodiment of this invention R¹⁰ is group 17AA. tn another embodiment of this invention R¹⁰ is group 1 SAA. In another embodiment of this invention R¹⁰ is group 19AA. Sn another embodiment of this invention R^*'⁰ is group 20AA. in another embodiment of this invention R¹⁰ is group 21 AA. In another embodiment of this invention R¹⁰ is group 22AA. In another embodiment of this invention R¹⁰ is group 23AA. tn another embodiment of this invention R¹⁰ is group 24AA. In another embodiment of this invention R^1δ is group 25AA. in another embodiment of this invention R¹⁰ is group 26AA. In another embodiment of this invention R^1G is group 27AA. In another embodiment of this invention R¹⁰ is group 28AA. in another embodiment of this invention R ^s0 is group 29AA. in another embodiment of this invention R¹⁰ is group 30AA. in another embodiment of this invention R¹⁰ is group 31AA. in another embodiment of this invention R¹⁰ is group 32AA. In another embodiment of this invention R¹⁰ is group 33AA. in another embodiment of this invention R¹⁰ is group 34AA. !n another embodiment of this invention R¹⁰ is group 35AA. fn another embodiment of this invention R¹⁰ is group 36AA. In another embodiment of this invention R¹⁰ is group 37AA. In another embodiment of this invention R'⁰ is group 38AA. In another embodiment of this invention R¹⁰ is group 39A. in another embodiment of this invention R¹⁰ is group 40AA. in another embodiment of this invention R¹⁰ is group 41 AA. fn another embodiment of this invention R¹⁰ is group 42AA. in another embodiment of this invention R¹⁰ is aryi. in another embodiment of this invention R¹⁰ ary! is aryl and said aryi is phenyl.

In another embodiment of this invention R¹⁰ is aryl substituted with one or more R²¹ groups. fn another embodiment of this invention R¹⁰ is aryl substituted with one or more R²¹ groups, and said aryi is phenyl, i.e., said R¹⁰ group is phenyl substituted with one or more R²¹ groups.

In another embodiment of this invention R¹⁰ is phenyl substituted with one or more R²¹ groups, and each R²¹ group is the same or different -OR¹⁵ group. In another embodiment of this invention R¹⁰ is phenyl substituted with one or more R²¹ groups, and each R²¹ group is the same or different -OR¹⁵ group, and said R¹⁵ is alky], and each alky! is independently seiected.

In another embodiment of this invention R¹⁰ is phenyl substituted with one R²¹ group, and said R²¹ group is -OR¹⁵, and said R¹⁵ is alky!. In another embodiment of this invention R¹⁰ is phenyl substituted with one R²¹ group, and said R²¹ group is -OR¹⁵, and said R¹⁵ is alkyl, and said alkyi is methyl.

In another embodiment of this invention R¹⁰ is phenyl substituted with one or more (e.g., one or two, or one) independently selected R²¹ halo groups.

In another embodiment of this invention R¹⁰ is phenyl substituted with one R²¹ group, and said R²¹ group is halo.

In another embodiment of this invention R¹⁰ is phenyl substituted with one R²¹ group, and said R²¹ group is F. In another embodiment of this invention R¹⁰ is phenyl substituted with one R²¹ group and said R²¹ is an -OR¹⁵ group, and R¹⁵ is an {R¹⁸)_naiky! group, and R^1S is halo, and n is 1 to 3, and each haϊo is independently selected. in another embodiment of this invention R¹⁰ is phenyl substituted with one R²¹ group and said R²¹ is an -OR¹⁵ group, and R¹⁵ is an (R^1β)_nalkyl group, and R¹⁸ is F, and n is 3.

!n another embodiment of this invention R¹⁰ is phenyl substituted with one R²¹ group and said R²¹ is an -OR¹⁵ group, and R¹⁵ is an (R¹⁸)_nalkyl group, and R¹⁸ is F, and n is 3, and the alkyl is methyl (i.e., the R²¹ substituent is -OCF₃). in another embodiment of this invention R¹⁰ is heteroaryi.

In another embodiment of this invention R¹⁰ is heteroaryi substituted with one or more R²¹ groups.

In another embodiment of this invention R⁹ is selected from the group consisting of:

W 199 , W 2gg / V 3gg . -° 4gg , w _5gg

In another embodiment of this invention R¹⁰ is selected from the group consisting of 1AA to 42AA₁ and R⁹ is selected from the group consiting of 1gg to

I3gg.

In another embodiment of this invention R¹⁰ is selected from the group consisting of 1AA to 42AA, and R⁹ is 2gg. Examples of the R⁹-R¹⁰- moiety include, but are not limited to:

in another embodiment the R -R Ϊ10 - moiety is 1 bb. in another embodiment the R⁹-R¹⁰- moiety is 2bb. \n another embodiment the R⁹-R¹⁰- moiety is 3bb. Jn another embodiment the R -R ^■»10 - moiety is 4bb. In another embodiment the R -R 10 - moiety is

5bb. In another embodiment the R -R j10 - moiety is 6bb. In another embodiment the R⁹-R¹⁰- moiety is 7bb. in another embodiment the R⁹-R¹⁰- moiety is 8bb. in another embodiment the R⁹-R¹⁰- moiety is 9bb. In another embodiment the R⁹-R¹⁰- moiety is tObb. In another embodiment the R j9- aRlO- moiety is 11 bb. In another embodiment the R -.9 - »R10 - moiety is 12bb. In another embodiment the R ,9 - rRjtO- moiety is 13bb. In another embodiment the R -R ,10 - moiety is 14bb. In another embodiment the R -R 10-

10 moiety is 15bb, In another embodiment the R -R - moiety is 16bb. In another embodiment the R >9- cR-v 10- moiety is 17bb. in another embodiment the R 9- _OR1ϋ- moiety is

18bb. In another embodiment the R -R »10 - moiety is 19bb. In another embodiment the R⁹-R¹⁰- moiety is 20bb. In another embodiment the R⁹-R¹⁰- moiety is 21 bb. In another embodiment the R⁹-R¹⁰- moiety is 22bb. in another embodiment the R⁹~R¹⁰- moiety is 23bb. In another embodiment the R⁹-R¹⁰- moiety is 24bb. In another embodiment the R⁹-R¹⁰- moiety is 25bb. In another embodiment the R⁹-R¹⁰- moiety is 26bb. in another embodiment the R⁹-R¹⁰- moiety is 27bb. In another embodiment the R⁹-R¹⁰- moiety is 28bb, In another embodiment the R⁹-R¹⁰- moiety is 29bb. In another embodiment the R³-R^t0- moiety is 30bb. In another embodiment the R⁹-R^1G- moiety is 31 bb. In another embodiment the R⁹-R¹⁰- moiety is 32bb. In another embodiment the R⁹-R¹⁰- moiety is 33bb. In another embodiment the R⁹-R¹⁰- moiety is 34bb. in another embodiment the R⁹-R¹⁰- moiety is 35bb. fn another embodiment the R⁹-R¹⁰- moiety is 36bb. In another embodiment the R⁹-R¹⁰- moiety is 37bb. In another embodiment the R⁹-R¹⁰- moiety is 38bb. In another embodiment the R⁹-R¹⁰- moiety is 39bb. in another embodiment the R⁹-R^1Q- moiety is 40bb.

In another embodiment of this invention R⁹ is heteroaryl. In another embodiment of this invention R⁹ is heteroaryl substituted with one or more R groups.

In another embodiment of this invention R⁹ is heteroaryl substituted with one or more R²¹ groups, and said R²¹ groups are the same or different alkyl.

In another embodiment of this invention R⁹ is heteroaryl substituted with one R²¹ group, and said R²¹ is aikyl.

In another embodiment of this invention R⁹ is heteroaryl substituted with one R²¹ group, and said R²¹ is alkyi, and said alkyl is methyl.

In another embodiment of this invention R⁹ is and said heteroaryl is imidazoyl. fn another embodiment of this invention R^a is imidazαly! substituted with one or more R²¹ groups.

In another embodiment of this invention R⁹ is tmidazolyl substituted with one or more R²¹ groups, and said R²¹ groups are the same or different alkyl.

In another embodiment of this invention R⁹ is imidazolyl substituted with one R²¹ group, and said R^Z1 is alkyl. Jn another embodiment of this invention R⁹ is imidazolyl substituted with one

R²¹ group, and said R²¹ is alkyl, and said aikyl is methyi.

In another embodiment of this invention R¹⁰ is selected from the group consisting of aryl and aryl substituted with one or more R^2Λ groups, and said R⁹ group is selected from the group consisting of heteroaryl and heteroaryi substituted with one or more R^z1 groups, wherein each R²¹ is independently setected.

In another embodiment of this invention R¹⁰ is phenyl substituted with one or more R²¹ groups, and said R⁹ is imidazoiy! substituted with one or more R²¹ groups, wherein each R²¹ is independently selected. fn another embodiment of this invention R¹⁰ is phenyi substituted with one R²¹ group, and said R⁹ is imidazolyi substituted with one R²¹ group, wherein each R²¹ is independently selected. in another embodiment of this invention R¹⁰Is phenyi substituted with one or more independently selected -OR¹⁵ groups, and said R⁹ is imidazolyl substituted with one or more independently selected alky! groups.

In another embodiment of this invention R¹⁰ is phenyl substituted with one or more independently selected -OR¹⁵ groups, and said R⁹ is imidazolyi substituted with oonnee oorr mmoorree iinnddeeppeenndently selected alkyl groups, and each R¹⁵ is the same or different alky! group.

In another embodiment of this invention R¹⁰ is phenyi substituted with one -OR¹⁵ group, and said R⁹ is imidazoiy! substituted with one alky! group.

In another embodiment of this invention R¹⁰Ss phenyl substituted with one -OR¹⁵ group, and said R⁹ is imidazolyt substituted with one alkyl group, and R¹⁵ is alkyi, and wherein the R¹⁵ alkyl group, and the alkyl group on said imidazolyl are independently selected.

In another embodiment of this invention R¹⁰ Js phenyi substituted with one -OR¹⁵ group, and said R⁹ is imidazolyt substituted with one methyl group, and R¹⁵ is methyl, and wherein the R¹⁵ aikyl group, and the afkyl group on said imidazoiy! are independently selected.

In another embodiment of this invention the R⁹-R¹⁰- moiety is:

In another embodiment of this invention the R⁹~R¹⁰- moiety is:

in another embodiment of this invention the R^y-R »1^ι0^u- moiety is

in another embodiment of this invention the R 9- rRj 10- moiety is

in another embodiment of this invention the R ,9^s-R »1'0^υ- moiety is

In another embodiment of this invention the R 9- _DR 10 - moiety is

In another embodiment of this invention R^1A is an unsubstituted or substituted aryl (e.g., phenyl) group.

In another embodiment of this invention R^1A is an unsubstituted aryl (e.g., phenyl) or aryl (e.g., phenyl) substituted with one or more independently selected R²¹ groups.

In another embodiment of this invention R^1Λ is an aryi group.

In another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with one or more independently selected R²¹ groups. In another embodiment of this invention R^1Λ is an aryl group, and said aryl group is substituted with 1 to 3 independently selected R²¹ groups.

In another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with one or more R²¹ groups, and each R²¹ group is the same or different haio. in another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with 1 to 3 R²¹ groups, and each R²¹ group is the same or different halo.

In another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with three R²¹ hafo groups, and each R²¹ group is the same or different haio.

In another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with two R²¹ haio groups, and each R²¹ group is the same or different halo.

In another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with one R²¹ halo group.

In another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with one R²¹ halo groups, and each R²¹ group is the same or different halo. In another embodiment of this invention R^1Λ is an aryl group, and said aryl group is substituted with one F (i.e., said aryl is substituted with one R²¹ group, and said R²¹ group is halo, and said halo is F).

In another embodiment of this invention R^1A is an aryl group, and said aryl group is substituted with two F atoms (i.e., said aryl is substituted with two R²¹ groups, and said R²¹ groups are halo, and said halo is F).

In another embodiment of this invention R^1A is an aryS group, and said aryl group is substituted with three F atoms (i.e., said aryl is substituted with three R²¹ groups, and said R²¹ groups are halo, and said halo is F). In another embodiment of this invention R^1A is phenyl.

In another embodiment of this invention R^1Λ is phenyl, and said phenyl is substituted with one or more independently selected R²¹ groups. in another embodiment of this invention R^1A is phenyl, and said phenyl is substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A is a phenyl, and said phenyl is substituted with one or more R²¹ groups, and each R²¹ group is the same or different halo.

In another embodiment of this invention R^1A is phenyl, and said phenyl is substituted with 1 to 3 R²¹ groups, and each R²¹ group is the same or different halo. In another embodiment of this invention R^1A is phenyl, and said phenyl is substituted with three R²¹ halo groups, and each R²¹ group is the same or different halo. tn another embodiment of this invention R^1A is phenyl, and said phenyl is substituted with two R²¹ halo groups, and each R²¹ group is the same or different halo.

IInn aannootthheerr eemmbt odiment of this invention R^1A is phenyl, and said phenyl is substituted with one R²¹ halo group. fn another embodiment of this invention R^1A is phenyl, and said phenyl is substituted with one R²¹ halo group. In another embodiment of this invention R^1A is phenyl, and said phenyl is substituted with one F (i.e., said aryl is substituted with one R group, and said R group is halo, and said halo is F). In another embodiment of this invention R ,1A i ^■s phenyl, and said phenyl is substituted with two F atoms (i.e., said ary! is substituted with two R²¹ groups, and said R²¹ groups are halo, and said halo is F).

In another embodiment of this invention R^1A is phenyl, and said phenyl is substituted with three F atoms (i.e,, said aryl is substituted with three R²¹ groups, and said R²¹ groups are halo, and said halo is F).

In another embodiment of this invention R^1A is selected from the group consisting of:

In another embodiment of this invention R >1A i ;s, selected from the group consisting of:

In another embodiment of this invention R ₄1A _: is, selected from the group consisting of:

in another embodiment of this invention R >1A i ^■s selected from the group consisting of:

In another embodiment of this invention R^1A is:

Jn another embodiment of this invention R IA i :s,

(n another embodiment of this invention R 1A , ivs

In another embodiment of this invention R^1A is

In another embodiment of this invention R is

In another embodiment of this invention R 1A ^■ is:

In another embodiment of this invention R^1A is:

* α

In another embodiment of this invention R IA i ■s

In another embodiment of this invention R i1A is:

In another embodiment of this invention R 1A • is

_, in another embodiment of this invention R^1A is:

.

In another embodiment of this invention R^1A is:

in another embodiment of this invention R^1A is:

Jn another embodiment of this invention R 1A i ^■s

In another embodiment of this invention R 1A • is:

_

In another embodiment of this invention R IA is

in another embodiment of this invention R ,1A i .s:

In another embodiment of this invention R^1A is:

In another embodiment of this invention R 1A i ;,s:

In another embodiment of this invention R^1A is

In another embodiment of this invention R 1A i ;s, :

!n another embodiment of this invention R IA - is:

(π another embodiment of this invention R^1A is:

In another embodiment of this invention R^1A is:

In another embodiment, R is phenyl substituted with 1-3 halos independently selected from the group consisting of F and Ct. In one example said phenyl is substituted with one F and one Cl.

In another embodiment R^1A is aryl (e.g., phenyl) substituted with 1 to 3 independentϊy selected R²¹ moieties wherein at (east one R²¹ moiety is selected from the group consisting of -SF₅, -OSF₅ and -Si(R^15A)₃ (and in one example each R^1SA is the same or different alkyl, and in another example the -Si(R²⁴)₃ group is -Si(CH₃)₃ or -Si(CH₂CH₃^CH₃, and in another example the -Si(R²⁴)₃ group is -Si(CH₃)S). In another embodiment R^1A is aryl (e.g., phenyl) substituted with 1 to 3 independently selected R²¹ moieties wherein at least one R²¹ moiety is selected from the group consisting of -SF₅ and -OSF₅.

In another embodiment R^1A is aryi (e.g., phenyl) substituted with 1 to 3 R²¹ moieties independently selected from the group consisting of: halo (e.g., F), -SF₅, -OSF₅ and -Si(R^15A)₃ (and in one example each R^15A is the same or different alkyl, and in another example the -Si(R^1SA)₃ group is -Si(CH₃)₃ or -Si(CH2CH₃)2CH₃, and in another example the -Si(R^t5A)₃ group is -Si(CH₃)S), and wherein at least one R²¹ moiety is selected from the group consisting of -SF₅, -OSFg and -Si(R^15A)s (and in one example each R^15A is the same or different alkyl, and in another example the -Si(R^15A)₃ group is -Si(CH₃)₃ or -Si(CH₂CHs)₂CH₃, and in another example the ~~Si(R²⁴)₃ group is -Si(CHg)₃). In another embodiment R^1A is aryl (e.g., phenyl) substituted with 1 to 3 R²¹ moieties independently selected from the group consisting of: halo (e.g., F), -SF₅ and -OSF₅, and wherein at least one R²¹ moiety is selected from the group consisting of -SF₅ and -OSF₅, In another embodiment R^1A is aryl (e.g., phenyl) substituted with 1 to 3 independently selected R²¹ moieties wherein at least one R²¹ moiety is selected from the group consisting of -SF₅, -OSF₅ and -Si(R^15A)₃ (and in one example each R^15A is the same or different alky), and in another example the ~Si(R^15A)₃ group is -Si(CH₃)₃ or -Si(CH₂CHa)₂CH₃, and in another example the -Si(R^15A)₃ group is -Si(CH₃)₃). In another embodiment, R^1A is phenyl substituted with 1-3 R^2t groups independently selected from the group consisting of hafos, -SF₅ and -OSF₅, wherein at least one R²¹ group is -SF₅ Or-OSF₅.

In another embodiment, H^1A is phenyl substituted with 1-3 R²¹ groups independently selected from the group consisting of halos, -SF₅ and -OSF₅, wherein at least one R²¹ group is -SF₅ or -OSF₅. fn another embodiment, R^1A is phenyl substituted with 1-3 R²¹ groups independently selected from the group consisting of F, Cl₁ -SFs and -OSF₅.

In another embodiment, R^1A is phenyl substituted with 1-3 R²¹ groups independently selected from the group consisting of -SF₅ and -OSFs. In another embodiment, R^1A is phenyl substituted with 1-3 R²¹ groups independently selected from the group consisting of F, -SF₅ and -OSF₅, wherein at feast one R²¹ group is -SF₅ or -OSF₅. in another embodiment, R^1A is phenyl substituted with one -SFs group.

In another embodiment, R^fA is phenyl substituted with two -SF₅ groups, In another embodiment, R^1A is phenyl substituted with three -SF₅ groups.

In another embodiment, R^1A is phenyl substituted with one -OSF₅ group. in another embodiment, R^1A is phenyl substituted with two -OSF₅ groups.

In another embodiment, R^1A is phenyl substituted with three -OSF₅ groups.

In another embodiment, R^1A is phenyl substituted with 1 F, In another embodiment, R^1A is phenyl substituted with 1 F, and also substituted with 1 to 2 groups independently selected from the group consisting of -SF₅ and -OSF₅. in another embodiment R^1A is phenyl substituted with 2 F. in another embodiment R^1A is phenyl substituted with 3F. In another embodiment of this invention R¹⁰ is selected from the group consisting of aryl and aryl substituted with one or more R²¹ groups, and said R^δ group is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more R²¹ groups, and wherein each R²¹ is independently selected, In another embodiment of this invention: (a) R^1A is an aryl group, or R^1A is an aryl group substituted with 1 to 3 independently selected R²¹ groups, and (b) R¹⁰ is selected from the group consisting of aryl and aryf substituted with one or more independently selected R²¹ groups, and (c) R⁹ is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more independently selected R²¹ groups.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ groups, and (b) R¹⁰ is selected from the group consisting of aryi and aryi substituted with one or more independently selected R²¹ groups, and (c) R⁹ is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more independently selected R²¹ groups.

(n another embodiment of this invention." (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or more independently selected R²¹ groups, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one or more independently selected R²¹ groups.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or more independently selected -OR¹⁵ groups, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one or more independently selected alkyf groups groups.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 2 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alkyl, and (c) R⁹ is selected from the group consisting of imidazofyl and tmϊdazolyl substituted with one or two independently selected alky! groups groups. In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 R²¹ halo group, and (5) R^m is seiected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alkyl, and (c) R⁹ is selected from the group consisting of imidazoiyl and imidazolyi substituted with one or two independently selected alkyl groups groups. In another embodiment of this invention: (a) R^1Λ is phenyl, or R^1A is phenyl, substituted with 1 to 3 F (i.e., R^1A is phenyl substituted with 1 to 3 R²¹ groups, and said R²¹ groups are halo, and said halo is F), and (b) R^1δ is seiected from the group consisting of phenyl and phenyl substituted with one or two independently selected - OR¹⁵ groups, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyJ and smidazoiy! substituted with one or two independently selected methyl groups groups.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl, substituted with 1 to 2 F (i.e., R^1A is phenyl substituted with 1 to 2 R²¹ groups, and said R²¹ groups are halo, and said halo is F)₁ and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected - OR¹⁵ groups, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyi and imidazolyi substituted with one or two independently selected methyl groups groups. In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl, substituted with 1 F (i.e., R^1A is phenyl substituted with 1 R²¹ group, and said R²¹ group is halo, and said halo is F), and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is methyl, and (c) R⁹ is seiected from the group consisting of imidazolyi and imidazolyi substituted with one or two independently selected methyl groups groups. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

In another embodiment of this invention R ₅1A i .s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

In another embodiment of this invention R i1A . is selected from the group consisting of:

and wherein the R^δ-Rⁱ⁰- motety is:

in another embodiment of this invention R *1A i -s selected from the group consisting of:

and wherein the R⁹-R¹⁰- moiety is:

In another embodiment of this invention R >1A i ■s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

in another embodiment of this invention: (a) R 1A is phenyl, or R ,1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R^ϊ0 is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alkyl, and (c) R⁹ is selected from the group consisting of imidazolyi and imidazofy! substituted with one or two independently selected alkyi groups groups. In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ hafo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is aikyl, and (c) R^θ is selected from the group consisting of imidazolyl and imidazofyl substituted with one or two independently selected alkyl groups groups, and (d) G is -C(O)-,

!n another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alkyl, and (c) R⁹ is sefected from the group consisting of imidazolyl and irnidazolyt substituted with one or two independently selected alkyl groups groups, and (d) G is -(C=NR²)-.

In another embodiment of this invention: (a) R^1A is phenyi, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independent^ selected -OR¹⁵ groups, wherein R¹⁵ is afkyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazoly! substituted with one or two independently selected alkyl groups groups, and (d) G is -(C=C(R⁶)₂)-.

In another embodiment of this invention: (a) R^1A is pheny), or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alkyl, and (c) R⁹ is selected from the group consisting of imidazolyt and imidazoiyl substituted with one or two independently selected aikyl groups groups, and (d) G is -CHR³-;. In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyi and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alky!, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one or two independently selected alky{ groups groups, and (d) G is -CHz-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 Independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and pheny! substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alkyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyi substituted with one or two independently seiected alkyt groups groups, and (d) G is -(CHOH)-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyi substituted with one methyl group.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁶ is methyl, and (c) R⁹ is seiected from the group consisting of imidazoiyl and imidazolyl substituted with one methyl group, and (d) G is -C(O)-. In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one methyl group, and (d) G is -(C=NR²)-. In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is seiected from the group consisting of imidazolyl and imidazolyl substituted with one methyl group, and (d) G is -(C=C(R⁶^)-. in another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of im/dazoJyJ and imidazolyl substituted with one methyl group, and (d) G is -CHR³-. In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R^f0 is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one methyl group, and (d) G is -CH₂-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyf and imidazofyi substituted with one methyl group, and (d) G is -(CHOH)-.

wherein the R⁹-R¹⁰- moiety is:

alkyt

In another embodiment of this invention R *1¹A^A - is selected from the group consisting of:

wherein the R 9⁹-R ΓVI^ιO^υ- moiety is:

G is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

and

G is -(C=NFt)-. in another embodiment of this invention R ,1ⁱA^/λ - is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

_{t anc}i

G is -NHC(O^.

In another embodiment of this invention R^1A is selected from the group consisting of.

wherein the R⁹-R¹⁰- moiety is:

, and G is -CHR³-. in another embodiment of this invention R > 1'^ΛA i ■s selected from the group consisting of;

wherein the R⁹-R^t0- moiety is:

G iS -=-.. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

In another embodiment of this invention R^1Λ is selected from the group consisting of:

q in wherein the R -R - moiety is;

Sn another embodiment of this invention R »1A i.s selected from the group consisting of:

wherein the R⁹-R¹⁰~ moiety is:

G is -C(O)-.

wherein the R⁹~R¹⁰- moiety is:

G is -(C-NR²)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -CHR -. In another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R^1δ- moiety is;

G is

In another embodiment of this invention R *1A i •s selected from the group consisting of:

wherein the R^δ-R¹⁰- moiety is;

G is

, and wherein the R⁹-R¹⁰- moiety is:

wherein the R⁹~R¹⁰- moiety is:

G is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -(C= -~NMRnAl-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R^δ-R¹⁰- moiety is:

G is -CHR'-.

In another embodiment of this i ^'nvention R^1A is selected from the group consisting of:

, and wherein the R⁹-R¹⁰- moiety is:

G is

Irv another embodimen

t of this invention s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -≡- fn another embodiment of this inventhn R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety Is:

wherein the R⁹~R¹⁰- moiety is:

G is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -(C~NR²>.

, and wherein the R⁹-R¹⁰- moiety is:

G is -NHC(Oh-

wherein the R⁹-R¹⁰- moiety is:

and

G is -CHR³-. fn another embodiment of this invention R^1A is selected from the group consisting of:

, and wherein the R⁹-R¹⁰- moiety Is:

, and G is

In another embodiment of this invention R ,1A i .s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is

In another embodiment of this invention R is selected from the group consisting of:

wherein the R^δ-R¹⁰- moiety is:

, and wherein the R -R ,10- moiety is:

M3C , and

G is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -(C-NR²)-. fn another embodiment of this inventiorr R^1A is selected from the group consisting of:

, and wherein the R -R »10 - moiety is;

and G is -NHC(O)-. •

\n another embodiment of this invention R'" is selected from the group consisting of:

wherein the R^β-R^1G- moiety is:

G is -CHR³-.

wherein the R 9-R _D10 - moiety is:

G is

In another embodiment of this invention R ,1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -Ξ

Jn another embodiment of this invention: (a) R 1A i :s, phenyl, or R j1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alky!, and (c) R⁹ is selected from the group consisting of imidazoiyl and imidazolyl substituted with one or two independently selected alkyi groups groups, and (d) G is selected from the group consisting of-NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond,

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one methyl group, and (d) G is selected from the group consisting of-NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(Oy, -S(O}₂- and a direct bond.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O~, -S-, -S(O)-, -S(O)₂- and a direct bond.

.1A .

In another embodiment of this invention R^w is selected from the group consisting of:

, and wherein the R »^y- _DR1^ι0^u- moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O- , -S-, -S(O)-, -S(O)₂- and a direct bond. tn another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

HX and

In another embodiment of this invention: (a) R 1A • is phenyt, or R i1A ; i,s phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one methyl group, and (d) G is selected from the group consisting Of -NH-, -O- , -S-, -S(O)~, -S(O)₂- and a direct bond, and (e) W is -C(O)-.

wherein the R -R¹⁰- moiety is:

_{( and}

G is selected from the group consisting of -NH-, -O- , -S-, -S(O)-, -S(O^- and a direct bond, and W is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -Cs -S-, -S(O)-, -S(O)₂- and a direct bond, and W is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O- , -S-, -S(O)-, -S(O)₂- and a direct bond, and W is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O)₂~ and a direct bond, and W is -C(O)-.

Jn another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

^H3° , and

G is selected from the group consisting of -NH-, -O- , -S-, -S(O)-, -3(0)₂- and a direct bond, and W is -C(O)-. in another embodiment of this invention: (a} R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazoly! and imidazolyi substituted with one methyl group, and (d) G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond, and (e) W is -S(O)».

Sn another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -0-, -S-, -S(O)-, -S(O)₂- and a direct bond, and W is -S(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

n if! wherein the R -R - moiety is:

G is selected from the group consisting of -NH-, -O- , -S-, -S(O)-, -S(O)₂- and a direct bond, and W is -S(O)-.

, and wherein the R -R - moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O)2~ and a direct bond, and W is -S(O)-.

wherein the R^δ-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O}₂~ and a direct bond, and W is -S(O)-.

!n another embodiment of this invention R^1Λ is selected from the group consisting of:

, and wherein the R⁹-R^t0- moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S{0)2- and a direct bond, and W is -S(O)-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R 10 is phenyl substituted with one-OR ,15 group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of Imidazolyl and imidazoiyl substituted with on® methyl group, and (d) G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond, and (e) W is -S(O)₂-.

wherein the R^a-R¹⁰- moiety is:

, and G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(OV and a direct bond, and W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(OV and a direct bond, and W is -S(O)₂-.

wherein the R^θ-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -0-, -S-, -S(O)-, -S(OV and a direct bond, and W is -S(O)₂-, In another embodiment of this invention R >1A i •s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is seJected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S{0>₂- and a direct bond, and W iS -S(O)₂-.

wherein the R^δ-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond, and W is -S(O)₂-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R to t is phenyl substituted with one-OR ,15 group, wherein R _>15 is methyl, and (c) R is selected from the group consisting of imidazolyl and imidazolyi substituted with one methyl group, and (d) G is selected from the group consisting of -NH-, -O- , -S-, -S(O)-, -S(O)₂- and a direct bond, and (e) W is -C(=NR²)-.

wherein the R -R - moiety is:

G is selected from the group consisting of -NH-, -O-, -S-, -S(O)-, -S(O>2- and a direct bond, and W is -C(=NR²)-.

wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -0-, -S-, -S(O)-, -S(Q)₂- and a direct bond, and W is -C(^NR²)-. ,1A .

, and wherein the R⁹-R¹⁰- moiety is:

G is selected from the group consisting of -MH-, -O- , -S-, -S(O)-, -S(OV ^{and a} direct bond, and W is -C(=NR²}-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R^δ-R¹⁰- moiety is:

G is selected from the group consisting of -NH-, -0-, -S-, -S(O)-, -S(O)₂- and a direct bond, and W is -C(=NR²)-, in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R^θ-R^tQ- moiety is:

G is selected from the group consisting of -NH-, -O- , -S-, -S(O)-, -S(O)₂~ and a direct bond, and W is -C(=NR²h

In another embodiment of this invention: (a) R IA i ;s, phenyl, or R *1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R^t5 is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyl substituted with one methyl group, and (d) G is -C(O)-, and (e) W is -C(O)-.

In another embodiment of this invention R^M is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -C(O)-, and W is -C(O)-. In another embodiment of this invention R »1A . is selected from the group consisting of:

, and wherein the R⁹~R¹⁰- moiety is:

G is -C(O)-, and W is -C(O)-.

wherein the R⁹-R^t0- moiety is:

G is -C(O)-, and W is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -C(O)-, and W is -C(O)-.

, and wherein the R 9 - nR10- moiety is:

G is -C(O)-, and W is -C(O)-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one~OR¹⁵ group, wherein R¹⁵ is methyt, and (c) R⁹ is selected from the group consisting of imidazoiy! and imidazoiyi substituted with one methyl group, and (d) G is -C(O)-, and (e) W is -S(OK

wherein the R ,9 - _DR1¹G - moiety is:

G is -C(O)-, and W is -S(O)-.

wherein the R^s-R¹⁰- moiety is;

G is -C(O)-, and W is -S(O)-. tn another embodiment of this invention R^1A is selected from the group consisting of:

and

, and wherein the R^v-R 10 - moiety is:

G is -C(Oh and W is -S(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -C(O)-, and W is -S(O)-.

In another embodiment of this invention R^tA is selected from the group consisting of:

, and wherein the R^θ-R¹⁰- moiety is:

G is -C(O)-, and W is -S(O)-.

In another embodiment of this invention; (a) R^1A is phenyl, or R^tA is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-~OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazoiyi and imidazolyl substituted with one methyl group, and (d) G is -C(O)-, and (e) W is -S(O)₂-.

In another embodiment of this invention R^1A is sefected from the group consisting of:

,10 wherein the R -R - moiety is:

_{f and}

G is -C(O)-, and W is -S(O)₂-.

Sn another embodiment of this invention R^1A is sefected from the group consisting of:

, and

10 wherein the FT-R "~ moiety is:

G is -C(Oh and W is -S(O)₂-.

wherein the R 9- rR»10- moiety is:

G is -C(O)-, and W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is -C(O)-, and W is -S(O)₂-,

In another embodiment of this invention R j1^ιnA i -s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -C(O)-, and W is -S(O)₂-.

In another embodiment of this invention: (a) R^1A is phenyi, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazoiyl and fmidazoiyl substituted with one methyl group, and (d) G is -C(O)-, and (e) W is -C(^NR²)-.

wherein the R⁹-R¹⁰- moiety is:

_{^ and}

G is -C(O)-, and W is ~C(~NR²)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -C(O)-, and W is -C(=NR²)-.

wherein the R⁹-R¹⁰- moiety is:

« and G is -C(O)-, and W is -C(~NR²}-.

In another embodiment of this invention R *1 ^PMA i •s selected from the group consisting of:

wherein the R⁹-R^1Q- moiety is:

G is -C(O)-, and W is ™C(=NR²)-.

In another embodiment of this invention R i1 ^IΛA i ■s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

In another embodiment of this invention: (a) R 1A is phenyl, or R i1A . is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R" is methyl, and (c) R ϋ9 : is, selected from the group consisting of imidazoiyi and imidazoiyl substituted with one methyl group, and (d) G is -(C=NR²)- artd (e) W is -C(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -(C=NR²)-, and W is -C(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -(C=NR²)-, and W is -C(O)-.

wherein the R^s-R¹⁰- moiety is:

wherein the R⁹-R¹⁰- moiety is:

, and wherein the R⁹-R¹⁰- moiety is:

G is -(C=NFTh and W is -C(O)-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazoiyf and imidazoiyl substituted with one methyl group, and (d) G is -(C=NR²)-, and (e) W is -S(O)-.

wherein the R 9- rR-,10- moiety is:

_{) and}

G is -(C=NR²)-, and W is -S(O)-. f n another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -(ONR²)-, and W is -S(Oh in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -(C=NR²)-, and W is -S(O)-.

IInn aannoother embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -(C-NR²)-, and W is -S(O)-. fn another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R^1Q- moiety is:

G is -(C=NR²)-, and W is -S(O)-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR^t5 group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyi and imidazoiyl substituted with one methyl group, and (d) G is -(C=NR²)-, and (e) W is -S(O)₂-.

, and wherein the R⁹-R¹⁰- moiety is:

G is -(C=NR²)-, and W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is -(C-NR²)-, and W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

, and G is -(C=NR²)-, and W is -S(O)₂-.

wherein the R -R - moiety is:

G is -(C=NR²)-, and W is -S(O)₂-.

!n another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

-S(O)₂-. in another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyi and tmidazotyi substituted with one methyl group, and (d) G is -(C=NR²)-, and (e) W is -C(=NR²)-.

wherein the R⁹-R¹⁰- moiety is:

_{f and}

G is -(C=NR²)-, and W is -C(=NR²)~.

wherein the R⁹-R¹⁰- moiety is:

G is -(C=NR²)-, and W is -C(=NR²)-.

wherein the R⁹-R¹⁰- moiety is:

G is -(C=NR²)-, and W is -C(=NR²)-. iinn aannoo"ther embodiment of this invention R^1A is selected from the group consisting of;

wherein the R -R - moiety is:

G is -(C=NR²)-, and W is -C(=NR²)-. in another embodiment of this invention R^1A is selected from the group consisting of;

, and wherein the R⁹-R¹⁰- moiety is:

in another embodiment of this invention: (a) R 1A is phenyl, or R >1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyi, and (c) R⁹ is selected from the group consisting of imJdazolyl and imidazolyl substituted with one methyl group, and (d) G is -NHC(OH and (e) W is -C(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(OK, and W is -C(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰~ moiety is:

G is -NHC(Oy₁ and W is -C(O}~.

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(OK and W is -C(O)-.

wherein the R⁹~R¹⁰- moiety is:

G is -NHC(OK and W is -C(O)-.

wherein the R⁹-R¹⁰~ moiety is:

G is -NHC(Oh, and W is -C(O)-.

In another embodiment of this invention: (a) R^tA is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyf substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazofyl and imtdazofy! substituted with one methyl group, and (d) G is -NHC(O)-, and (e) W is -S(O)-,

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(OH and W is -S(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(OH and W is -S(O)-.

In another embodiment of this invention R^1A is selected from the group consisting of;

, and wherein the R⁹-R¹⁰- moiety is:

, and G is -NHC(OK and W is -S(O)-.

In another embodiment of this invention R i1'^aA i .s selected from the group consisting of:

» and wherein the R 9-R cj10- moiety is:

G is -NHC(OK and W is -S(O)-.

wherein the R 9- _aRW- moiety is:

G is -NHC(OK. and W is -S(O)-. in another embodiment of this invention: (a) R 1A i .s, phenyl, or R »1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyi substituted with one methyl group, and (d) G is -(C=C(R^)₂)-, and (e) W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(O)-, and W is -S(O)₂-. tn another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(Oh, and W is -S(O)₂-.

In another embodiment of this invention R »1^!A^Λ - is. selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(O)-, and W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(O)-, and W is -S(O)₂-.

, and wherein the R⁹-R'°- moiety is:

G is -NHC(O)-, and W is -S(O)₂-. in another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazoly! and imidazolyl substituted with one methyl group, and (d) G is -NHC(O)-, and (e) W is -C(=NR²)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

and

G is -NHC(OK and W is -C(-NFr)-.

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(OH, and W is -C(=NR²)-.

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(O)-, and W is ~C(=NR²)-.

In another embodiment of this invention R ,1ⁱA^Λ - is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(O)-, and W is ~C(=NR>.

wherein the R⁹-R¹⁰- moiety is:

G is -NHC(OK and W is ~C(=NR>.

(n another embodiment of this invention: (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyf, and (c) R⁹ is selected from the group consisting of imtdazolyl and imidazoly! substituted with one methyf group, and (d) G is -CHR³- (e.g. -CHOH)₁ and (e) W is -C(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R ^'-R 10 - moiety is:

G rs -CHR³- (e.g., -CHOH), and W fs -C(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

, and wherein the R⁹-R¹⁰~ moiety is:

G is -CHR³" (e.g., -CHOH)₁ and W is -C(O)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R -R ■>τo - moiety is:

, and G is -CHR³- (e.g., -CHOH)₁ and W is -C(O)-.

wherein the R -R - moiety is:

G is -CHR³- (e.g., -CHOH), and W is -C(O)-.

wherein the R⁹-R¹⁰- moiety is:

v3

G is -CHR^J- (e.g., -CHOH), and W is -C(O)-.

In another embodiment of this invention: (a) R^1A is phenyl, or R^1Λ is phenyl

10 • ,15 substituted with 1 to 3 F atoms, and (b) R is phenyl substituted with one-OR group, wherein R¹⁵ is methyt, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazofyl substituted with one methyl group, and (d) G is -CHR³- (e.g., -CHOH), and (e) W is -S(O)-.

wherein the R⁹-R¹⁰- moiety is:

_{f and}

G is -CHR³- (e.g., -CHOH)₁ and W is -S(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -S(O)-. in another embodiment of this invention R >1A i -s selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -S(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -S(O)-.

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -S(O)-.

In another embodiment of this invention: (a) R 1A is phenyl, or R _Ϊ1 A ^■ is phenyl substituted with 1 to 3 F atoms, and (b) R¹⁰ is phenyl substituted with one-OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of ϊmidazotyi and imidazolyt substituted with one methyl group, and (d) G is -CHR³- (e.g., -CHOH), and (e) W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -S(O)₂-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R -R - moiety is:

G is -CHR³- (e.g., -CHOH)₁ and W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is -CHR - (e.g., -CHOH), and W is -S(O)₂-.

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -S(O)₂--

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH)₁ and W is -S(O)₂-.

Jn another embodiment of this invention: (a) R 1A _: is, phenyf, or R »1A is phenyl substituted with 1 to 3 F atoms, and (b) R 10 is phenyl substituted with one-OR ,15 group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyi and imidazoiyf substituted with one methyl group, and (d) G is -CHR³- (e.g., -CHOH), and (e) W is -C(=NR²)~.

, and wherein the R^θ-R^1υ~ moiety is:

G is -CHR³- (e.g., -CHOH), and W is -C(=NR²)-. in another embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH)₁ and W is -C(=NR²)-.

wherein the R⁹-R¹⁰- moiety is:

and G is -CHR - (e.g., -CHOH), and W is -C(-NR>.

IInn aannoo'ther embodiment of this invention R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -C(=NR²)-. in another embodiment of this invention R >1A : is„ selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

G is -CHR³- (e.g., -CHOH), and W is -C(=NR>.

Other embodiments of this invention are directed to compounds of formula (I) wherein R^1A is selected from the group consisting of: benzofusedcycfoaϋkyl (i.e., fused benzocycloatkyl), fused benzoheterocycloalkyi, fused heteroaryicycioaikyi, fused heteroaryfheterocycSoalkyi, and wherein said R^1A groups are optionally substituted with 1-5 independently selected R²¹ groups. In one example, the R²¹ groups are halo

(e.g., F).

Examples of the fused ring R ,1A groups include, but are not limited to:

wherein each Y is independently selected from the group consisting of: -O-, -NR¹⁴- and ™C(R²¹)_q-, wherein q is as defined above (i.e., 0, 1 or 2 and each R²¹ is independently selected), and wherein R¹⁴ and R²¹ are as defined for formula (I).

Examples of these R _Ϊ 1A groups include, for example:

Compounds of formula (!) also include compounds wherein R 1A is an aikyl group (e.g., ethyl) substituted with one R²¹ group. Examples of said R^1A groups include alkyl (e.g., methy! or ethyl) substituted with the R²¹ moiety aryi (e.g., phenyl or naphthyl). Examples of said R^1A groups also include alkyf (e.g., methyl or ethyl) substituted with the R²¹ moiety aryt (e.g., phenyl or naphthyl), which in turn is substituted with one or more (e.g., one or two) independently selected R²² groups (e.g., R²² is haio, such as, for example, F).

Examples of the substituted R^1Λ alkyi groups include, but are not limited to:

Other embodiments of this invention are directed to compounds of formula (I) wherein R >1A i ;s a cycloalky! group (e.g., cyciopropyl or cyclobutyl) substituted with one R²¹ group (e.g., ary!, such as, for example, phenyl), or a cycloalkyi group (e.g., cyclopentyl or cyclohexyl) substituted with one R²¹ group (e.g., aryl, such as, for example, phenyl) which in turn is substituted with one or more (e.g., one or two) independently selected R²² groups (e.g., hato, such as, for example, F). In one example the R²¹ group is bound to the same carbon of the R^1A group that binds the R^1A group to the rest of the molecule.

Examples of the cycloalkyi R^1A groups include, but are not limited to:

such as, for example,

wherein s is 0 (i.e., the ring is cyciopropyl), or 1 (i.e., the ring is cyclobutyl). Examples of these R^1A groups include, but are not limited to:

such as, for example,

wherein s is 0 (i.e., the ring is cyciopropyl), or 1 (Le., the ring is cyclobutyl).

Other embodiments of this invention are directed to compounds of formula (I) wherein R^1A is

as, for example,

wherein Z is selected from the group consisting of: (1) -O₁ (2) -NR¹⁴-, (3) -C(R²¹X,- wherein q is 0, 1 or 2, and each R ,21 is independently selected, (4) -C(R 21 ) \_q-C(R i21 )ι_q- wherein each q is independently 0, 1 or 2 and each R²¹ is indepenendently selected, (5) -(C{R²¹)q)_q-O-(C(R²¹)c,)_q- wherein each q is independently 0, 1 or 2, and each R²¹ is independently selected, and (6) -(C(R²¹)_q)_q-N(R¹⁴)-(C{R²ⁱ)_q)c,- wherein each q is independently 0, 1 or 2, and each R²¹ is independently selected. Examples of R²¹ include, but are not limited to, aryl (e.g., phenyl) and ary! (e.g., phenyl) substituted with one or more (e.g., one or two, or one) independently selected R²² groups (e.g., halo, such as, for example, F). Examples of this R^1A include, but are not limited to:

Thus, examples of this R ,1A group include, but are not limited to:

Examples of R >1A also include, but are not limited to:

such as, for example,

Examples of the R^1A group

also include, but are not limited to:

Examples of the R^1A group

also include, but are not limited to: such as, for example,

Examples of the R^1A group

also include, but are not limited to:

Examples of the R^1A group

also include, but are not limited to: I

Other embodiments of this invention are directed to compounds of formula (I) wherein R¹⁰ is aryi (e.g., phenyl) or ary! (e.g., phenyl) substituted with one or more (e.g., one or two, or one) R²¹ groups (e.g., -OR¹⁵, wherein, for example, R¹⁵ is alkyl, such as, for example, methyl), and R⁹ is heteroaryl (e.g., imidazoly!) or heteroaryl (e.g., ϊmidazolyl) substituted with one or more (e.g., one or two, or one) R²¹ groups (e.g., alkyi, such as, for example, methyl). Thus, examples of the

moiety of the compounds of this invention include, but are not limited to:

wherein q is 0, 1 or 2, such as, for example, (R²¹)i or 2

such as, for example,

wherein R¹⁵ is alky! (e.g., methyl), such as, for example,

wherein R¹⁵ is alkyl (e.g., methyl), such as, for example,

wherein R¹⁵ is alkyl (e.g., methyl), such as, for example,

Other embodiments of this invention are directed to the compounds of formula

(I) wherein R¹⁰ is heteroaryf or heteroaryl substituted with one or more R²¹ groups, and R⁹ is heteroaryl (e.g., ϊmidazoiy!) or heteroaryi (e.g., ϊmidazσiyi) substituted with one or more (e.g., one or two, or one) R²¹ groups (e.g., alky!, such as, for example, methyl).

In another embodiment of the compounds of formula (I) R¹⁰ is aryl substituted with one R²¹ group, wherein said R²¹ group is -OR¹⁰, in one example, R¹⁵ is alkyl. In another exampie R^w is methyl.

In another embodiment of the compounds of formula (t) R^TO is phenyl substituted with one R²¹ group, wherein said R²¹ group is -OR^T5. In one example, R¹⁵ is alky!. In another example R¹⁵ is methyl.

In another embodiment of the compounds of formula (I) R¹⁰ is heteroaryl. fn another embodiment of the compounds of formula (I) R⁹ is heteroaryl,

In another embodiment of the compounds of formula (I) R⁹ is heteroaryl substituted with one or more (e.g., one) independently selected R²¹ groups. fn another embodiment of the compounds of formula (i) R⁹ is heteroaryl substituted with one or more (e.g., one) independently selected R²¹ groups, wherein each R²¹ group is the same or different alkyl group (e.g., methyl).

Sn another embodiment of the compounds of formula (I) R⁹ is heteroaryi substituted with one R²¹ group.

In another embodiment of the compounds of formula (I) R⁹ is heteroaryl substituted with one R²¹ group, wherein R²¹ is an alkyl group (e.g., methyl). In another embodiment of the compounds of formula (I) R⁹ is imidazolyl.

In another embodiment of the compounds of formula (I) R⁹ is imidazolyl substituted with one or more (e.g., one) independently selected R²¹ groups.

In another embodiment of the compounds of formula (I) R⁹ is imidazolyf substituted with one or more (e.g., one) independently selected R²¹ groups, wherein each R²¹ group is the same or different aikyl group (e.g., methyl).

In another embodiment of the compounds of formula (!) R⁹ is irnidazoiy! substituted with one R²¹ group. in another embodiment of the compounds of formula (I) R⁹ is imidazolyl substituted with one R²¹ group, wherein R²¹ is an alkyl group (e.g., methyl). in another embodiment of the compou jnπdαss o ofr f roornmnuultaa ( (_IΪ); R r^"5 i ^:s^" heteroaryl, optionally substituted with one or more R² 21¹ groups, and R¹⁰ is aryl optionally substituted with one or more (e.g., one) R 21 groups. In another embodiment of the compounds of formula (I) R⁹ is heteroaryl, optionally substituted with one R²¹ group, and R¹⁰ is aryl optionally substituted with one R²¹ group.

In another embodiment of the compounds of formula (I) R⁹ is heteroaryJ, optionally substituted with one or more R²¹ groups, and R¹⁰ is phenyl optionaily substituted with one or more (e.g., one) R²¹ groups. in another embodiment of the compounds of formula (!) R⁹ is heteroaryf, optionally substituted with one R²¹ group, and R¹⁰ is phenyl optionally substituted with one R²¹ group, in another embodiment of the compounds of formula (I) R^& is imidazoiyf, optionally substituted with one or more R²¹ groups, and R¹⁰ is aryl optionally substituted with one or more (e.g., one) R²¹ groups.

In another embodiment of the compounds of formula (I) R⁹ is imidazolyl, optionaily substituted with one R²¹ group, and R¹⁰ is aryl optionally substituted with one R²¹ group. in another embodiment of the compounds of formula (I) R^θ is imidazolyl, optionally substituted with one or more R²¹ groups, and R¹⁰ is phenyl optionally substituted with one or more (e.g., one) R²¹ groups.

In another embodiment of the compounds of formula (I) R⁹ is imidazolyl, optionally substituted with one R²¹ group, and R¹⁰ is phenyl optionally substituted with one R²¹ group.

Other embodiments of the compounds of formula (I) are directed to any one of the above embodiments wherein R⁹ is

Other embodiments of the compounds of formula (I) are directed to any one of the above embodiments wherein R 10 i :s, ;

(wherein the -OR¹⁵ is ortho to the carbon to which R⁹ is bound to, i.e., the R⁹-R¹⁰- moϊety is:

Other embodiments for the compounds of formula (i) are directed to any one of the above embodiments wherein R¹⁰ is:

(wherein the -OCH₃ is ortho to the carbon to which R⁹ is bound to, i.e., the R⁹-R¹⁰- moiety is:

In another embodiment of the compounds of formula (i) R^1A is benzofusedcycioalkyl. In another embodiment of the compounds of formula (I) R^1A is:

In another embodiment of the compounds of formula (I) R 1^mA i ;s„

In another embodiment of the compounds of formula (I) R 1¹A^A is:

In another embodiment of the compounds of formula (J) R 1 ^mA j is,

in another embodiment of the compounds of formula (I) R I¹A^M is atkyl substituted with one R 2'1 ^! group. in another embodiment of the compounds of formula (I) R is alkyf substituted with one R²¹ group, and said alkyl is

In another embodiment of the compounds of formula (!) R J'A^rt i :s„ aikyl (e.g., (a),

(b) or π (c) described above) substituted with one R²¹ group wherein said R²¹ group is aryl.

In another embodiment of the compounds of formula (I) R^1A is afkyl (e.g., (a), (b) or (c) described above) substituted with one R²¹ group wherein said R²¹ group is phenyl. In another embodiment of the compounds of formula (I) R^1A is alkyl (e.g., (a),

(b) or (c) described above) substituted with one R²¹ group wherein said R²¹ group is naphthyl.

In another embodiment of the compounds of formula (I) R^1A is alky! substituted with one R group, and said R group is substituted with two independently selected R²² groups. in another embodiment of the compounds of formula (i) R^1A is alky! substituted with one R²¹ group, and said R²¹ group is substituted with one R²² group.

In another embodiment of the compounds of formula (I) R^1Λ is alkyl substituted with one R²¹ group, wherein said alkyf group is (a) (e.g., (b) or (c)), as described above, and said R group is substituted with two independently selected R groups,.

In another embodiment of the compounds of formula (I) R^1A is alkyl substituted with one R²¹ group, wherein said alkyl group is (a) (e.g., (b) or (c)), as described above, and said R²¹ group is substituted with one R²² group.

In another embodiment of the compounds of formula (I) R^1A is atkyl substituted with one R²¹ group, wherein said R²¹ group is aryl, and said R²¹ group is substituted with two independently selected R²² groups.

Jn another embodiment of the compounds of formula (!) R^1A is alkyl substituted with one R²¹ group, wherein said R²¹ group is aryl, and said R²¹ group is substituted with one R²² group. !n another embodiment of the compounds of formula (I) R^1A is atkyl substituted with one R²¹ group, wherein said R²¹ group is aryf, said alkyl group Is (a) (e.g., (b) or (c)), as described above, and said R²¹ group is substituted with two independently selected R²² groups. in another embodiment of the compounds of formula (J) R^1A is alkyl substituted with one R²¹ group, wherein said R²¹ group is aryl_; wherein said alkyl group is (a) (e.g., (b) or (c))_s as described above, and said R²¹ group is substituted with one R²² group.

In another embodiment of the compounds of formula (i) R^1A is alkyl substituted with one R²¹ group, wherein said R²¹ group is aryl, said R²¹ group is substituted with two independently selected R ² groups, and each R²² is halo.

In another embodiment of the compounds of formula (I) R 1A i ■s alkyl substituted with one R²¹ group, wherein said R²¹ group is aryl, and said R²¹ group is substituted with one R²² group, and said R²² is halo. In another embodiment of the compounds of formula (I) R^1A is alkyl substituted with one R²¹ group, wherein said R²ⁱ group is aryf, said alkyl group is (a) (e.g., (b) or (c)), as described above, and said R²¹ group is substituted with two independently selected R²² groups, and each R²² is halo.

In another embodiment of the compounds of formula (I) R^1A is alkyl substituted with one R²¹ group, wherein said R²¹ group is aryl, wherein said aikyl group is (a) (e.g., (b) or (c)), as described above, and said R²¹ group is substituted with one R²² group, and said R²² is halo.

In another embodiment of the compounds of formula (I) R^1A is aikyl substituted with one R²¹ group, wherein said R²¹ group is aryl, said R²¹ group is substituted with two independently selected R²² groups, and each R²² is F.

In another embodiment of the compounds of formula (I) R^1A is alkyl substituted with one R²¹ group, wherein said R²¹ group is aryl, and said R²¹ group is substituted with one R²² group, and said R²² is F.

In another embodiment of the compounds of formula (I) R^1A is alkyl substituted with one R²¹ group, wherein said R²¹ group is aryi, said alkyl group is (a) (e.g., (b) or (c)), as described above, and said R²¹ group is substituted with two independently selected R²² groups, and each R²² is F,

In another embodiment of the compounds of formula (!) R^1A is afkyl substituted with one R²¹ group, wherein said R²¹ group is aryl, wherein said alkyl group is (a) (e.g., (b) or (c)), as described above, and said R group is substituted with one R ~ group, and said R²² is F.

In another embodiment of the compounds of formula (J) R^1A is:

In another embodiment of the compounds of formula (I) R^1A is:

in another embodiment of the compounds of formula (I) R^1A is:

In another embodiment of this invention R^1A is:

Examples of R²¹ groups include -OR¹⁵ wherein, for example, R¹⁵ is alkyl (such as methyl or ethyl), or R¹⁵ is cycloalkyiafkyi (such as, for example, -CH^-cyclopropyl), or R¹⁵ is -a!kyl-(R¹⁸)r, (wherein, for example, said R¹⁸ is -OR²⁰, and said R²⁰ is aikyi, and wherein examples of said -alkyJ-(R^ia)_n moiety is -(CH₂^OCHs). Examples of R²¹ also include -C(O)OR¹⁵ wherein, for example, R¹⁵ is alkyl, such as, for example, methyl).

Examples of R²¹ also include -C(O)NR¹⁵R¹⁶ , wherein, for example, one of R¹⁵ or R^1β is H₁ and the other is selected from the group consisting of: (R^1s)_n-ary!alkyi-, (R¹Vafkyh and cycloaϊkyl. In one example of this -C(O)NR¹⁵R¹⁸ moiety the R¹⁸ is -OR²⁰, n is 1, R²⁰ is aikyi, said cycloalkyl is cyclobutyl, and said aryialkyl- is benzyl. Examples of R²¹ also include halo (e.g., Br₅ Cl or F). Examples of R²¹ also include aryialkyl, such as_r for example, benzyl. The dashed line between G¹ and the C that R^1A is bound to in the formulas below represents the presence of Ring B (i.e., Ring B is present in the formulas with the dashed line between G¹ and the C that R^1A is bound to). Thus, for example, Ring B is present in formulas IA to IH, 6.2, 10,2, 10.3, 20.2 21.2, and 23.2.

In another embodiment of this invention, the compound of formula (i) is a compound of formula (IA):

(IA) in another embodiment of this invention, the compound of formula (I) is a compound of formula (IB):

(IB)

In another embodiment of this invention, the optional bond between G¹ and G² is present in formula (I).

In another embodiment of this invention, the optional bond between G¹ and G²s absent in formula (I).

In another embodiment of this invention, the optional bond between G¹ and G²s present in formula (!A). in another embodiment of this invention, the optional bond between G¹ and G²s absent in formula (IA). in another embodiment of this invention, the optional bond between G¹ and G²s present in formula (IB). in another embodiment of this invention, the optional bond between G¹ and G² is absent in formula (JB).

In another embodiment of this invention, the compound of formula (i) is a compound of formula (IC):

(IC) in one embodiment of this invention, the compound of formula (I) is a compound of formula (ID):

m

In one embodiment of this invention, the compound of formuia (i) is a compound of formuia (IE):

(JE)

In one embodiment of this invention, the compound of formula (J) is a compound of formula (IF):

(IF)

In one embodiment of this invention, the compound of formula (I) is a compound of formula (IG):

(IG)

In one embodiment of this invention, the compound of formula (I) is a compound of formula (IH):

(IH) in one embodiment of this invention, the compound of formula (I) is a compound of formula (6.2):

In one embodiment of this invention, the compound of formula (J) is a compound of formula (10.2):

In one embodiment of this invention, the compound of formula (I) is a compound of formula (10.3):

In one embodiment of this invention, the compound of formula (!) is a compound of formula (20.2):

In one embodiment of this invention, the compound of formula (I) is a compound of formula (21.2):

in one embodiment of this invention, the compound of formula (I) is a compound of formuta (23.2):

In another embodiment of this invention, Ring (B) is a 6 membered (including the atoms common to Rings (A) and (B)) heterocycloaikyi ring, optionally comprising one additional heteroatom (e.g., -NR²- or -O-),

In another embodiment of this invention, Ring (B) is a 5 membered (including the atoms common to Rings (A) and (B)) heterocycloaikyi ring, optionally comprising one additional heteroatom (e.g., -NR²- or -O-).

In another embodiment of this invention, Ring (B) is a 6 membered (including the atoms common to Rings (A) and (B)) heteroary! ring, optionally comprising one or two additional heteroatoms (e.g., each independently selected from -NR²- or -O-).

In another embodiment of this invention, Ring (B) is a 5 membered (including the atoms common to Rings (A) and (B)) heterocycloaikyi ring, optionally comprising one or two additional heteroatom (e.g., each independently selected from -NR²- or -O-).

Another embodiment of this invention is directed to compounds of formula (I) having the formula:

In one embodiment of this invention R^1A in compound 2A is aryl or substituted aryl, In another embodiment R^1A in compound 2A is phenyl or substituted phenyl. In another embodiment R^1A in compound 2A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 2A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. in another embodiment of this invention R^1A in compound 2A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 2A is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formuta (f) having the formula:

In one embodiment of this invention R OA in compound 2C is aryl or substituted aryi. In another embodiment R OA in compound 2C is phenyl or substituted phenyl. In another embodiment R^1A in compound 2C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 2C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 2C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 2C is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (I) having the formufa:

O R^1A

R⁹-R 10

In one embodiment of this invention R »1A in compound 3A is aryl or substituted aryl. in another embodiment R _\1A i ■n compound 3A is phenyl or substituted phenyl. In another embodiment R^1A in compound 3A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 3A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 3A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 3A is phenyl substituted with 1 F atom. Another embodiment of this invention is directed to compounds of formula ({) having the formula:

iπ one embodiment of this invention R^1A in compound 3C is aryl or substituted aryl. In another embodiment R^1Λ in compound 3C is phenyl or substituted phenyl, in another embodiment R^1A in compound 3C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 3C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1} independently selected halos. (n another embodiment of this invention R^1A in compound 3C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 3C is phenyf substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formufa (I) having the formula:

4A

In one embodiment of this invention R^1A in compound 4A is aryl or substituted aryl. In another embodiment R^1A in compound 4A is phenyl or substituted phenyl, in another embodiment R^1A in compound 4A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A ϊn compound 4A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 4A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 4A is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (!) having the formula:

In one embodiment of this invention R^1A in compound 4C is aryl or substituted aryi. in another embodiment R^1A in compound AC is phenyl or substituted phenyl. In another embodiment R^1A in compound 4C is phenyl substituted with 1 to 3 independently selected R²¹ groups, in another embodiment of this invention R^IA in compound 4C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 4C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) F atoms. In another embodiment of this invention R^1A in compound 4C is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (f) having the formula:

5A In one embodiment of this invention R^1Λ in compound 5A is aryl or substituted aryl. In another embodiment R^1A in compound 5A is phenyl or substituted phenyl. In another embodiment R^1A in compound 5A is phenyl substituted with 1 to 3 independently selected R²¹ groups, fn another embodiment of this invention R^1A in compound 5A is phenyl substituted with 1 to 3 (e.g., 1 to 3_» or 1 to 2, or 1) independently selected halos, In another embodiment of this invention R^1A m ^" compound 5A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 5A is phenyl substituted with 1 F atom.

5B

Another embodiment of this invention is directed to compounds of formula (I) having the formula;

In one embodiment of this invention R ,1A - in compound 5C is aryl or substituted aryl.

In another embodiment R >1A i_:n compound 5C is phenyf or substituted phenyl, in another embodiment R^1A in compound 5C is phenyl substituted with 1 to 3 independently selected R²¹ groups. Jn another embodiment of this invention R^1A in compound 5C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 5Cis phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^tA in compound SC is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (() having the formula:

in one embodiment of this invention R _>1A in compound 6A is ary! or substituted aryf.

,1A • in another embodiment R in compound 6A is phenyl or substituted phenyl. In another embodiment R ,1A in compound 6A is phenyl substituted with 1 to 3 independently selected R _Ϊ2"1 ' groups. In another embodiment of this invention R 1A - in compound 6A is phenyl substituted with 1 to 3 (e.g., 1 to 3. or 1 to 2, or 1 ) independently selected haios. In another embodiment of this invention R^1A in compound 6A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. in another embodiment of this invention R^1Λ in compound 5A is phenyl substituted with 1 F atom.

In one embodiment of this invention R^1A in compound 6C is aryl or substituted aryi. in another embodiment R^1Λ in compound 6C is phenyl or substituted phenyl. In another embodiment R^1A in compound 6C is phenyl substituted with 1 to 3 independently selected R²¹ groups, in another embodiment of this invention R^1A in compound 6C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 6C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 6C is phenyl substituted with 1 F atom.

In one embodiment of this invention R^1A in compound 7A is aryi or substituted aryt In another embodiment R^1A in compound 7A is phenyl or substituted phenyl. In another embodiment R^1A in compound 7A is phenyl substituted with 1 to 3 Independently selected R²¹ groups. In another embodiment of this invention R^1Λ in compound 7A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^M in compound 7A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. !n another embodiment of this invention R^1A in compound 7A is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (f } having the formula:

In one embodiment of this invention R^1A in compound 7C is aryi or substituted aryl. in another embodiment R^1A in compound 7C is phenyl or substituted phenyl, in another embodiment R^1A in compound 7C is phenyl substituted with 1 to 3 independently selected R²¹ groups, in another embodiment of this invention R^1A in compound 7C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) Independently selected halos. In another embodiment of this invention R^1A in compound 7C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 7C is phenyl substituted with 1 F atom.

In one embodiment of this invention R »1A in compound 8A is aryl or substituted aryl.

In another embodiment R i1A i;n compound 8A is phenyl or substituted phenyl. In another embodiment R *1A i ■n compound 8A is phenyl substituted with 1 to 3 independently selected R »21 groups. In another embodiment of this invention R 1A ; i„n compound 8A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1} independently selected halos, In another embodiment of this invention R^1A in compound 8A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms, in another embodiment of this invention R^1A in compound 8A is phenyl substituted with 1 F atom.

in one embodiment of this invention R^1A in compound 8C is aryl or substituted aryl. In another embodiment R^1A in compound 8C is phenyl or substituted phenyl Sn another embodiment R^1Λ in compound 8C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound BC is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. trt another embodiment of this invention R^1A in compound 8C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1} F atoms. In another embodiment of this invention R^1A in compound 8C is phenyl substituted with 1 F atom.

!n one embodiment of this invention R^1A in compound 9A is aryl or substituted ary). In another embodiment R^1A in compound 9A is phenyl or substituted phenyl. In another embodiment R^1A in compound 9A is phenyl substituted with 1 to 3 independently selected R²¹ groups, in another embodiment of this invention R^1A in compound 9A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A In compound 9A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 9A is phenyl substituted with 1 F atom. Another embodiment of this invention is directed to compounds of formula (I) having the formula:

Another embodiment of this invention is directed to compounds of formula (I) having the formula: T7US2008/086030

- 157 -

In one embodiment of this invention R^1A in compound 9C is aryl or substituted aryl In another embodiment R^1A in compound 9C is phenyl or substituted phenyl In another embodiment R^1A in compound 9C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 9C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) independently selected halos. in another embodiment of this invention R^1A in compound 9C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 9C is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formuia (I) having the formula:

In one embodiment of this invention R^iA in compound 12A is aryl or substituted ary!. In another embodiment R^1A in compound 12A is phenyl or substituted phenyl In another embodiment R^1A in compound 12A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 12A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 12A is phenyf substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 12A is phenyl substituted with 1 F atom.

In one embodiment of this invention R^1A in compound 12C is aryl or substituted aryi. in another embodiment R^1A in compound 12C is phenyl or substituted phenyf. in another embodiment R^1A in compound 12C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 12C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. tn another embodiment of this invention R^1A in compound 12C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms, in another embodiment of this invention R^1A in compound 12C is phenyi substituted with 1 F atom. Another embodiment of this invention is directed to compounds of formula (I) having the formula:

In one embodiment of this invention R^1A in compound 13A is aryl or substituted aryi. In another embodiment R^1A in compound 13A is phenyl or substituted phenyl. In another embodiment R^1A in compound 13A is phenyl substituted with 1 to 3 independently selected R²¹ groups, In another embodiment of this invention R^1A in compound 13A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected haios. Jn another embodiment of this invention R^1A in compound 13A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 13A is phenyl substituted with 1 F atom.

in one embodiment of this invention R^1A in compound 13C is aryl or substituted aryt. In another embodiment R^1A in compound 13C is phenyl or substituted phenyl. In another embodiment R^1A in compound 13C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 13C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 13C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. Another embodiment of this invention is directed to compounds of formula (I) having the formula:

Another embodiment of this invention is directed to compounds of formula (I) having the formula :

14A

In one embodiment of this invention R^1A in compound 14A is aryi or substituted ary!. In another embodiment R^1A in compound 14A is phenyl or substituted phenyl. In

,1A - another embodiment R in compound 14A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 14A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) independently selected hatos. In another embodiment of this invention R^1A in compound 14A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms, in another embodiment of this invention R^1A in compound 14A is phenyS substituted with 1 F atom.

In one embodiment of this invention R^1A in compound 14C is aryl or substituted aryi. In another embodiment R^1A in compound 14C is phenyl or substituted phenyl. In another embodiment R^1A in compound 14C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 14C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected haios. in another embodiment of this invention R^1A in compound 14C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 15C is phenyl substituted with 1 F atom.

in one embodiment of this invention R ,1A in compound 15A is aryi or substituted aryi. in another embodiment R )1A i .n compound 15A is phenyl or substituted phenyl. In another embodiment R^1A in compound 15A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 15A is phenyl substituted with 1 to 3 (e.g., 1 to 3₅ or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 15A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 15A is phenyl substituted with 1 F atom

in one embodiment of this invention R^1A in compound 15C is ary) or substituted aryl.

In another embodiment R >1A i •n compound 15C is phenyl or substituted phenyl. In another embodiment R^1A in compound 15C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 15C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R in compound 15C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1} F atoms. In another embodiment of this invention R^1A in compound 15C is phenyl substituted with 1 F atom.

16A

In one embodiment of this invention R i 1A i -n compound 16A is ary! or substituted aryl. In another embodiment R^1A in compound 16A is phenyl or substituted phenyl. In another embodiment R *1A ; in compound 16A is phenyl substituted with 1 to 3 independently selected R²¹ groups, fn another embodiment of this invention R^1A in compound 16A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1} independently selected halos. in another embodiment of this invention R^1A in compound 16A Is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 16A is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to . compounds of formula (I) having the formula:

in one embodiment of this invention R^1A in compound 16C is aryl or substituted aryl. In another embodiment R^1A in compound 16C is phenyl or substituted phenyl, in another embodiment R^1A in compound 16C is phenyl substituted with 1 to 3 independently selected R²¹ groups, fn another embodiment of this invention R^1A in compound 16C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 16C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1} F atoms, in another embodiment of this invention R^1A in compound 16C is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (S) having the formula:

In one embodiment of this invention R^1A fn compound 17A is aryl or substituted aryi. In another embodiment R^1A in compound 17A is phenyl or substituted phenyl. In another embodiment R^1A in compound 17A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 17A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. Jn another embodiment of this invention R^1A in compound 17A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms, in another embodiment of this invention R^1A in compound 17A is phenyl substituted with 1 F atom.

in one embodiment of this invention R^1A in compound 17C is aryl or substituted aryi. In another embodiment R^1A in compound 17C is phenyl or substituted phenyl, fn another embodiment R^1A in compound 17C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 17C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) independently selected hatos. In another embodiment of this invention R^1A in compound 17C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 17C is phenyl substituted with 1 F atom.

In one embodiment of this invention R^1A in compound 18A is aryi or substituted aryl. In another embodiment R^1A in compound 18A is phenyl or substituted phenyl. In another embodiment R^1A in compound 18A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 18A is phenyl substituted with 1 to 3 (e.g., 1 to 3» or 1 to 2, or 1) independently selected halos. in another embodiment of this invention R^1A in compound 18A is phenyl substituted with 1 to 3 {e.g., 1 to 3, or 1 to 2, or 1 ) F atoms. In another embodiment of this invention R^1A in compound 18A is phenyl substituted with 1 F atom.

in one embodiment of this invention R^1A in compound 18C is ary( or substituted aryl. In another embodiment R^1A in compound 18C is phenyl or substituted phenyl, fn another embodiment R^1A in compound f 8C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 18C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) independently selected hafos. In another embodiment of this invention R^1A in compound 18C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) F atoms. In another embodiment of this invention R^1A in compound 18C is phenyl substituted with 1 F atom.

in one embodiment of this invention R >1A i _:n, compound 2OA is aryl or substituted aryl. in another embodiment R^1A in compound 2QA is pheny! or substituted phenyl. In another embodiment R^1A in compound 2OA is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 2OA is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 2OA is phenyl substituted with 1 to 3 (e.g., 1 to 3» or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 2OA is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (!) having the formuia:

In one embodiment of this invention R i1A in compound 2OC is ary! or substituted aryl.

In another embodiment R »1A : in compound 2OC is phenyf or substituted phenyl. In another embodiment R^1A in compound 2OC is phenyl substituted with 1 to 3 independently selected R²¹ groups, in another embodiment of this invention R^1A in compound 2OC is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 20C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 2OC is phenyl substituted with 1 F atom.

fn one embodiment of this invention R^1A in compound 21A is aryi or substituted aryi. In another embodiment R^1A in compound 21A is phenyl or substituted phenyl. In another embodiment R'^A in compound 21 A is phenyl substituted with 1 to 3 independently selected R²¹ groups, in another embodiment of this invention R^1A in compound 21 A is phenyl substituted with 1 to 3 (e.g., 1 to 3_r or 1 to 2, or 1} independently selected halos. In another embodiment of this invention R^1A in compound 21A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 21 A is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (I) having the formuia:

In one embodiment of this invention R^1A in compound 21 C is aryf or substituted aryf. in another embodiment R^1A in compound 21 C is phenyl or substituted phenyl Jn another embodiment R^1A in compound 21 C is phenyl substituted with 1 to 3 independently selected R²¹ groups. Jn another embodiment of this invention R^1A in compound 21C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) Independently selected halos. In another embodiment of this invention R^1A in compound 21C is phenyi substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 21C is phenyi substituted with 1 F atom.

In one embodiment of this invention R 1A i ■n compound 4OA is aryl or substituted aryt.

In another embodiment R i1A i •n compound 4OA is phenyl or substituted phenyl. In another embodiment R^1A in compound 4OA is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 4OA is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected hafos. In another embodiment of this invention R^1A in compound 4OA is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 4OA is phenyl substituted with 1 F atom

In one embodiment of this invention R^1A in compound 4OC is aryl or substituted aryf. In another embodiment R^1A in compound 4OC is phenyl or substituted phenyl. !n another embodiment R^1A in compound 4OC is phenyl substituted with 1 to 3 independently selected R²¹ groups, In another embodiment of this invention R^1A in compound 4OC is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected haios. In another embodiment of this invention R^1A in compound 4OC is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. in another embodiment of this invention R^1A in compound 4OC is phenyl substituted with 1 F atom.

Sn one embodiment of this invention R^1A in compound 41 A is aryl or substituted aryl. In another embodiment R^1A in compound 41 A is phenyl or substituted phenyl Jn another embodiment R^1A in compound 41 A is phenyl substituted with 1 to 3 independently selected R²¹ groups, in another embodiment of this invention R^1A in compound 41 A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected haios. In another embodiment of this invention R^1A in compound 41 A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 41 A is phenyl substituted with 1 F atom

in one embodiment of this invention R^1A in compound 41 C is aryt or substituted aryi. In another embodiment R^1A in compound 41 C is phenyl or substituted phenyl. In another embodiment R^1A in compound 41 C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 41 C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2_» or 1) independently selected halos. In another embodiment of this invention R^1A in compound 41C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2_S or 1) F atoms, in another embodiment of this Invention R^1A in compound 41 C is phenyl substituted with 1 F atom.

Another embodiment of this invention is directed to compounds of formula (I ) having the formula:

In one embodiment of this invention R 1A i :„n compound 42A is aryi or substituted aryt.

}π another embodiment R ,1A i -n compound 42A is phenyl or substituted phenyl. In another embodiment R^1A in compound 42A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 42A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. (n another embodiment of this invention R^1A in compound 42A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. !n another embodiment of this invention R^1A in compound 42A is phenyl substituted with 1 F atom

In one embodiment of this invention R %1A in compound 42C is aryl or substituted aryl.

In another embodiment R ,1A i ;n compound 42C is phenyl or substituted phenyl. In another embodiment R^1A in compound 42C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R'^A in compound 42C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 42C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms. In another embodiment of this invention R^1A in compound 42C is phenyl substituted with 1 F atom.

In one embodiment of this invention R ,1A in compound 43A is aryl or substituted aryf.

In another embodiment R i1A in compound 43A is phenyl or substituted phenyl Jn another embodiment R j1A in compound 43A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 43A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) independently selected haios. In another embodiment of this invention R^1A in compound 43A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) F atoms. In another embodiment of this invention R^1A in compound 43A is phenyl substituted with 1 F atom.

In one embodiment of this invention R^1A in compound 43C is aryl or substituted aryl. In another embodiment R^1A in compound 43C is phenyl or substituted phenyl. In another embodiment R^1A in compound 43C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 43C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 43C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1 ) F atoms. in another embodiment of this invention R^1A in compound 43C is phenyl substituted with 1 F atom.

tn one embodiment of this invention R 1A i :n. compound 55A is aryϊ or substituted aryl.

In another embodiment R ,1A i .n compound 55A is phenyl or substituted phenyl. In another embodiment R^1Λ in compound 55A is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 55A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected halos. In another embodiment of this invention R^1A in compound 55A is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) F atoms, in another embodiment of this invention R^1A in compound 55A is phenyl substituted with 1 F atom.

In one embodiment of this invention R^1A in compound 55C is aryl or substituted aryi. In another embodiment R^1A in compound 55C is phenyl or substituted phenyl, In another embodiment R^1A in compound 55C is phenyl substituted with 1 to 3 independently selected R²¹ groups. In another embodiment of this invention R^1A in compound 55C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1) independently selected haios. In another embodiment of this invention R^1A in compound 55C is phenyl substituted with 1 to 3 (e.g., 1 to 3, or 1 to 2, or 1} F atoms. In another embodiment of this invention R^1A in compound 55C is phenyl substituted with 1 F atom.

Examples of the R²¹ moiety in the embodiments of this invention include, but are not limited to: (a) -OR¹⁵, (b) -OR¹⁵ wherein R¹⁵ is alkyl, (c) -OR¹⁵ wherein R¹⁵ is alkyl and said alkyl is methyl or ethyl, (d) -OR¹⁵ wherein R¹⁵ is cycloalkylatkyl, (e) -OR¹⁵ wherein R¹⁵ is -alkyl-(R¹⁸)_n, (f) -OR¹⁵ wherein R¹⁵ is ~aikyi-(R¹⁸)_n and wherein said R¹⁸ is -OR²⁰, (g) -OR¹⁵ wherein R¹⁵ is -alkyl-(R¹⁸)_n and wherein said R¹⁸ is -OR²⁰ and said R²⁰ is alkyl. Examples of the R²¹ moiety include but are not limited to: -OCH₃, -OCH₂CH₃, -O(CH₂)2OCH₃, and -CHrCydopropyl.

Examples of R²¹ also include -C(O)OR¹⁵ wherein, for example, R¹⁵ is alkyl, such as, for example, methyl). Examptes of R²¹ also include -C(O)NR¹⁵R¹⁶ .wherein, for example, one of R¹⁵ or R¹⁶ is H, and the other is selected from the group consisting of: (R^1s)_n-aryfalkyh (R¹⁸)n-aikyl- and cycloafkyi. In one example of this -C(O)NR¹⁵R¹⁶ moiety the R¹⁸ is -OR²⁰, n is 1, R²⁰ is alkyl, said cycioalkyl is cycfobutyl, and said aryfaikyl- is benzyl. Examples of R²¹ afso include halo (e.g., Br₅ Ci or F).

Examples of R²¹ also include arylaikyi, such as, for example, benzyl. in another embodiment of this invention the compound of formula (}) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (IE), (IF), (IG), and !(H) wherein (a) R^1Λ is a phenyl, or R^1A is a phenyl substituted with one, two or three F,

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: 2A» 3A, 4A, 5A₁ 6A, 7A, 8A₁ 9A, 12A, 13A, 14A, 15A, 16A, 17A₅ 18A, 2OA, 21A, 4OA, 41A, 42A, 43A, and 55A wherein

(a) R^ΪA is a phenyl, or R^1A is a phenyl substituted with one, two or three F.

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: 2C, 3C₁ 4C, 5C, 6C, 7C, 8C, 9C, 12C, 13C, 14C₁ 15C, 16C, 17C, 18C, 20C₁ 21 C, 4OC, 41C₁ 42C, 43C, and 55C wherein (a) R^1Λ is a phenyl, or R^1A is a phenyl substituted with one, two or three F.

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (IE), (IF), (IG), and I(H) wherein (a) R^1A is a phenyl, or R^1A is a phenyl substituted with one, two or three F and

(b) R¹⁰ is phenyl substituted with one -OR¹⁵ group, wherein R^1S is methyl, and (c) R^δ is selected from the group consisting of ϊmidazolyi and imtdazofyl substituted with one methyl group, In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G and G is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (IE), (IF), (IG), and I(H) wherein (a) R^1A is a phenyl substituted with one, two or three F and (b) R¹⁰ is phenyl substituted with one -OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is smidazoiyl substituted with one methyl group.

In another embodiment of this invention the compound of formula (i) is a compound selected from the group consisting of: 2A, 3A, 4A, 5A, QA, 7A, 8A, 9A,

12A₁ 13A, 14A, 15A₅ 16A, 17A, 18A, 20A₁ 21A₁ 4OA, 41A₁ 42A, 43A, and 55A wherein (a) R^1A is a phenyl, or R^1A is a phenyl substituted with one, two or three F and (b) R¹⁰ is phenyf substituted with one -OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazoly! and imidazolyl substituted with one methyl group.

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: 2A, 3A, 4A, 5A, 6A, 7A₅ 8A, 9A, 12A, 13A₅ 14A, 15A, 16A, 17A, 18A₅ 2OA, 21 A, 40A₅ 41 A, 42A, 43A, and 55A wherein (a) R^1A is a phenyl substituted with one, two or three F and (b) R¹⁰ is phenyl substituted with one -OR¹⁵ group, wherein R¹⁵ is methyl, and (c) R⁹ is imidazolyl substituted with one methyl group.

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (IE), (IF), (IG), I(H), 2A, 3A, 4A, 5A₁ 6A, 7A₁ 8A, 9A, 12A, 13A, 14A₅ 15A_t 16A, 17A, 18A, 20A₅ 21A, 40A₅ 41A, 42A, 43A₁ and 55A wherein R^1A is selected from the group consisting of:

!n another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (IE), (IF), (IG), I(H), 2A, 3A, 4A, SA, 6A, 7A₁ 8A, 9A₁ 12A₅ 13A, 14A, 15A, 16A, 17A, 18A, 2OA, 21 A, 40A₁ 41 A, 42A₁ 43A, and 55A wherein R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (!E)₁ (IF), ((G), 1(H)₁ 2A, 3A, 4A, 5A, 6A, 7A, 8A₁ 9A, 12A₁ 13A, 14A, 15A, 16A, 17A, 18A, 20A₁ 21 A, 40A₁ 41 A,

42A₁ 43A, and 55A wherein R *1A ; is selected from the group consisting of:

wherein the R⁹~R¹⁰- moiety is:

In another embodiment of this invention the compound of formula (f) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and & is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (IE), (IF), (IG), i(H), 2A₁ 3A, 4A, 5A₅ 6A, 7A, 8A, 9A, 12A_S 13A, 14A, 15A, 16A, 17A, 18A₁ 2OA, 21 A, 4OA, 41 A, 42A, 43A, and 55A wherein R^1Λ is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (IC), (ID), (IE), (IF), (IG), I(H), 2A, 3A, 4A, 5A₁ 6A₁ 7A, 8A, 9A₁ 12A₅ 13A, 14A, 15A, 16A₁ 17A₅ 18A, 2OA, 21 A, 40A₁ 41A₁

42A, 43A, and 55A wherein R ,1A i .s selected from the group consisting of:

wherein the R⁹-R¹ - moiety is:

In another embodiment of this invention the compound of formula (I) is a compound selected from the group consisting of: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (iC), (ID), (IE), (IF), (IG)₁ J(H), 2A, 3A, 4A₁ 5A, 6A, 7A, 8A, 9A, 12A, 13A, 14A, 15A, 16A, 17A, 18A, 2OA, 21 A, 40A₁ 41 A, 42A, 43A₁ and 55A wherein R^1A is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

Another embodiment of this invention is directed to compounds of formula (I) selected from the group consisting of: compounds of formulas (!A) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, (C to IH₁ 2 to 9, 12 to 18, 20, 21, 40 to 43, 55, 2A to 9A, 12A to 18A, 2OA, 21 A, 4OA to 43A, 55A, 2B to 9B₁ 12B to 18B₁ 2OB, 21B, 40B to 43B₁ 558, 2C to 9C, 12C to 18C, 2OC, 21C₁ 4OC to 43C₁ 55C, 6,2, 9.1 , 10.1, 10.2, 10.3, 14.1, 16.1, 16.2, 18.1 , 19.1, 20.2, 21.2, 23.2, 25.1 , 26.1 , 27.1 , 28.1 , 30.1 , 36.1 , 37.1 , 38,1 , 39.1 , 41.1 , 43.1 , 45,1 , 46.1 , 47.1 , 48.1 , 49,1 , 50.1, 51.1, 52.1, 59.1, 60.1 , 61.1 , 64.1 , 65.1 , 68.1 , 70.1 , E1, E2, and E3.

Another embodiment of this invention is directed to compounds of formula (I) selected from the group consisting of: compounds of formulas (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (SB) wherein the optional bond between G ' and G^* is absent, (IB) wherein the optional bond between G¹ and G² is present, and IC to IH. Another embodiment of this invention is directed to compounds of formula (I) selected from the group consisting of: compounds of formulas 2 to 9, 12 to 18, 20, 21 , 40 to 43, and 55.

Another embodiment of this invention is directed to compounds of formula (I) sefected from the group consisting of: compounds of formulas 2A to 9A, 12A to 18A₁ 2OA, 21 A, 40A to 43A, and 55A.

Another embodiment of this invention is directed to compounds of formula (J) selected from the group consisting of: compounds of formulas 2B to 9B, 12B to 18B, 20B, 21 B, 4OB to 43B, and 55B. Another embodiment of this invention is directed to compounds of formula (I) selected from the group consisting of: compounds of formulas 2C to 9C₁12C to 18C, 20C₁21C, 4OC to 43C₅ and 55C.

Another embodiment of this invention is directed to compounds of formula (!) selected from the group consisting of: compounds of formulas 6.2, 9.1, 10.1, 10.2, 10.3, 14.1, 16.1, 16.2, 18.1, 19.1, 20.2, 21.2, 23.2, 25.1, 26.1, 27.1, 28.1, 30.1, 36.1, 37.1, 38.1, 39.1, 41.1, 43.1, 45.1, 46.1, 47.1, 48.1, 49.1, 50.1, 51.1, 52.1, 59.1, 60.1, 61.1, 64.1, 65.1, 68.1, and 70.1.

Another embodiment of this invention is directed to compounds of formula (i) selected from the group consisting of: compounds of formulas E1, E2, and E3. Another embodiment of this invention is directed to compound E1.

Another embodiment of this invention is directed to compound E2.

Another embodiment of this invention is directed to compound E3. tn the embodiments below Groups A, B, C, D₅ E, F₁ G and H are as defined as follows: (1) Group A: compounds (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, IC to IH, 2 to 9, 12 to 18, 20, 21 , 40 to 43, 55, 2A to 9A, 12A to 18A, 2OA, 21A, 4OA to 43A, 55A, 2B to 9B, 12B to 18B, 20B₅21B, 4OB to 43B, 55B, 2Cto9C_t 12Cto 18C, 20C₅21C, 4OC to 43C₁55C, 6.2, 9.1, 10.1, 10.2,

10.3, 14.1, 16.1, 16.2, 18.1, 19.1, 20.2, 21.2, 23.2, 25.1, 26.1, 27.1, 28.1, 30.1, 36.1, 37.1, 38.1,39.1,41.1,43.1,45.1,46,1,47.1, 48.1, 49.1, 50.1, 51.1, 52.1, 59.1,60.1, 61.1, 64.1, 65.1, 68.1, 70.1, E1, E2, and E3; {2} Group B: compounds (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, and IC to IH; (3) Group C: compounds 2 to 9, 12 to 18, 20, 21 , 40 to 43, and 55;

(4) Group D: compounds 2A to 9A, 12A to 18A, 2OA, 21 A, 4OA to 43A, and 55A;

(5) Group E: compounds 2B to 98, 12B to 188, 20B₁ 21B, 4OB to 43B, and 55B; (6) Group F: compounds 2C to 9C, 12C to 18C, 20C₁ 21C₁ 4OC to 43C, and

55C;

(7) Group G: compounds 6.2, 9.1 , 10.1 , 10.2, 10.3, 14.1 , 16.1 , 16.2, 18.1 , 19.1 , 20.2, 212, 23.2, 25,1 , 26.1 , 27.1 , 28.1 , 30.1 , 36.1 , 37.1 , 38.1 , 39.1 , 41.1 , 43.1 , 45.1, 46.1, 47.1, 48.1, 49.1, 50.1, 51.1 , 52.1, 59.1 , 60.1 , 61.1 , 64.1, 65.1, 68.1 , and 70.1 ; and

(8) Group H: compounds E1, £2, and E3.

Another embodiment of this invention is directed to a compound of formula (I). Another embodiment of this invention is directed to a pharmaceutically acceptable salt of a compound of formula (I). And in one example the salt is a salt of a compound selected from the group consisting of Group A. And in another example the salt is a salt of a compound selected from the group consisting of Group B. And in another example the salt is a sait of a compound selected from the group consisting of Group C. And in another example the salt is a salt of a compound selected from the group consisting of Group D. And in another example the saft is a salt of a compound selected from the group consisting of Group E. And in another example the salt is a saft of a compound selected from the group consisting of Group F. And in another example the salt is a salt of a compound selected from the group consisting of Group G. And in another example the salt is a salt of a compound selected from the group consisting of Group H. Another embodiment of this invention is directed to a pharmaceutically acceptable ester of a compound of formula (I). And in one example the ester is an ester of a compound selected from the group consisting of Group A. And in another example the ester is an ester of a compound selected from the group consisting of Group B. And in another example the ester is an ester of a compound selected from the group consisting of Group C. And in another example the ester is an ester of a compound selected from the group consisting of Group D, And in another example the ester is an ester of a compound selected from the group consisting of Group E. And in another example the ester is an ester of a compound selected from the group consisting of Group F. And in another example the ester is an ester of a compound selected from the group consisting of Group G, And in another example the ester is an ester of a compound selected from the group consisting of Group H,

Another embodiment of this invention is directed to a solvate of a compound of formula (i). And in one example the solvate is a solvate of a compound selected from the group consisting of Group A. And in another example the solvate is a solvate of a compound selected from the group consisting of Group B. And in another example the solvate is a solvate of a compound selected from the group consisting of Group C, And in another example the solvate is a solvate of a compound selected from the group consisting of Group D. And in another example the solvate is a solvate of a compound selected from the group consisting of Group E. And in another example the solvate is a solvate of a compound selected from the group consisting of Group F. And in another example the solvate is a solvate of a compound selected from the group consisting of Group G. And in another example the solvate is a solvate of a compound selected from the group consisting of Group H. Another embodiment of this invention is directed to a compound of formula (I) in isolated form. And in one example the compound of formula (I) is selected from the group consisting of Group A. And in one example the compound of formula (!) is selected from the group consisting of Group D. And in one example the compound of formula (I) is selected from the group consisting of Group E. And in one example the compound of formula (I) is selected from the group consisting of Group F. And in one example the compound of formula (I) is selected from the group consisting of Group G. And in one example the compound of formula (I) is selected from the group consisting of Group H,

Another embodment of this invention is directed to a compound of formula (I) in pure form. And in one example the compound of formula (I) is selected from the group consisting of Group A. And in one example the compound of formula (!) is selected from the group consisting of Group D. And in one example the compound of formula (I) is selected from the group consisting of Group E. And in one example the compound of formula (I) is selected from the group consisting of Group F. And in one example the compound of formula (I) is selected from the group consisting of Group G. And in one example the compound of formula (I) is selected from the group consisting of Group H.

Another embodiment of this invention is directed to a compound of formula (!) in pure and isolated form. And in one example the compound of formula (J) fs selected from the group consisting of Group A. And in one example the compound of formula (I) is selected from the group consisting of Group D. And in one example the compound of formula (I) is selected from the group consisting of Group E. And in one example the compound of formula (!) is selected from the group consisting of Group F. And in one example the compound of formula (I) is selected from the group consisting of Group G. And in one example the compound of formula (I) is selected from the group consisting of Group H.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, or ester thereof, and one or more (e.g., one) pharmaceutically acceptable carriers.

Another embodiment is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I) and a pharmaceutically acceptable carrier. Another embodiment is directed to a pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable salt of one or more (e.g., one) compounds of formula (I) and a pharmaceutically acceptable carrier.

Another embodiment is directed to a pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable ester of one or more (e.g., one) compounds of formula (I) and a pharmaceutically acceptable carrier.

Another embodiment is directed to a pharmaceutical composition comprising an effective amount of a solvate of one or more {e.g., one) compounds of formula 0) and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and an effective amount of one or more (e.g., one) other pharmaceutically active ingredients (e.g., drugs), and a pharmaceutically acceptable carrier. Examples of the other pharmaceutically active ingredients include, but are not limited to drugs selected form the group consisting of: (a) drugs useful for the treatment of US2008/086030

- 188 -

Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase. Another embodiment of this invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of one or more (e.g. one) compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, or ester thereof, and one or more (e.g., one) pharmaceutically acceptable carriers, and an effective amount of one or more compounds selected from the group consisting of chotinesterase inhibitors, Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more BACE inhibitors, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more cholinesterase inhibitors (e.g., acetyl- and/or butyrytchlolinesterase inhibitors), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I).

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more muscarinic antagonists (e.g., mi agonist or m₂ antagonists), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I)₁ and effective amount of Exelon (rivastigmine), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of Cognex (tacrine), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of a Tau kinase inhibitor, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more Tau kinase inhibitor (e.g., GSK3beta inhibitor, cdk5 inhibitor, ERK inhibitor), and a pharmaceutically acceptable carrier,

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one anti-Abeta vaccine (active immunization), and a pharmaceutically acceptable carrier. Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more APP ligands, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more agents that upregulate insulin degrading enzyme and/or neprilysin, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more cholesterol towering agents (for example, statins such as Atorvastatin, Fiuvastatin, Lovastatin, Mevastatin, Pravastatin, Pravastatin, Rosuvastatin, Simvastatin, and chøtesteroi absorption inhibitor such as Ezetimibe), and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more fibrates (for example, clofibrate, Clofibride, Etofibrate, Aluminium Clofibrate), and a pharmaceutically acceptable carrier 2008/086030

- 190 -

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more LXR agonists, and a pharmaceutically acceptable carrier. Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (!), and effective amount of one or more LRP mimics, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more 5-HT6 receptor antagonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more nicotinic receptor agonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more H3 receptor antagonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (i), and effective amount of one or more histone deacetylase inhibitors, and a pharmaceutically acceptable carrier. Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formufa ((), and effective amount of one or more hsp90 inhibitors, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more ml muscarinic receptor agonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to combinations, i.e., a pharmaceutical composition, comprising a pharmaceutically acceptable carrier, an effective (i.e., therapeutically effective) amount of one or more compounds of formula

(I), in combination with an effective (i.e., therapeutically effective) amount of one or more compounds selected from the group consisting of choϊinesterase inhibitors

(such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(pheny!methyl)-4- piperidiny!jmethyij~1 W -inden-1-one hydrochloride, i.e., donepezif hydrochloride, available as the Aricept^® brand of donepezi! hydrochloride), βψ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more 5-HT6 receptor antagonists mGluRI or mGIuRS positive allosteric modulators or agonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more one mGluR2/3 antagonists, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (J), and effective amount of one or more anti-inflammatory agents that can reduce neuroinflammation, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more Prostaglandin EP2 receptor antagonists, and a pharmaceutically acceptable carrier. Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formufa (I), and effective amount of one or more PAf-1 inhibitors, and a pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a pharmaceutical composition comprising an effective amount of one or more (e.g., one) compounds of formula (I), and effective amount of one or more agents that can induce Abeta efflux such as gelsolin, and a pharmaceutically acceptable carrier. Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula (I) is selected from the group consisting of Group A.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula (I) is selected from the group consisting of Group B.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula (I) is selected from the group consisting of Group C. Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula (t) is selected from the group consisting of Group D.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula (I) is selected from the group consisting of Group E,

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula ((} is selected from the group consisting of Group F.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula (I) is selected from the group consisting of Group G.

Other embodiments of this invention are directed to any one of the above embodiments directed to pharmaceutical compositions wherein the compound of formula (J) is selected from the group consisting of Group H. The compounds of formula (I) can be useful as gamma secretase modulators and can be useful in the treatment and prevention of diseases such as, for exampfe, central nervous system disorders (such as Alzheimers disease and Downs Syndrome), mild cognitive impairment, glaucoma, cerebral amyloid angiopathy, stroke, dementia, microglϊosis, brain inflammation, and olfactory function loss. Another embodiment of this invention is directed to a method of treating a central nervous system disorder comprising administering a therapeutically effective amount of at least one compound of formula (!) to a patient in need of such treatment.

Another embodiment of this invention is directed to a method of treating a centrai nervous system disorder comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formula (I)₁ or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier.

Another embodiment of this invention is directed to a method of treating a centrat nervous system disorder comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formula (1), or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and a therapeutically effective amount of one or more compounds selected from the group consisting of choϋnesterase inhibitors, flφ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors.

Thus, another embodiment of this invention is directed to a method for modulating (including inhibiting, antagonizing and the like) gamma-secretase comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I) to a patient in need of such treatment.

Another embodiment of this invention is directed to a method for modulating (including inhibiting, antagonizing and the like) gamma-secretase, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (I) to a patient in need of treatment. Another embodiment of this invention is directed to a method of treating one or more neurodegenerative diseases, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating one or more neurodegenerative diseases, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (i) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (t) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (I) to a patient in need of treatment. Another embodiment of this invention is directed to a method of treating

Alzheimer's disease, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (t) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating mild cognitive impairment, glaucoma, cerebral amyloid angiopathy, stroke, dementia, microgliosis, brain inflammation, or olfactory function loss, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating mild cognitive impairment, glaucoma, cerebral amyloid angiopathy, stroke, dementia, microgliosis, brain inflammation, or olfactory function loss, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating mild cognitive impairment, comprising administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating glaucoma, comprising administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating cerebral amyloid angiopathy, comprising administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating stroke, comprising administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment. Another embodiment of this invention is directed to a method of treating dementia, comprising administering an effective amount of one or more (e.g., one} compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating microgϋosis, comprising administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating brain inflammation, comprising administering an effective amount of one or more (e.g., one) compounds of formula (I) to a patient in need of treatment. Another embodiment of this invention is directed to a method of treating olfactory function loss, comprising administering an effective amount of one or more (e.g., one) compounds of formufa (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Downs syndrome, comprising administering an effective amount of one or more (e.g., one) compounds of formula (t) to a patient in need of treatment.

Another embodiment of this invention Is directed to a method of treating Downs syndrome, comprising administering an effective amount of a compound of formula (I) to a patient in need of treatment.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (I) is selected from the group consisting of Group A.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (i) is selected from the group consisting of Group B. Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (I) is selected from the group consisting of Group C.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (I) is selected from the group consisting of Group D.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (I) is selected from the group consisting of Group E. Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (I) is selected from the group consisting of Group F,

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (I) is selected from the group consisting of Group G.

Other embodiments of this invention are directed to any one of the above embodiments directed to methods of treating wherein the compound of formula (f) is selected from the group consisting of Group H. This invention also provides combination therapies for (1 ) modulating gamma- secretase, or (2) treating one or more neurodegenerative diseases, or (3) inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (4) treating Alzheimer's disease. The combination therapies are directed to methods comprising the administration of one or more (e.g. one) compounds of formula (i) and the administration of one or more (e.g., one) other pharmaceutical active ingredients (e.g., drugs). The compounds of formula (I) and the other drugs can be administered separately (i.e., each is in its own separate dosage form), or the compounds of formula (I) can be combined with the other drugs in the same dosage form. Thus, other embodiments of this invention are directed to any one of the methods of treatment, or methods of inhibiting, described herein, wherein an effective amount of the compound of formuia (i) is used in combination with an effective amount of one or more other pharmaceutically active ingredients (e.g., drugs). The other pharmaceutically active ingredients (i.e., drugs) are selected from the group consisting of: BACE inhibitors (beta secretase inhibitors), muscarinic antagonists (e.g., m-i agonists or m₂ antagonists), choltnesterase inhibitors (e.g., acetyl- and/or butyη/ichtoim^' esterase inhibitors); gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyi-D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB 1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABAA inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors; Exefon (rivastigmϊne); Cognex (tacrine); Tau kinase inhibitors {e.g., GSKSbeta inhibitors, cdk5 inhibitors, or ERK inhibitors); anti- Abeta vaccine; APP iigands; agents that upregυiate insulin cholesterol lowering agents (for example, statins such as Atorvastatin, Fluvastatin, Lovastatin, Mevastatin, Pravastatin, Pravastatin, Rosuvastatin, Simvastatin); cholesterol absorption inhibitors (such as Ezetimibe); fibrates (such as, for example, for example, ctafibrate, Clofibride, Etofibrate, and Aluminium Clofibrate); LXR agonists; LRP mimics; nicotinic receptor agonists; H3 receptor antagonists; histone deacβtyfase inhibitors; hspδO inhibitors; ml muscarinic receptor agonists; 5-HT6 receptor antagonists; mGfuRf ; mGiuRS; positive altosteric modulators or agonists; mGluR2/3 antagonists; anti-inflammatory agents that can reduce neuroinflammation; Prostaglandin EP2 receptor antagonists; PAI-1 inhibitors; and agents that can induce Abeta efflux such as gelsolin.

Other embodiments of this invention are directed to any one of the methods of treatment, or methods of inhibiting, described herein, wherein the compound of formula (I) is used in combination with an effective amount of one or more other pharmaceutically active ingredients selected from the group consisting of: BACE inhibitors (beta secretase inhibitors), muscarinic antagonists (e.g., mi agonist or rri₂ antagonists), cholinesterase inhibitors (e.g., acetyl- and/or butyrylchlolinesterase inhibitors); gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyl-D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB 1 receptor inverse agonists or CB 1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AIvIPA agonists; PDE4 inhibitors; GABA_A inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE- 10 inhibitors and cholesterol absorption inhibitors (e.g., ezetimibe).

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I), in combination with an effective (i.e., therapeutically effective) amount of one or more choffnesterase inhibitors (such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyi)-4- piperidinyi]methyi]-1 H -inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept^® brand of donepezil hydrochloride), to a patient in need of treatment. Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (I)₁ in combination with an effective (i.e., therapeutically effective) amount of one or more (e.g., one) choiinesterase inhibitors (such as, for example, (±)-2,3-dihydro-5,6-dimethoxy-2-[f1-(phenyimethy!)-4- piperidinyt]methy!]~1 H -inden-1-one hydrochloride, i.e., donepezit hydrochloride, available as the Aricept^® brand of donepezil hydrochloride), to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (J), in combination with an effective (i.e., therapeutically effective) amount of one or more compounds selected from the group consisting of Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors. Another embodiment of this invention is directed to a method of treating

Alzheimer's disease, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I), in combination with an effective (i.e., therapeutically effective) amount of one or more BACE inhibitors. Another embodiment of this invention is directed to a method of treating

Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (J), in combination with an effective amount of Exelon (rivastigmine).

Another embodiment of this invention Is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (!), in combination with an effective amount of Cognex (tacrine).

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (i), in combination with an effective amount of a Tau kinase inhibitor.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more Tau kinase inhibitor (e.g., GSK3beta inhibitor, cdkδ inhibitor, ERK inhibitor).

This invention atso provides a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula {!), in combination with an effective amount of one anti-Abeta vaccination (active immunization).

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formufa (I)₅ in combination with an effective amount of one or more APP ligands.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more agents that upregulate insulin degrading enzyme and/or neprilysin. Another embodiment of this invention is directed to a method of treating

Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more cholesterol lowering agents (for example, statins such as Atorvastatin, Fluvastattn, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, and cholesterol absorption inhibitor such as Ezetimibe).

This invention also provides a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more fibrates (for example, ciofibrate, Clofibride, Etofibrate, Aluminium CJofibrate). Another embodiment of this invention is directed to a method of treating

Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I)₁ in combination with an effective amount of one or more LXR agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more LRP mimics.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering: an effective amount of one or more - 20G - compounds of formula (I), in combination with an effective amount of one or more 5- HT6 receptor antagonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more nicotinic receptor agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more H3 receptor antagonists.

This invention also provides a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I)₁ in combination with an effective amount of one or more histone deacetylase inhibitors. Another embodiment of this invention is directed to a method of treating

Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more hsp9G inhibitors.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I)₅ in combination with an effective amount of one or more ml muscarinic receptor agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (f), in combination with an effective amount of one or more 5- HT6 receptor antagonists mG!uR1 or mGluRS positive aliosteric modulators or agonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more mGluR2/3 antagonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's <feease_s comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more anti-inflammatory agents that can reduce neuroinffammation.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more Prostaglandin EP2 receptor antagonists.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more PAI-1 inhibitors.

Another embodiment of this invention is directed to a method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula (I), in combination with an effective amount of one or more agents that can induce Abeta efflux such as gelsolin. Another embodiment of this invention is directed to a method of treating

Downs syndrome, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (i) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Downs syndrome, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (I) to a patient in need of treatment.

Another embodiment of this invention is directed to a method of treating Downs syndrome, comprising administering an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I), in combination with an effective (i.e., therapeutically effective) amount of one or more cholinesterase inhibitors (such as, for example, (±)-2,3~dihydro-5,6-dimethoxy~2-[[1-(phenylmethyl)-4~ pipertdmyljmethyl]-1 H-inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept^® brand of donepezil hydrochloride), to a patient in need of treatment, Another embodiment of this invention is directed to a method of treating

Downs syndrome, comprising administering an effective (i.e., therapeutically effective) amount of a compound of formula (I), in combination with an effective (i.e., therapeutically effective) amount of one or more (e.g., one) cholinesterase inhibitors (such as, for example, (±)-2,3-dfhydro-5,6-dimethoxy~2-[f1~(pneny!metnyi>-4- piperidinyljmethyl]-1 H -inden-1-one hydrochloride, i.e., donepezil hydrochloride, available as the Artcept^® brand of donepezil hydrochloride), to a patient in need of treatment.

Another embodiment of this invention is directed to combinations (i.e., pharmaceutical compositions) comprising an effective (i.e., therapeutically effective) amount of one or more (e.g., one) compounds of formula (I)₁ in combination with an effective (i.e., therapeutically effective) amount of one or more compounds selected from the group consisting of choiinesterase inhibitors (such as, for example, (±)-2,3- dihydro-5,6-dimethoxy-2-[[1 -(phenytmethyl)-4-piperidinyi]methyi]-1 H -inden-1 -one hydrochloride, i.e., donepezil hydrochloride, available as the Aricept^® brand of donepezil hydrochloride), Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors. The pharmaceutical compositions also comprise a pharmaceutically acceptable carrier.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (I) are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula (I) is selected from the group consisting of Group A.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (I) are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula (I) is selected from the group consisting of Group B.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (I) are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formufa (I) is selected from the group consisting of Group C.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (!) are used in combination with other pharmaceutically active ingredients, Le., drugs) wherein the compound of formula (I) is selected from the group consisting of Group D. Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (I) are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula (I) is selected from the group consisting of Group E.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (!) are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula (1) is selected from the group consisting of Group F.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (I) are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula (I) is selected from the group consisting of Group G.

Other embodiments of this invention are directed to any one of the above embodiments directed to combination therapies (i.e., the above methods of treating wherein compounds of formula (I) are used in combination with other pharmaceutically active ingredients, i.e., drugs) wherein the compound of formula (I) is selected from the group consisting of Group H.

Another embodiment of this invention is directed to a kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of formula (I) in a pharmaceutically acceptable carrier, and another container (i.e., a second container) comprises an effective amount of another pharmaceutically active ingredient (as described above), the combined quantities of the compound of formula (I) and the other pharmaceutically active Ingredient being effective to: (a) treat Alzheimer's disease, or (b) inhibit the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (c) treat neurodegenerative diseases, or (d) modulate the activity of gamma-secretase, or (e) mild cognitive impairment, or (f) glaucoma, or (g) cerebral amyloid angiopathy, or (h) stroke, or (i) dementia, or (J) microgliosis, or (k) brain inflammation, or (I) olfactory function loss. Another embodiment of this invention is directed to a kit comprising, in separate containers_* in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of one or more (e.g., one) compounds of formula (I) in a pharmaceutically acceptable carrier, and another container (i.e., a second container) comprises an effective amount of another pharmaceutically active ingredient (as described above), the combined quantities of the compounds of formula (I) and the other pharmaceutically active ingredient being effective to: (a) treat Alzheimer's disease, or (b) inhibit the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g_M the brain), or (c) treat neurodegenerative diseases, or (d) modulate the activity of gamma- secretase.

Another embodiment of this invention is directed to a kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of formula (I) in a pharmaceutically acceptable carrier, and another container (i.e., a second container) comprises an effective amount of another pharmaceutically active ingredient (as described above), the combined quantities of the compound of formula (I) and the other pharmaceutically active ingredient being effective to: (a) treat Alzheimer's disease, or (b) inhibit the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain), or (c) treat neurodegenerative diseases, or (d) modulate the activity of gamma-secretase.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula (J) is selected from the group consisting of Group A. Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula (I) is selected from the group consisting of Group B.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula (I) is selected from the group consisting of Group C.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula (!) is selected from the group consisting of Group D. Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formufa (I) is selected from the group consisting of Group E.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formufa (I) is selected from the group consisting of Group F.

Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula (J) is selected from the group consisting of Group G. Other embodiments of this invention are directed to any one of the above embodiments directed to kits wherein the compound of formula (I) is selected from the group consisting of Group H.

Examples of cholinesterase inhibitors are tacrine, donepezii, rivastigmine, galantamine, pyridostigmine and neostigmine, with tacrine, donepezii, rivastigmine and gaiantamine being preferred.

Examples of mi agonists are known in the art. Examples of m≤ antagonists are also known in the art; in particular, m₂ antagonists are disclosed in US patents 5,883,006; 6,037,352; 5,889,006; 6,043,255; 5,952,349; 5,935,958; 6,066,636; 5,977,138; 6,294,554; 6,043,255; and 6,458,812; and in WO 03/031412, all of which are incorporated herein by reference.

Examples of BACE inhibitors include those described in: US2005/0119227 published 06/02/2005 (see also WO2005/016876 published 02/24/2005), US2005/0043290 published 02/24/2005 (see also WO2005/014540 published 02/17/2005 ), WO2005/058311 published 06/30/2005 (see also US2007/0072852 published 03/29/2007), US2006/0111370 published 05/25/2006 (see also

WO2006/065277 published 06/22/2006), US Application Serial No. 11/710582 filed 02/23/2007, US2006/0040994 published 02/23/2006 (see also WO2006/014762 published 02/09/2006), WO2006/014944 published 02/09/2006 (see also US2006/0040948 published 02/23/2006), WO2006/138266 published 12/28/2006 (see also US2007/0010667 published 01/11/2007), WO2006/138265 published 12/28/2006, WO2006/138230 published 12/28/2006, WO2006/138195 published 12/28/2006 (see also US2006/0281729 published 12/14/2006), WO2006/138264 published 12/28/2006 (see also US2007/0060575 published 03/15/2007), WO2006/138192 pubfished 12/28/2006 (see also US2006/0281730 published 12/14/2006), WO2006/138217 published 12/28/2006 (see also US2006/0287294 published 12/21/2006), US2007/0099898 published 05/03/200 (see also WO2007/050721 published 05/03/2007), WO2007/053506 published 05/10/2007 (see also US2007/099875 published 05/03/2007), U.S. Application Serial No. 11 /759336 filed 06/07/2007, U.S. Application Serial No. 60/874362 filed 12/12/2006, and U.S. Application Serial No. 60/874419 filed 12/12/2006, the disclosures of each being incorporated incorporated herein by reference thereto.

It is noted that the carbons of formula (I) and other formulas herein may be replaced with 1 to 3 silicon atoms so long as ail valency requirements are satisfied. As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

"Patient" includes both human and animals.

"Mammal" means humans and other mammalian animals.

One or more" means that there is at least one and there can be more than one, and examples include 1 , 2 or 3, or 1 and 2, or 1.

"At least one" means there is at least one and there can be more than one, and examples include 1 , 2 or 3, or 1 and 2, or 1.

"BINAP" means 2,2'-bis(diphenylphosphϊno)-1_!1'-binaphthyl.

"Bn" means benzyl. "DCM" means dichloromethane.

"DlEA" means N^-diisopropyiethylamine.

"EDC" means 1-(3-dtmethy!aminopropyl)-3-ethylcarbodiimide.

"Ef means ethyl.

"HOBT" means 1~hydroxybenzotriazole. "i-pr" means isopropyt.

"Me" means methyl.

"NBS" means N-bromosuccinimide.

"NMP" means 1-methyl~2-pyrrolidinone.

"OTMS" means trimetbytsilyloxy. "PEG" means polyethylene glycol

"Pr" means propyl.

¹I-Bu" means tert-butyl.

"TMSOTf means trimethyisifyi trffluoromethanesulfonate. Tused benzocycloalkyi ring" means a phenyl ring fused to a cycioatkyi ring (as cycloalkyi is defined below), such as, for example,

"Alky!" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyi groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyi chain. "Lower aikyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. "Alkyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyi, cyano, hydroxy, aikoxy, alkylthio, amino, oxime (e.g., =N- OH)₅ -NH(alkyi), -NH(cycioalkyl), -N(alky!)₂, -O-C(O)-alkyl, -O-C(O)-aryl, -0-C(O)- cycloalkyi, carboxy and -C(O)O-alkyl. Non-limiting examples of suitable alkyf groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.

"Aikenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred aikenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alky! groups such as methyl, ethyl or propyl, are attached to a linear aikenyl chain. "Lower aikenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched, "Atkenyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substϊtuenf being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyi, cyano, aikoxy and -S(alkyl). Non-limiting examples of suitable alkeny! groups include ethenyi, propenyl, n-butenyl, 3-methy!but-2-enyl, n-pentenyi, octenyl and decenyl.

"Alkylene" means a difunctional group obtained by removal of a hydrogen atom from an afkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene. "AlkynyS" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear aikynyt chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyϊ groups include ethynyl, propynyl, 2-butynyl and 3-methyibutynyl. "Alkynyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyi, aryl and cycloalkyl.

"Aryl" means an aromatic monocyclic or muiticyciic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.

"Heteroaryl" means an aromatic monocyclic or muiticyciic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom, A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N- oxide. "Heteroaryl" may also include a heteroaryl as defined above fused to an aryl as defined above. Non-limiting examples of suitable heteroaryls include pyridyl, pyraziny!, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazoϊyl, isothiazolyl, oxazolyl, thiazofyt, pyrazolyl, furazanyl, pyrrøiyl, pyrazofyl, triazotyl, 1 ,2,4-thiadiazoiyi, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyi, oxindolyl, fmidazo[1,2-a3pyridinyl, imidazof2,1-b]thiazo!y!, benzofurazanyl, indoiyl, azaindolyl, benzimidazolyf, benzothienyl, qurnolinyf, imidazolyl_r thienopyridyl, quinazoiinyl, thienopyrimidyl, pyrroiopyridyi, imidazopyridyl, isoquinotinyl, benzoazaindolyl, 1,2,4- triazinyi, benzothiazoiyl and the like. The term "heteroary!" also refers to partially saturated heteroary! moieties such as, for example, tetrahydroisαquinolyt, tetrahydroquinoiyl and the iike.

"Aralkyf or "arytaikyl" means an aryl-alkyl- group in which the aryl and alkyϊ are as previously described. Preferred aralkyls comprise a tower alky! group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethy( and naphthatenylmethyl. The bond to the parent moiety is through the alkyi.

"Afkyiaryf" means an afkyl-aryl- group in which the alkyi and aryl are as previously described. Preferred alkylaryls comprise a lower alkyi group. Non-limiting example of a suitable atkytaryl group is tolyl. The bond to the parent moiety is through the aryl.

"Cycloaikyl" means a non-aromatic mono- or multicyciic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyt can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls incfude 1-decafinyl, norbornyl, adamantyl and the like. "Cycloalkylalkyl" means a cycloalkyl moiety as defined above linked via an alkyi moiety (defined above) to a parent core. Non-limiting examples of suitable cyclαalkylalkyis include cyclohexySmethyl, adamantylmethyl and the like.

"Cycloalkenyl" means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contains at least one carbon-carbon double bond. Preferred cydoatkenyi rings contain about 5 to about 7 ring atoms. The cycioalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloaikenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1 ,3-dienyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbornylenyJ.

"Cycloalkenylafkyi" means a cycloalkenyl moiety as defined above linked via an alkyi moiety (defined above) to a parent core. Non-limiting examples of suitable cycfoalkenylalkyls incfude cyclopentenylmethyl, cyclohexenyJmethyl and the like. "Haiogen" means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine. "Halo" refers to fiuoro, chloro, bromo or iodo.

"Ring system sυbstitυent" means a substituent attached to an aromatic or non- aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of afkyt, alkeny!, alkynyi, aryl, heteroaryi, aralkyl, afkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyf, atkylheteroaryf, hydroxy, hydroxyalkyl, aikoxy, aryϊoxy, aralkoxy, acyl, aroyi, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsuifony!, aikytthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, =0, =N-OYi, -O-C(O)~alkyl, -O- C(O)-aryi, -O-C(O)-cyc!oalkyl, -C(=N-CN)-NH₂, -C(=NH)-NH₂, -C(=NH)-NB(alkyi), oxime (e.g., =N-OH), YiY₂N-, YiY₂N-alkyi-, Y₁Y₂NC(O)-, Y₁Y₂NSO₂- and -SO₂NYiY₂, wherein Y₁ and Y₂ can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycioalkyl, and aralkyl. "Ring system substituent" may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH₃)₂- and the like which form moieties such as, for example:

"Heteroarylaikyl" means a heteroaryi moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryls include 2-pyridinylmethyl, qutnolinylmethyl and the like.

"Heterocyciyl" or "heterocycloalkyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms m the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thta before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz)₁ - N(Tos) group and the like; such protections are aiso considered part of this invention. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or suifur atom of the heterocyclyl can be optionaity oxidrzed to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morphofinyi, thiomorphoiinyl, thiazoiidinyl, 1 ,4-dioxanyl, tetrahydrofurany!, tetranydrothiopπenyi, lactam, lactone, and the like. "Heterocyclyl" also includes rings wherein =0 replaces two available hydrogens on the same carbon atom on a ring system (i.e., heterocyciyl includes rings having a carbonyl in the ring). An example of such moiety is pyrrolidone:

"Heterocyclylalkyl" (or "heterocycloalkylalkyl") means a heterocyclyf moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.

"Heterocyclenyl" (or "heterocycloalkenyl") means a non-aromatic monocyclic or multicyciic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon- nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom, The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above. The nitrogen or suifur atom of the heterocycienyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitabfe heterocyclenyl groups include 1 ,2,3,4- tetrahydropyridinyl, 1 ,2-dihydropyήdsnyi, 1 ,4~dthydropyridinyl, 1 ,2,3,6- tetrahydropyridinyl, 1 ,4,5,6-tetrahydropyrimidinyi, 2-pyrrolinyl, 3-pyrroiinyi, 2- imidazolinyl, 2-pyrazolinyl, dihydroimidazolyi, dihydrooxazofy!, dihydrooxadiazolyl, dihydrothiazolyl, 3,4~dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, 7- oxabicycio[2.2.13hepteny!_s dihydrothiophenyl, dihydrothiopyranyl, and the tike. "Heterocycienyl" also includes rings wherein =0 replaces two available hydrogens on the same carbon atom on a ring system (i.e., heterocyclyt includes rings having a carbonyl in the ring). An example of such moiety is pyrrolidinone:

"Heterocyclenyfalkyi" (or "heterocycloalkenylaϊkyl") means a heterocyclenyi moiety as defined above linked via an aikyl moiety (defined above) to a parent core.

It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxy! groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:

there is no -OH attached directly to carbons marked 2 and 5.

It should also be noted that tautomeric forms such as, for example, the moieties:

are considered equivalent in certain embodiments of this invention.

"Alkynyialkyf means an alkynyl-alkyl- group in which the aikynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower aikynyl and a lower alkyi group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynyialkyl groups include propargylrnethyl.

Ηeteroaralky!" means a heteroaryl-alkyl- group in which the heteroaryi and atkyi are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyi, and quinolin-3-yImethyf. The bond to the parent moiety is through the aikyl.

"Bydroxyalkyi" means a HO-afkyl- group in which alkyt is as previously defined. Preferred hydroxyalkyls contain lower a!ky!. Non-limiting examples of suitable hydroxyalkyl groups include hydrøxymethy! and 2-hydroxyethy!.

"Acyl" means an H-C(O)-, alkyl-C(O)- or cycioalkyi-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyi. Preferred acyis contain a tower atkyl. Non-iimiting examples of suitable acyi groups include formyl, acetyl and propanoyl. "Aroyl" means an aryi-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyi. Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.

"Alkoxy" means an alkyl-O- group in which the aikyl group is as previously described. Non-timiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.

"Aryloxy" means an ary!-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen. "Aralkyloxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.

"Alkylthio" means an alkyl-S- group in which the afkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthϊo and ethylthio. The bond to the parent moiety is through the sulfur.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthytthio. The bond to the parent moiety is through the sulfur. "Aralkylthio^*1 means an aralkyl-S- group in which the arafkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is bertzylthio. The bond to the parent moiety is through the sulfur. "Alkoxycarbonyl" means an alkyi-O-CO- group. Non-limiting examples of suitable alkαxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyi.

"Aryfoxycarbonyi" means an aryl-O-C(O)- group. Non-limiting exampies of suitable aryloxycarbonyi groups include phenoxycarbαnyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyi.

"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyi. "Alkylsulfonyf means an aikyi-S(C>₂)~ group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.

"Arylsulfonyl" means an aryl-S(O₂)- group. The bond to the parent moiety is through the suJfonyi. The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties, The term "purified", "in purified form^* or "in isolated and purified form" for a compound refers to the physical state of said compound after being isolated from a synthetic process (e.g, from a reaction mixture), or natural source or combination thereof. Thus, the term "purified", "in purified form" or In isolated and purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystaϊlization and the like) , in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

When a functional group in a compound is termed "protected", this means that the group is in modified form to precfude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene etah Protective Groups in organic Synthesis (1991), Wiley, New York. When any variable (e.g., aryl, heterocycie, R², etc.) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g., a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Prodrugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987. For example, if a compound of Formula (J) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci~C_s)alkyi, (Cg- Ci₂)alkanoytoxymethyi, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1- methyM-(alkanoyioxy)-ethy[ having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1~ (aikoxycarbonytoxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyi)aminσmethyf having from 3 to 9 carbon atoms, 1-(N-

(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyI, 4- crotonolactonyi, gamma-butyrolacton-4-yl, di-N_>N-(Ci-C₂)alkylamino(C₂-C₃)aIkyi (such as /?-dimeihylaminoethyl), carbamoyl~(Gt-C2)a)kyi, N.N-di (Cr C₂)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2~ C₃)alkyl, and the like.

Similarly, if a compound of Formula (I) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (CrCeJalkanoyioxymethyl, 1-((Cr C₆)alkanoyloxy)ethy}₅ 1~methyi-1-((Ci-C₆)alkanoyloxy)ethyl, (C-i- C₆)alkoxycarbonyloxymethyl, N^CrCβialkoxycarbonylaminomethyl, succinoyl, (C_r C₆)alkanoyl, α-amino(Ci-C₄)aikanyl, aryfacyl and α-aminoacyf, or α-aminoacykx- aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)₂, -P(O)(O(C_rC₆)alkyl)₂ or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetaf form of a carbohydrate), and the like.

If a compound of Formula (I) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyt, RO-carbonyl, NRR'-carbonyl where R and R' are each independently (CrCio)aikyl, (Ca-C₇) cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyf or natural α-amsnoacyl, — C(OH)C(O)OY¹ wherein Y¹ is H, (C₁-C₆)alkyl or benzyl, — C(OY²)Y³ wherein Y² is (C₁-C₄) alkyl and Y³ is (Ci-C₆)alkyl, carboxy (CrC₆)alkyl, amino(Ci-C₄)aIkyl or mono-N — or di-N,N-(CrC₆)alkyiaminoalkyl_s — C(Y⁴)Y⁵ wherein Y⁴ is H or methyl and Y⁵ is mono-N— or ds-N_>N-(CrC₆)alky!amino morphoϋno, piperidin-1-yf or pyrroiidin-1-yl, and the like. One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptabie solvents such as water, ethanol, and the ϋke, and it is intended that the invention embrace both solvated and unsoϊvated forms. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding, in certain instances the solvate wil) be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal tattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatabie solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H₂O.

One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira et a/, J, Pharmaceutical Sci., 93(3), 601 -611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et a/, AAPS PharmSciTech., 5(1}, article 12 (2004); and A. L. Bingham Bt a/, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example S. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate). "Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.

The compounds of Formula I can form salts which are also within the scope of this invention. Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)^H, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. Sn addition, when a compound of Formula I contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula I may be formed, for example, by reacting a compound of Formuia S with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophiϊizaϊion.

Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesuifonates, bisuffates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesuifonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toiuenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stan! et a/, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et ai, Journal of Pharmaceutical Sciences (1977) 66(1 ) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et ah The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-buty! amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), diaikyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.

Ail such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxytic acid esters obtained by esterifrcation of the hydroxy groups, in which the non-carbonyf moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain afkyi (for example, acetyl, n- propyi, t-butyl, or n-butyf), aikoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethy!), aryl (for example, phenyl optionally substituted with, for example, halogen,

or amino); (2) sulfonate esters, such as aikyl- or aralkylsuifony! (for example, methanesu!fonyi); (3) amino acid esters (for example, L-vafyl or L-ϊsoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C_1-2O alcohol or reactive derivative thereof, or by a 2,3-di (C₆-₂4)acy! glycerol.

Compounds of Formula (I), and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide, enol, keto or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.

The compounds of Formula (I) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomer^ forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention, in addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Diastereomehc mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiraf auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.

It is also possible that the compounds of Formula (I) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention. AIi stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (inciuding those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substitυents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4- pyridyi and 3-pyridyl). (For example, if a compound of Formula (S) incorporates a double bond or a fused ring, both the cis- and trans-forms, as weϊl as mixtures, are embraced within the scope of the invention. Also, for example, alt keto-enol and imine-enamine forms of the compounds are included in the invention.) individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with aff other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds. The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷0, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶CI, respectively.

Certain isotopicaily-labeiled compounds of Formula (I) (e.g., those labeled with ³H and ^⁴C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., ³H) and carbon-14 (i.e., ¹⁴C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. SsotopicaJly iabeiled compounds of Formula (!) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples heretnbelow, by substituting an appropriate isotopicaliy iabefled reagent for a non-isotopicaliy labelled reagent.

Polymorphic forms of the compounds of Formula (!)_t and of the salts, solvates, esters and prodrugs of the compounds of Formula (I), are intended to be included in the present invention.

The compounds according to the invention can have pharmacological properties; in particular, the compounds of Formula (!) can be modulators of gamma secretase (including inhibitors, antagonists and the like).

More specifically, the compounds of Formula (I) can be useful in the treatment of a variety of disorders of the centra! nervous system including, for example, including, but not limited to, Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration and the like.

Another aspect of this invention is a method of treating a mammal (e.g., human) having a disease or condition of the central nervous system by administering a therapeutically effective amount of at feast one compound of Formula (I), or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound to the mammal.

A preferred dosage is about 0.001 to 500 mg/kg of body weight/day of the compound of Formula (I). An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.

The compounds of this invention may also be useful in combination (administered together or sequentially) with one or more additional agents listed above.

The compounds of this invention may also be useful in combination (administered together or sequentially) with one or more compounds selected from the group consisting of A0 antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agent or treatment within its dosage range.

Accordingly, in an aspect, this invention includes combinations comprising an amount of at least one compound of Formula (I), or a pharmaceutically acceptable sait, solvate, ester or prodrug thereof, and an amount of one or more additional agents listed above wherein the amounts of the compounds/ treatments result in desired therapeutic effect.

The pharmacological properties of the compounds of this invention may be confirmed fay a number of pharmacological assays. Certain assays are exemplified later in this document.

This invention is also directed to pharmaceutical compositions which comprise at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and at least one pharmaceutically acceptable carrier.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, disperstble granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18^th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen. Also included are sofid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may aiso be deliverable transdermaSly. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

The compounds of this invention may a!so be delivered subcutaneously.

Preferably the compound is administered orally. Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 100 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.

The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.

The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses. Another aspect of this invention is a kit comprising a therapeutically effective amount of at least one compound of Formula (I)₁ or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.

Yet another aspect of this invention is a kit comprising an amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and an amount of at least one additional agent listed above, wherein the amounts of the two or more ingredients result in desired therapeutic effect. The invention disclosed herein is exemplified by the following illustrative schemes and examples which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures wili be apparent to those skilled in the art.

The compounds of the invention can be prepared by the schemes and examples below. Compounds of the invention wherein the G moiety is bound to G³ (i.e., position (2)) can be prepared by the same chemistry unless indicated otherwise. in the reactions beiow R¹ represents:

in the reactions below Ring B, formed by the dashed line between R¹ and G¹, is present (i.e., the dashed line between R¹ and G¹ shows the presence of Ring B).

13.1

15.1

[O)

18.1 16.1

16.1

1

33,÷1^Gl-

34.1 35.1

3.1

56.1

58.1

SO₂Cl₂, MeCOTMS KNO₃, SO₂Ct₂

69.1

87.1

Example 1

Step A:

EI a E1b iPrMgCI.LiCI (39,3 mL, 1.3 M) was added to a solution of E1a (4.5 g) in THF

(50 mL) at room temperature. The mixture was stirred for 8 hours before ailyfbromide (7.35 mL) was added dropwise. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EA (300 mL) and NH₄CI solution (50 mL). The organic layer was washed with water, brine, dried over MgSCU, and concentrated to give the crude product which was purified by column chromatography eiuting with EtOAc/hexanes to yield ally! intermediate. This intermediate was taken up in CH₂Cb and MeOH (v/v = 75 mL/50 mL) and ozonized with an O₃ generator for 20 minutes before it was biowed with O₂ for 5 minutes until the blue color dispeared. The reaction was quenched with Mβ₂S (5 eq) and the mixture was stirred for 30 minutes. The mixture was difuted with EA (200 mL) and water (50 mL). The organic layer was washed with water, brine, dried over MgSO₄, and concentrated to give the crude product E1b which was used directly for next step without further purification.

Step B:

E1b ^¹C E1d

BFs-OEt₂ (10 eq, 10,8 mL) was added dropwise to a mixture of compound E1b (8.5 mmol) and E1c (2.5 eq, 4,4 g, prepared from corresponding ketone and TMSOTf.) in CH₂Cl₂ (100 mL) containing 4A MS at -78 ⁰C. The mixture was kept at this low temperature overnight before it was diluted with EtOAc (200 mL) and careful addition of NaHCO₃ solution (50 mL). The organic layer was washed with water, brine, dried over MgSO₄, and concentrated to give the crude product which was purified by column chromatography eluting with EtOAc/hexanes to yield compound E1c (1.2 g).

Step C:

E1ci E1e

MsCI (0.31 mL, 2.5 eq) was added to a solution of compound E1d (0,59 g) and NEt₃ (0.9 mL, 4 eq) in CH₂CI₂ (6.0 mL) at 0 ⁰C. The mixture was stirred for 1 hour before it was diluted with CH₂C^ (100 mL) and water (40 mL). The organic layer was washed with brine, dried over JvIgSO₄, and concentrated to give the crude product which was taken up in CH₂CI₂ and stirred with silica gef for 1 hour. The silica gel was filtered and the filtrate was concentrated to give the aikerte intermediate. The alkene intermediate was hydrogenated with a hydrogen baiioon with Pd/C (10 wt%) for 3 hours. The mixture was filtered through a ceϋte pad. Solvent was removed and the crude residue was taken up in MeOH, and treated with NaBH₄ (1eq). The mixture was stirred for 1 hour before it was diluted with EtOAc (100 mi_) and NH₄CI solution (40 mL). The organic layer was washed with water, brine, dried over IvIgSO^ and concentrated to give the crude product which was purified by column chromatography efuting with EtOAc/hexanes to yield compound E1e (0.131 g).

Step D:

E1e E1f

Eig

PBu₃ (0.21 mL, 2.0 eq) was added to a solution of compound E1e (0.112 g), Etf (0.21 g, 2.0 eq) in THF (4 mL) at room temperature. The resulting mixture was then heated at 80⁰C for 2 hours. The mixture was diluted with EtOAc (100 mL) and NaHCOs solution (20 mL). The organic iayer was washed with brine, dried over MgSO₄, and concentrated to give the crude product which was purified by column chromatography eiuting with EtOAc/nexanes to yield compound E1g (0.1 g).

Step E:

E1g ^

NBS (36.6 mg, 1.0 eq) was added to a solution of compound E1g (50 mg) in DMF (1.2 mL) at room temperature. The mixture was stirred overnight before it was diluted with EtOAc (50 mL) and careful addition of Na2S₂Oa solution (10 mL). The organic layer was washed with water, brine, dried over MgSO₄, and concentrated to give the crude product which was purified by coiumn chromatography etuting with EtOAc/hexanes to yield compound E1h (20 mg).

Step F:

Two equivalent of 4-mβthylimidazofe, 1 equivalent of 3-rnethoxy-4-fluoro- nitrobenzene and 5 eq. of K₂CO₃ were stirred in CH₃CN at room temperature over night. The reaction mixture was filtered and concentrated under reduced pressure. The crude product was recrystalized with EtOAc to give desired product E1i.

Step G:

Compound EIi was hydrogenated with hydrogen balloon in the presence of

Pd(C) as the cataiyst (10 wt%) in MeOH over night. The mixture was filtered and concentrated under reduced pressure to give product E1j. Step H:

E1h A mixture of compound E1h (0,118 mmol), E1j (0.118 mmol), Pd(OAc)₂ {1.06 mg, 0.00472 mmol), B(NAP (2.94 mg, 0.00472 mmoi) and K₂CO₃ (81.4 mg, 0.5δ mmol) in toluene will be vacuum/nitrogen exchange degassed for 3 times before it will be heated at 120⁰C for 48 hours. The reaction mixture will be cooled and will be diluted with EtOAc (50 mL) and NH₄CI solution (10 mL). The organic layer will be washed with water, brine, and will be dried over MgSO4, and will be concentrated to give the crude product. The crude residue will be purified by Giison reverse phase HPLC to yield Compound E1.

Example 2

Step A:

A mixture of compound E2a (2.03 g, 10 mmoi), Cu₂O (0.288 g, 2 mmol), PEG

(4.0), Cs₂CO₃ (9,77 g, 30 mmol), 4-methyiimidazGie (0.98 g, 12 mmol) and E2b (0.72 g, 3 mmol) in HMP (15 mL) was vacuum-nitrogen exchange degassed and stirred in a sealed tube at 120 ⁰C for 48 hours. The mixture was cooled to room temperature and diluted with CH₂CI₂ followed with addition of siϋca gel. The mixture was stirred for 20 minutes and filtered. The organic layer was washed with water (3x), brine, dried over MgSO₄, and concentrated to give the crude product. The crude residue was purified by column chromatography eluting with CH₂CIaZMeOH to yield compound E2c (0.2 g). Step B:

A mixture of compound E1h (0.141 mmoi), E2c (28.8 mg, 0.141 mmol), K₂CO₃ (0.117 g, 0,846 mmol) and CuBrMe₂S (58 mg, 0.282 mmol) in pyridine (1.0 mL) will be heated at 140 ⁰C overnight. The mixture will be diluted with EtOAc (50 mL) and NH₄C! solution (10 mL, saturated}. The organic layer wilf be washed with water, brine, dried over MgSO₄, and concentrated to give the crude product. The crude residue will be purified by Gilson reverse phase HPLC to yield compound E2.

Example 3

Step A:

i-PrMgBr + MeOCOCN *-

E1h ^E3a

To a solution of compound E1h (1 eq) in THF will be added 'PrIVfgCϋ.LiCi (1M in THF, 1 ,3 eq) and wiii be stirred for 2D min. This wilf be followed with addition of methyl cyanoformate (1.0 eq). The resulting mixture will be stirred at RT for 2 hours. then it will be diluted with saturated aqueous NH^Ci, wilt be extracted with EtOAc, wil be dried (Na₂SO₄), will be concentrated and wi!S be purified by silica ge! flash chromatography (Hex/EtOAc) to afford compound E3a.

Step B:

^E3a E3b

E3a will be hydrolysed with LiOH in water/MeOH/TΗF to give E3b.

Step C:

E3b

Compound E1j (0.596mmol) and E3b (0.596mmol) will be mixed in DCM (4ml) at RT, which wiil then be followed by the addition of HOBT (96mg_s 0.715mmoS), EDC (136mg, 0.715mmol) and D!EA (300μL» 1,2mmoi). The resultant mixture will be kept stirring at RT for 16h. The mixture will be diluted with CH≤Cb (1OmI), wilt be washed with NaHCO₃ (Sat.) (6ml), and brine (6ml), respectively, will be dried over anhydrous MgSO₄, and will be concentrated. The residue will be purified via silica gel column (DCM/ MeOH (2N NH₃)= 30:1), which will be followed by PTLC (DCM/ MeOH (2N NH₃)= 20:1 ) to give E3. Assay:

Secretase Reaction and Aβ Analysis in Whole Cells: HEK293 ceifs overexpressiπg APP with Swedish and London mutations is treated with the specified compounds for 5 hour at 37 "C in 100 ml of DMEM medium containing 10% fetal bovine serum. At the end of the incubation, total Aβ, Aβ40 and Aβ42 is measured using electrochemiluminescence (ECL) based sandwich immunoassays. Total Aβ is determined using a pair of antibodies TAG-W02 and biotin-4G8, Aβ40 is identified with antibody pairs TAG-G2-10 and biotin- 4G8, whiie Aβ42 is identified with TAG-G2- 11 and biotin-4G8. The ECL signal is measured using Sector Imager 2400 (Meso Scale Discovery),

MS Analysis of Aβ Profile: Aβ profile in conditioned media is determined using surface enhanced laser desorption/ionization (SELDI) mass spectrometry. Conditioned media is incubated with antibody W02 coated PS20 ProteinChip array. Mass spectra of Aβ captured on the array is read on SELDi ProteinChip Reader (Bio- Rad) according to manufacturer's instructions.

CSF Aβ Analysis: Aβ in rat CSF is determined using MSD technology as described above. Aβ40 is measured using antibody pair Tag-G2-10 and biotin-4G8, while Aβ42 is measured using Tag-anti Aβ42 (Meso Scale Discovery) and biotin-4G8. The ECL signal is measured using Sector Imager 2400 (Meso Scale Discovery). Matrix-assisted laser desorption/ionization mass spectrometric (MALDI MS) analysis of kβ is performed on a Voyager-DE STR mass spectrometer (ABI, Framingham, MA). The instrument is equipped with a pulsed nitrogen laser (337 nm). Mass spectra is acquired in the linear mode with an acceleration voltage of 20 kV. Each spectrum presented in this work represents an average of 256 laser shots. To prepare the sample-matrix solution, 1 μL of immunoprecipitated Aβ sample is mixed with 3 /i, of saturated α~cyano-4~hydroxycinnamic acid solution in 0,1% TFA/acetonitrile. The sample-matrix solution is then applied to the sample plate and dried at ambient temperature prior to mass spectrometric analysis. AH the spectra are externally calibrated with a mixture of bovine insulin and ACTH (18-39 clip). While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims

WHAT IS CLAIMED IS.

1. A compound of the formula (I):

(3) or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

R^1A, G¹, G², G³, G⁴, (B), G, R⁹, R¹⁰, and W are independently selected; letters (A) and (B) in formula (I) are reference letters to identify the rings present in formula (I); the numbers (1), (2), (3), (4), and (5) are reference numbers to identify positions of the Ring (A); G⁴ is at position (1 ), G³ is at position (2), G² is at position (3), G¹ is at position (4) and the N is at position (5); the moiety -G-R¹⁰-R⁹ is bound through G to G⁴ or G³, and when G is bound to G⁴ then G⁴ is a -C-, and when G is bound to G³ then G³ is a -C-; the dotted line between G¹ and G² represents an optional bond; Ring (B) is the ring formed from the N at position (5) and G\ and G¹ is carbon or N, and when G¹ is N the optional bond between G¹ and G² is absent; said Ring (B) is a 4 to 8 membered heterocycloalkyl, heteroaryl, or heterocycloalkenyl ring; said heterocydoalkyl, heterocyctoalkenyl, or a heteroaryl ring Ring (B)₁ in addition to the nitrogen common to Ring (A) and Ring (B)₁ optionally comprises, at least one other heteroatom selected from the group consisting of: -NR²-, -O₁ -S-, -S(O)-, and -S(O)₂-; said Ring (B) is optionally substituted with 1 to 6 independently selected R²¹ substituents; d is O or 1 ; m is O to 6; n is 1 to 5; p is O to 5; q is O, 1 or 2, and each q is independently selected; r is 1 to 5; t is 1 or 2

W is selected from the group consisting of: -C(O)-, -S(O)₂-, -S(O)-, and -C(=NR²)- (and in one example W is -C(O)-); G is selected from the group consisting of: a direct bond, -C(O)-, -(C=NR²)-,

-(C=C(R⁶J₂J-, -CHR³- (e.g., -CHOH), C(R⁴)₂, -CF₂-, -N(R²)-, -0-, -S-, -S(O)₁,

-CR⁴(OH)-_t -CR⁴(OR⁴)-, -C=C-, alkynyl, -(CH₂J_rN(R²J-, -(CHR⁴JrN(R²J-, ~(C(R⁴)₂)_rN(R²h -N(R²)(CH₂)_r -, -N(R²χCHRV,-N(R²χC(R⁴)₂)_r- -(CH₂)_rO-, -(CHR⁴)_rO-, -(C(R⁴J₂Jr-O-, -0-(CH₂)_r -, -0-(CHR V, -O-(C(R⁴)₂)_r -, -(CH₂)_r -O-C(O)-, -(CHR⁴Jr -0-0(Oh -(C(R⁴)₂)_r -O-C(O)-, -C(O)-O-(CH₂)r -, -C(O)-O-(CHR⁴J_r - -C(OKHC(R⁴J₂Jr- -C(O)NR⁵-, -0-C(O)-, -C(O)-O-, -0-C(O)-NR⁵-, -NR⁵C(O)-, -(CH₂)_rNR⁵-C(O)-, -(CHR⁴)_rNR⁵-C(Oh ~(C(R⁴)₂)_rNR⁵-C(O)-, ~C(O)NR⁵(CH₂)_r-, -C(O)NR⁵ (CHR⁴Jr -, -C(O)NR⁵ (C(R⁴J₂Jr -, -NR⁵S(O)₁-, -(CH₂)_rNR⁵S(O)_t-, -(CHR⁴JrNR⁵S(OJt -, -(C(R⁴J₂JrNR⁵S(O)₁-, -S(O)_tNR⁵-, -S(OJ_tNR⁵(CH₂J_r-, -S(O)_tNR⁵(CHR⁴)_r -, -S(O)_tNR⁵(C(R⁴)₂)_r -, -NR⁵-C(O)-O-, -NR^S-C(OJ-NR⁵-, -NR⁵-S(O)t-NR⁵-, -NR⁵~C(=NR²)-NR⁵-, -NR⁵-C(=NR²)-O-_t -O-C(=NR²J-NR⁶-, -C(R⁴J=N-O-, -0-N=C(R⁴J-, -0-C(R⁴J=N-, -N=C(R⁴J-O-, -(CH₂J_2-3-, -(C(R⁴J₂J M-, and -(CHR⁴Ja_-3-, cycloalkyl, heterocycfoalkyl (comprising 1 to 4 heteroatoms independently selected from the group consisting of: -O- , -NR²-, -S-, -S(OJ-, and - S(O)₂J;

G¹ is selected from the group consisting of:

(1) -C(R²¹ )q~ wherein q is O when the optional bond is present,

(2) -C(R²¹Jq- wherein q is 1 when the optional bond is absent,

(3) -CH- when the optional bond is absent, and (4) -N(R²)_d- wherein d is O, and the optional bond is absent;

G² is selected from the group consisting of: a direct bond, -C(R²¹J₅,, -N(R²J_d-, -C(O)-, S(O), S(O)₂, -C(N(R²J₂J-, and -C(=NR²)-; and with the provisos that:

(1 J when the optional bond between G¹ and G² is not present then G² is not -C(N(R²J₂J-, and (2 J when the optional bond between G¹ and G² is present, then: (a) q for the -C(R²¹ )_q group is 0 or 1 (and when q is 0 then there is a H on the carbon), and

(b) d for the -N(R²)_d- group is 0; and

(c) G² is not a direct bond, -C(O)-, -C(=NR²)- )-, -S(O)₂, or S(O)-; G³ is selected from the group consisting of: (a) -C(R²¹ )_q wherein q is 0,

(b) -CH-, (c) -C(R²¹ )_q wherein q is 1 , and (d) -N(R²)_d wherein d is 0; and with the proviso that: when moiety G is bound to G³, then G³ is carbon;

G⁴ is selected from the group consisting of: (a) -C(R²¹ )_q wherein q is 0, (b) -CH-, (c) -C(R²¹ )_q wherein q is 1 , and (d) -N(R²)_d wherein d is 0; and with the proviso that: when moiety G is bound to G⁴, then G⁴ is carbon; and provided that 0 to 2 of the G¹, G², G³, and G⁴ moieties are -N(R²)_d- and each R² is independently selected and each d is independently selected, and provided that Ring (A) does not have three consecutive ring nitrogen atoms;

R^1A is selected from the group consisting of: alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyh alkytaryh cycioalkyl, cycloalkenyl, cycioalkylalkyl-, fused benzocycloalkyh fused benzoheterocycfoalkyh fused beteroarylcycloalkyh fused heteroarylheterocycioalkyh fused cycloalkylaryl , fused heterocycloalkyiaryh fused cycloalkylheteroaryh fused heterocycloatkylheteroaryh fused benzocycloalkylalkyi-, fused benzoheterocycloaikylalkyh fused heteroarylcycloalkylalkyl-, fused heteroarylheterocycloaikylalkyl-, fused cycloalkyiarylalky!-, fused heterocycloalkylaryϊalkyh fused cycloalkyfheteroaryjafkyh fused heterocycloalkylheteroarylalkyi-, heteroaryl-, heteroarylalkyh heterocyciyh heterocyclenyl-, and heterocyclyalkyi-; wherein each of said aSkyh alkenyl-, alkynyi-, aryl-, aryfalkyh aikyfaryh cycfoatkyt, cycloaikeny!, cycloalkyialkyh fused benzocycloalkyl, fused benzoheterocycloalkyl, fused heteroarylcycloalkyl, fused heteroarylheterocycloalkyl, fused cycloalkylaryl, fused heterocycloalkylaryl, fused cycfoalkyiheteroaryf, fused heterocycloalkylheteroary!, fused benzocycioalkyiølkyh fused benzoheterocycioaikyialkyh fused heteroarylcycloatkylalkyi-, fused heteroarylheterocycloalkylalkyl-, fused cycloaikylarytaikyl-, fused heterocycloaikylaryialkyh fused cycJoalkylheteroarylalkyh fused heterocycioaJkylheteroaryialkyh heteroaryl, heteroarylalkyh heterocyclyS, heterocycienyf and heterocyciyalky!- R^1A groups is optionally substituted with 1-5 independently selected R²¹ groups; Each R² is independently selected from the group consisting of: H, -OH, -O-alkyl, ~O-(hafo substituted alky), -NH(R⁴), -N(R⁴)₂, -NH₂, -S(O)R⁴, S(O)(OR⁴), -S(O)₂R⁴, -S(O)₂(OR⁴X -S(O)NHR⁴, -S(O)N(R⁴)₂, -S(O)NH₂, -S(O)₂NHR⁴, -S(O)₂N(R⁴J₂, -S(O)₂NH₂, -CN, -C(O)₂R⁴, -C(O)NHR⁴, -C(O)N(R⁴)₂, -C(O)NH₂, -C(O)R⁴, unsubstituted aryl, substituted aryl, unsubstituted heteroaryi, substituted heteroaryi, unsubstituted alkyl, substituted alkyl, unsubstituted arylaiky!-, substituted arytalkyh unsubstituted heteroarylaikyh substituted heteroaryialkyl-, unsubstituted alkenyl, substituted alkeny!, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycfoafkyl, and substituted cycioalkyl, wherein said substituted aryl, heteroaryi, alkyl, aryialkyh heteroaryialkyl-, aikenyf, aikynyl and cycfoafkyl groups are substituted with 1 to 5 independently selected R²¹ groups;

R³ is selected from the group consisting of: H₁ -OH, halo, -O-alkyl, -O-(halo substituted alky), -NH(R⁴), -N(R⁴)₂, -NH₂, -S(R⁴), -S(O)R⁴, -S(O)(OR⁴), -S(O)₂R⁴, -S(O)₂(OR⁴), -S(O)NHR⁴, -S(O)N(R⁴)₂, -S(O)NH₂, -S(O)₂NHR⁴, -S(O)₂N(R⁴)_2l -S(O)₂NH₂, -CN₁ -C(O)₂R⁴, -C(O)NHR⁴, -C(O)N(R⁴)₂, -C(O)NH₂,

-C(O)R⁴, unsubstituted aryl, substituted aryl, unsubstituted heteroaryi, substituted heteroaryi, unsubstituted alkyl, substituted alkyl, unsubstituted arylaiky!-, substituted aryialkyh unsubstituted heteroarylaikyh substituted heteroaryialkyl-, unsubstituted alkenyl, substituted alkenyl, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycioalkyl, and substituted cycloalky!, wherein said substituted aryl, heteroaryi, alkyl, aryialkyh heteroaryialkyl-, alkeny!, alkynyl and cycloafkyl groups are substituted with 1 to 5 independently selected R²¹ groups; each R⁴ is independently selected from the group consisting of: unsubstituted aryi, substituted aryl, unsubstituted heteroaryi, substituted heteroaryi, unsubstituted alkyl, substituted a!kyt, unsubstituted arylaikyh substituted arylaiky!-, unsubstituted heteroaryialkyl-, substituted heteroaryialkyl-, unsubstituted atkenyl, substituted aikenyf, unsubstituted alkynyl, substituted afkynyl, unsubstituted cycloalkyi, and substituted cycioaikyl, wherein said substituted aryl, heteroaryi, alkyl, aryialkyh heteroaryi a iky !-, alkenyl, alkynyl and cycioalkyl groups are substituted with 1 to 5 independently selected R²¹ groups; each R⁵ is independently selected from the group consisting of: H, unsubstϊtued alky!, substituted alkyl, unsubstitued alkeny!, substituted aikenyf, unsubstitued alkynyl, substituted aikyny!, unsubstitued cycioalkyl, substituted cycfoalkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryi and substituted heteroaryi; wherein said substituted groups are substituted with one or more substituents independently selected from: R²;

Each R⁶ is independently selected from the group consisting of: H, halo, -CF₃, -O-alkyl, -O-(halo substituted alky), -S(O)R⁴, -S(O)(OR⁴), -S(O)NHR⁴, -S(O)N(R⁴)₂ (wherein each R⁴ is independently selected), -S(O)NH₂, -S(O)₂NHR⁴, -S(O)₂N(R⁴J₂ (wherein each R⁴ is independently selected), -S(O)₂NH₂, ~-C(-NOR²⁴)R²⁵, and -S(O)₂R²⁴; -CN, -C(O)₂R⁴, -C(O)NHR⁴, -C(O)N(R⁴)₂ (wherein each R⁴ is independently selected), -C(O)NH₂, -C(O)R⁴, unsubstituted aryl, substituted aryl, unsubstituted heteroary!, substituted heteroaryi, unsubstituted alky!, substituted alkyl, unsubstituted arylalkyh substituted arylatkyl-, unsubstituted heteroarylalkyi-, substituted heteroarylalkyh unsubstituted alkenyl, substituted alkenyi, unsubstituted alkynyl, substituted alkynyl, unsubstituted cycloaikyl, and substituted cycloalkyl, wherein said substituted aryl, heteroaryi, alkyl, aryialkyl-, heteroarylalkyi-, alkenyf, alkynyl and cycloalkyl groups are substituted with 1 to 5 independently selected R²¹ groups; R⁹ is selected from the group consisting of: arylalkoxy-, heteroarylalkoxy-, arylalkyiamino-, heteroarylalkylamino-, aryl, aryialkyl-, heteroaryi, heteroarylalkyi-, heterocyclyl, heterocyclenyl, and heterocyclyalkyh wherein each of said R⁹ arylalkoxy-, heteroarylalkoxy-, arylalkyiamino-, heteroarylaSkylamino-, aryl, aryialkyl-, heteroaryi, heteroarylalkyi-, heterocyclyl, heterocyclenyl, and heterocyclyalkyl- is optionally substituted with 1-5 independently selected R²¹ groups;

R¹⁰ is selected from the group consisting of: aryh heteroaryi-, cycloalkyl-, cycloalkenyl, cycloalkylaϊkyi-, heterocyclyl-, heterocyclenyl-, heterocyclylalkyl-, heterocyctyalkenyh fused benzocycioaikyh fused benzoheterocycloalkyl-, fused heteroaryicycloafkyh fused heteroaryfheterocycloafkyl-, fused cydoatkyfaryl, fused heterocycloaikylaryl-, fused cycloalkyiheteroaryh fused heterocycloalkylheteroaryl-,

ΛΛΛΛ

vAΛΛΛ

wherein X is selected from the group consisting of: 0, -N(R 14_\ )- and -S-; and wherein each of said R¹⁰ moieties is optionally substituted with 1-5 independently selected R²¹ groups; or

R and R Ϊ10 are linked together to form a fused tricyclic ring system wherein R and R¹⁰ are as defined above and the ring linking R⁹ and R¹⁰ is an alkyl ring, or a heteroaikyl ring, or an aryl ring, or a heteroaryl ring, or an alkeny! ring, or a heteroalkenyl ring (for example, the tricyclic ring system is formed by linking the atoms adjacent to the atoms by which R³ and R⁴ are bound together);

R¹⁴ is selected from the group consisting of H, alkyl, alkenyi, alkynyl, cycloalkyi, cycloatkylalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, heterocyclylalkyl, heterocydyalkenyh aryi, arylalkyS, heteroaryi, heteroarylalkyf, -CN, -C(O)R 15 -C(O)O

-C(=NOR >1¹5^O)vR_D16

R^15A, and R^t6A are independently selected from the group consisting of afkyl, alkenyi, aikynyl, cycloalkyi, cycloalkylatkyl, heterocyclyl, heterocyclylalkyl, aryl, arylaikyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyclyl, (R¹⁸)_n-afkyl, (R^tδ)_n-cycloa^{kyl, (R¹ Vcycloalkylatkyl, (R¹⁸)n-heterocycfyl, (R¹ Vheterocyclylalkyi, (R^ia)_n-aryl, (R¹⁸)_n-arylalky}, (R¹⁸)_π-heteroary1 and (R¹⁸)_n-heteroarylalkyl;

R¹⁵, R¹⁶ and R¹⁷ are independently selected from the group consisting of H₁ alkyl, alkenyf, alkynyi, cycloalkyi, cycloafkyialkyl, heterocyclyl, heterocycJylalky), aryl, arylalkyi, heteroaryl, heteroarylalkyi, arylcycloalkyl, arytheterocyclyi, (R^1s)_n-alkyl, (R¹⁸)_n-cycloa!kyl, (R¹⁸)_n-cycloalkylalkyl, (R^1s)_n-heterocyclyl, (R¹⁸)_n-heterocyclylalkyf, (R (I^tS^βl)_n-arytelkyl, (R , 1^ϊ8^d)_π-heteroary! and (R 1¹8^β)v

_π-heteroary!a!kyl; each R is independently selected from the group consisting of alky!, aikenyl, alkynyl, aryl, arylalkyl, arylafkenyi, arylaikynyi, -NO₂, halo, heteroaryi, HO-alkyoxyalkyl, -CF₃, -CN, aiky!-CN₍ -C(O)R¹⁹, -C(O)OH, -C(O)OR¹⁹, -C(O)NHR²⁰, -C(O)NH₂, -C(O)NH_rC(O)N(atkyl)₂, -C(O)N(alkyl)(aryl), -C(O)N(alkyl)(heteroaryi)₁ -SR¹⁹, -S(O)₂R²⁰, -S(O)NH₂, -S(O)NH(alkyl), -S(O)N(alkyiχalkyl), -S(O)NH(aryJ), -S(O)₂NH₂, -S(O)₂NHR¹⁹, -S(O)₂NH(heterocyciyf), -S(O)₂N(alkyl)₂, -S(O)₂N(aIkyl)(aryl), -OCF₃, -OH₁ -OR²⁰, -O-heterocyclyl, -O-cycloalkylalkyl, -O-hβterocyclylalkyl, -NH₂, -NHR²⁰, -N(aikyl)₂, -N(arylaikyl)₂, -N(aryia!kyl)-(heteroarylalkyt), -NHC(O)R²⁰, -NHC(O)NH₂, -NHC(O)NH(aikyl). -NHC(O)N(a!ky!)(alkyl), -N(alkyl)C(O)NH(a!kyl), -N(alkyl)C(O)N(alkyiχalkyl), -NHS(O)₂R²⁰, -NHS(O)₂NH(afkyf),

-NHS(O)₂N(alkyl)(aikyl), -N(a!kyl)S(O)₂NH(aikyl) and -N(alkyl)S(O)₂N(alkyiχalkyl); or two R^1S moieties on adjacent carbons can be linked together to form a

R¹⁹ is selected from the group consisting of: alkyi, cycloafkyl, aryl, arylaikyi and heteroaryialkyl;

R²⁰ is selected from the group consisting of: alkyl, cycloalkyl, aryl, halo substituted aryi, arylalky!, heteroaryl and heteroarylalkyi; each R²¹ is independently selected from the group consiting of: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylafkyl, cycloalkenyl, heterocycioalkyl, -O, =N-R², heterocycloalkyfalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyi, halo, -CN, -OR¹⁵, -C(O)R¹⁵, -C(O)OR¹⁵, -C(O)N(R¹⁵XR¹⁶), -SR¹⁵, -P(θχCH₃)₂, ~SO(=NR¹⁵)R¹⁶-, -SF₅, -OSFs, -Si(R^15A)₃ wherein each R^15A is independently selected -S(O)N(R¹⁵)(R¹⁶), -CH(R¹⁵XR¹⁶), -S(O)₂N(R¹⁵XR¹⁶) ,-C(=NOR¹⁵)R¹⁶, -P(O)(OR¹⁵)(OR¹⁶)₅ -N(R¹⁵)(R¹⁶), -alkyl-N(R¹⁵)(R¹⁶), -N(R^t5)C(O)R¹⁶, -CH₂-N(R¹⁵JC(O)R¹⁶, ~CH₂-N(R¹⁵)C(O)N(R¹⁶)(R¹⁷), -CH₂-R¹⁵; -CH₂N(R¹⁵)(R¹⁶), -N(R¹⁵)S(O)R^16A, -N(R¹⁵JS(O)₂R¹⁶^ -CH₂-N(R¹⁵)S(O)₂R^16A, -N(R¹⁵)S(O)₂N(R¹⁶)(R¹⁷), -N(R¹⁵)S(O)N(R¹⁶)(R¹⁷), -N(R¹⁵)C(O)N(R¹⁶)(R¹⁷), -CH₂~N(R¹⁵)C(O)N(R¹⁶)(R¹⁷), -N(R¹⁵)C(O)OR¹⁶, -CH₂-N(R¹⁵)C(O)OR^1δ, -S(O)R^15A, =NOR¹⁵, -N₃, -NO₂, -S(O)₂R^15A, ~O-N=C(R⁴)₂ (wherein each R⁴ is independently selected), and -O-N=C(R⁴)₂ wherein R⁴ is taken together with the carbon atom to which they are bound to form a 5 to 10 mernbered ring, said ring optionally containing 1 to 3 heteroatøms selected from the group consisting of -O-. -S-, -S(O)-, -S(O)₂-, and -NR^-; wherein each of said alkyf, alkenyl, alkynyl, cycloalkyl, cycioalkylaikyl, cycloalkenyl, heterocycloalkyϊ, heterocycloalkylalkyl, aryj, arylalkyi, heteroaryf, and heteroarylalkyl R²¹ groups is optionafiy substituted with 1 to 5 independently selected R²² groups; each R²² group is independently selected from the group consisting of alky!, cycloalkyf, cydoalkenyl, beteroeydoalkyl, aryl, heteroaryf, halo, -CF₃, -CN, -OR¹⁵, -C(O)R¹⁵, -C(O)OR¹⁵, -alkyl-C(O)OR¹⁵, C(O)N(R¹⁵)(R¹⁶), -SR¹⁵, -S(O)N(R¹⁵XR¹⁶), -S(O)₂N(R¹⁵KR¹⁶), ~C(=NOR¹⁵)R¹⁶, -P(O)(OR¹⁵)(OR¹⁶), -N(R¹⁵KR¹⁶), -a!ky!-N(R¹⁵)(R¹⁶), -N(R¹⁵)C(O)R¹⁶, -CH₂-N(R^1S)C(O)R¹⁶, -N(R¹⁵)S(O)R^16A, -N(R¹⁵)S(O)₂R^16A, -CH₂-N(R¹⁵)S(O)₂R^16A _I -N(R¹⁵)S(O)₂N(R¹⁶)(R¹⁷), -N(R¹⁵)S(O)N(R¹⁶)(R¹⁷), -N(R¹⁶)C(O)N(R¹⁶)(R¹⁷), -CH₂-N(R¹⁵)C(O)N(R^t6χR¹⁷)₅ -N(R¹⁵)C(O)OR¹⁶, -CH₂-N(R¹⁵JC(O)OR¹⁶, -N₃, =NOR¹⁵, -NO₂, -S(O)R^15A and -S(O)₂R^15A; and provided that: when W is -(C=O)-, and G is bound to G⁴, and when G¹, G² _, G³, and G⁴ are the same or different -C(R²¹ )_q- moiety, and G is -CHR³-, then R³ is not H, halo, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted aryiaikyl, substituted aryfalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted aikyl, substituted alkyl, or-O-alkyl; and when R²¹ is bound to a carbon that has three other fiiied valences then R²¹ is not =0, =NR², or =NOR¹⁵; and when G is bound to G⁴, and G¹ is a C(R²¹ )_q group, and the carbon of said G¹ group is bound to a =N- in Ring B, and the optional bond between G¹ and G² is not present, and G² is N(R²)_d, and G³ is -C(R²¹ )_q-, then G is not CHR³; and when G is bound to G⁴, and G¹ is a C(R²¹)_q group, and the carbon of said G¹ group is bound to an -NR²- in Ring B, and the optional bond between G¹ and G² is present, and G² is N(R²)_d, and G³ is -C(R²¹ }_q-, then G is not CHR³; and when G is bound to G⁴, and G¹ is a C(R²¹)_q group, and the carbon of said G¹ group is bound to a =N- in Ring B, and G² is a direct bond, and G³ is N, then G is not CHR³.

2. The compound of Claim 1 wherein R¹⁰ is selected from the group consisting of

■jxrxjxsx

3. The compound of Claim 2 wherein at least one group selected from the group c coonnssiissttiinngg ooff:: --SSFF₅s,, --OOSSFF₅₅,, aanndd --SSii((RR^1155AΛ))₃₃ ((wwhheerein each R^15A is independently selected) is present in the compounds of formula (I).

4. The compound of Claim 1 wherein R »9 ^■ is_ selected from the group consisting of: 1 gg to 13gg.

5. The compound of Claim 2 wherein R is selected from the group consisting of: 1gg to 13gg.

6. The compound of Claim 1 wherein the R⁹-R¹⁰- moiety is selected from the group consisting of: 1bb to 40bb.

7. The compound of Claim 1 wherein R^1A is selected from the group consisting of:

8. The compound of Claim 1 wherein R »1A is selected from the group consisting of:

9. The compound of Claim 1 wherein R »1A is phenyl substituted with 1 to 3 independently selected R²¹ moieties wherein at least one R²¹ moiety is selected from the group consisting of -SF₅, -OSF₅ and -Si(R 15A_V ^

10. The compound of Claim 1 wherein R^1A is phenyl substituted with 1 to 3 indepe ϊnnddeennttllyy sseelleecctteedd RR²²¹¹ mmooiieettiieess wwhheerein at least one R²¹ moiety is selected from the group consisting of -SF₅ and -OSF₅.

11. The compound of Claim 1 wherein the R 9-R »10 - moiety is:

12, The compound of Claim 7 wherein the R 9- oR10- moiety is:

13. The compound of Claim 8 wherein the R⁹-R¹⁰- moiety is:

14. The compound of Claim 1 wherein said R¹⁰ is selected from the group consisting of aryt and aryt substituted with one or more R²¹ groups, and said R⁹ group is selected from the group consisting of heteroaryl and heteroaryi substituted with one or more R²¹ groups, wherein each R²¹ is independently selected.

15. The compound of Claim 1 wherein said R¹⁰ is phenyl substituted with one R²¹ group, and said R⁹ is imidazolyl substituted with one R²¹ group, wherein each

R²¹ is independently selected.

16. The compound of Claim 1 wherein the R⁹-R¹⁰- moiety is:

17, The compound of Claim 1 wherein the R⁹~R¹⁰- moiety is:

or wherein the R⁹-R¹⁰- moiety is: wherein the R .9 -R n10 - moiety is:

wherein the R⁹-R¹⁰- moiety is:

wherein the R⁹-R¹⁰- moiety is:

18. The compound of Claim 1 wherein R^1A is an unsubstituted ary! or an aryl substituted with one or more independently selected R²¹ groups.

19. The compound of Claim 1 wherein:

R^1A is phenyl, or

R^1A is phenyl, and said pheny is substituted with 1 to 3 independently selected

R²¹ groups, or

R^1A is phenyl, and said phenyl is substituted with 1 to 3 R²¹ groups, and each R²¹ group is the same or different halo, or

R^1A is phenyl, and said phenyl is substituted with three R²¹ haio groups, and each R²¹ group is the same or different haio, or

R^1A is phenyl, and said pheny! is substituted with two R²¹ halo groups, and each R²¹ group is the same or different halo, or R^1A is phenyl, and said phenyl is substituted with one R²¹ halo group,

R^1A is phenyl, and said phenyl is substituted with one F, or R^1A is phenyl, and said phenyl is substituted with two F atoms, or R^1A is phenyl, and said phenyl is substituted with three F atoms.

20. The compound of Claim 1 wherein said R^1A is selected from the group consisting of:

21. The compound of Claim 1 wherein said R¹⁰ is selected from the group consisting of heteroaryi and heteroary! substituted with one or more R²¹ groups, and said R⁹ group is selected from the group consisting of heteroary! and heteroaryi substituted with one or more R²¹ groups, and wherein each R²¹ is independently selected.

22. The compound of Claim 1 wherein: (1) (a) R^1A is an aryl group, or R^1A is an aryi group substituted with 1 to 3 independently selected R²¹ groups, and (b) R¹⁰ is selected from the group consisting of aryl and aryt substituted with one or more independently selected R²¹ groups, and (c) R⁹ is selected from the group consisting of heteroaryl and heteroary! substituted with one or more independently selected R²¹ groups, or

(2) (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ groups, and (b) R¹⁰ is selected from the group consisting of aryl and aryl substituted with one or more independently selected R²¹ groups, and (c) R⁹ is selected from the group consisting of heteroaryl and heteroaryl substituted with one or more independently selected R²¹ groups, or

(3) (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or more independently selected R²¹ groups, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazoiyf substituted with one or more independently selected R²¹ groups, or

(4) (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 3 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or more independently selected -OR¹⁵ groups, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazojy! substituted with one or more independently selected alkyl groups groups, or

(5) (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 to 2 independently selected R²¹ halo groups, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is alkyl, and (c) R³ is selected from the group consisting of imidazoiyt and imidazolyl substituted with one or two independently selected alkyl groups groups, or

(6) (a) R^1A is phenyl, or R^1A is phenyl substituted with 1 R²¹ halo group, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R^1S is alkyl, and (c) R⁹ is selected from the group consisting of imϊdazoty! and imidazolyl substituted with one or two independently selected alkyl groups groups, or

(7) (a) R^1A is phenyl, or R^1A is phenyl, substituted with 1 to 3 F, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁰ groups, wherein R¹⁵ is methyl and (c) R⁹ is selected frorrt the group consisting of imidazolyl and imidazolyl substituted with one or two independently selected methyl groups groups, or

(8) (a) R^1A is phenyl, or R^1A is phenyl, substituted with 1 to 2 F, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyl and imidazolyi substituted with one or two independently selected methyl groups groups.

(9) (a) R^1A is phenyl, or R^1A is phenyl, substituted with 1 F, and (b) R¹⁰ is selected from the group consisting of phenyl and phenyl substituted with one or two independently selected -OR¹⁵ groups, wherein R¹⁵ is methyl, and (c) R⁹ is selected from the group consisting of imidazolyi and imidazolyl substituted with one or two independently selected methyl groups groups, or

(10) R^1Λ is selected from the group consisting of:

wherein the R⁹-R¹⁰- moiety is:

, or

(11 ) R ,1A i ^■s selected from the group consisting of:

, and wherein the R^θ-R¹⁰- moiety is:

(12) R »1A : is selected from the group consisting of: and

wherein the R⁹-R¹⁰- moiety is:

(13) R _liA i :s selected from the group consisting of:

wherein the R⁹-R¹⁰- rnotety is:

(14) R ilA is selected from the group consisting of:

, and wherein the R⁹-R¹⁰- moiety is:

23. The compound of Claim 10 wherein G is selected from the group consisting of: -C(O)-, -CH₂-, -C(CH₃)-, -(CHOH)-, -C(OCH₃)-, -Cf=NOCH₃)-, -(C=NR²)-, -(C=C(R⁶)₂)-, -CHR³-, -NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond.

24. The compound of Claim 11 wherein G is selected from the group consisting of:-C(O)-, -CH₂-, -C(CH₃)-, -(CHOH)-, -C(OCH₃)-, -C(=NOCH₃)-, -(C=NR²)-, ~(C=C(R⁶)₂)-, -CHR³-, -NH-, -O-, -S-, -S(O)-, -S(O)₂- and a direct bond, and W is -C(O)-.

25, The compound of Claim 1 selected from the group consisting of compounds of the formula: (IA) wherein the optional bond between G¹ and G² is absent, (IA) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (!B) wherein the optional bond between G¹ and G² is present, IC to IH, 2 to 9_S 12 to 18, 20, 21 , 40 to 43, 55, 2A to 9A, 12A to 18A, 2OA, 21 A, 4OA to 43A₁ 55A, 2B to 9B, 12B to 18B, 20B₁ 21 B, 4OB to 43B, 55B, 2C to 9C, 12C to 18C₁ 2OC, 21C, 40C tO 43C, 55C₁ 6.2, 9.1, 10.1, 10.2, 10.3, 14.1, 16.1 , 16.2, 18.1, 19.1 , 20.2, 21.2, 23.2, 25.1, 26.1, 27.1 , 28.1, 30.1, 36.1 , 37.1 , 38.1, 39.1 , 41.1, 43.1, 45.1 , 46.1, 47.1 , 48.1, 49.1, 50.1, 51.1, 52.1, 59.1, 60.1 , 61.1, 64.1, 65.1, 68.1, 70.1, E1, E2, and E3.

26. The compound of Claim 1 seiected from the group consisting of; (IA) wherein the optional bond between G¹ and G² is absent, {{A) wherein the optional bond between G¹ and G² is present, (IB) wherein the optional bond between G¹ and G² is absent, (IB) wherein the optional bond between G¹ and G² is present, and IC to IH.

27. The compound of Claim 1 selected from the group consisting of: 2 to 9, 12 to 18, 20, 21, 40 to 43, and 55.

28. The compound of Claim 1 selected from the group consisting of. 2A to

9A_T 12A to 18A₁ 2OA, 21 A, 4OA to 43A, and 55A.

29. The compound of Claim 1 selected from the group consisting of: 2B to 9B, 12B to 18B, 2OB, 21B, 4OB to 43B, and 55B.

30. The compound of Claim 1 selected from the group consisting of: 2C to 9C, 12C to 18C, 20C, 21 C, 4OC to 43C, and 55C.

31. The compound of Claim 1 selected from the group consisting of: 6.2, 9.1, 10.1, 10.2, 10.3, 14.1, 16.1, 16.2, 18.1, 19.1, 20.2, 21.2, 23.2, 25.1, 26.1, 27.1,

28.1 , 30,1 36.1 , 37.1 , 38.1 , 39.1 , 41.1 , 43.1 , 45.1 , 46.1, 47.1 , 48.1 , 49.1 , 50.1 , 51.1 , 52.1, 59.1 , 60.1, 61.1, 64.1, 65.1, 68.1, and 70.1.

32. The compound of Claim 1 selected from the group consisting of: E1 , E2₅ and E3.

33. The compound of Claim 1 wherein said compound is E1 ,

34. The compound of Claim 1 wherein said compound is E2.

35. The compopund of Claim 1 wherein said compound is E3.

36. The compound of Claim 1 in pure and isolated form.

37. The compound of Claim 32 in pure and isolated form.

38. A pharmaceutically acceptable salt of a compound of Claim 1.

39. A pharmaceutically acceptab!e salt of a compound of Claim 25,

40. A solvate of a compound of Claim 1.

41. A solvate of a compound of Claim 25.

42. A pharmaceutically acceptable ester of a compound of Claim 1.

43. A pharmaceutically acceptable ester of a compound of Claim 25.

44. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1, and a pharmaceutically acceptable carrier.

45. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 25, and a pharmaceutically acceptable carrier.

46. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 , and a pharmaceutically acceptable carrier, and and an effective amount of one or more other pharmaceutically active drugs selected form the group consisting of: fa) drugs useful for the treatment of Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue, (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase.

47. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 25, and a pharmaceutically acceptable carrier, and and an effective amount of one or more other pharmaceutically active drugs selected form the group consisting of: (a) drugs useful for the treatment of Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g.. amyloid beta protein) in, on or around neurological tissue, (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase.

48. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 , and a pharmaceutically acceptable carrier, and an effective amount of one or more BACE inhibitors.

49. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Ctaim 25, and a pharmaceutically acceptable carrier, and an effective amount of one or more BACE inhibitors.

50. A pharmaceutical composition:

(1 ) comprising a therapeutically effective amount of at feast one compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, or

(2) comprising a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of one or more other pharmaceutically active drugs selected form the group consisting of; (a) drugs useful for the treatment of Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue, (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase, or

(3) comprising a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of one or more BACE inhibitors,

(4) comprising a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and effective amount of one or more cholinesterase inhibitors, or

(5) comprising a therapeutically effective amount of at feast one compound of claim 1 , and at least one pharmaceutically acceptable carrier, and effective amount of one or more chofinesterase inhibitors, or (6) comprising a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt, sofvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and effective amount of one or more BACE inhibitors, muscarinic antagonists, cholinesterase inhibitors; gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-rnethy!~D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABA_A inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors and cholesterol absorption inhibitors, or

(7) comprising a therapeutically effective amount of at least one compound of claim 1 , and at least one pharmaceutically acceptable carrier, and effective amount of one or more BACE inhibitors, muscarinic antagonists, cholinesterase inhibitors; gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyl-D- aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB 1 receptor inverse agonists or CB 1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABA_A inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors and cholesterol absorption inhibitors, or

(8) comprising a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of donepezil hydrochloride, or

(9) comprising a therapeutically effective amount of at least one compound of claim 1 , and at least one pharmaceutically acceptable carrier, and an effective amount of donepezil hydrochloride.

51. A method of modulating gamma-secretase comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of such treatment.

52. A method of treating one or more neurodegenerative diseases, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment.

53. A method of inhibiting the deposition of amyloid protein in, on or around neurological tissue, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment,

54. A method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment.

55. A method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 25 to a patient in need of treatment.

56. A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of Claim 1 to a patient in need of treatment.

57. A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of Claim 25 to a patient in need of treatment.

58. A method of (a) modulating gamma-secretase, (b) treating one or more neurodegenerative diseases, (c) inhibiting the deposition of amyloid protein in, on or around neurological tissue, or (d) treating Alzheimer's disease, comprising administering administering:

(1 ) an effective amount of a compound of Claim 1 , and

(2) an effective amount of one or more other pharmaceutically active ingredients selected from the group consisting of; BACE inhibitors, muscarinic antagonists, cholinesterase inhibitors; gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; M~rnβthyl-D-asρartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 Inhibitors; GABA_A inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-1G inhibitors and cholesterol absorption inhibitors, to a patient in need of such treatment.

59. A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of Claim 1 , and an effective amount of one or more compounds selected from the group consisting of Ay? antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors, to a patient in need of such treatment.

60. A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of Claim 1 , and an effective amount of one or more BACE inhibitors, to a patient in need of such treatment.

61. A method of;

(1 ) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1, in combination with an effective amount of one or more cholinesterase, to a patient in need of treatment, or

(2) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1, in combination with an effective amount of donepezii hydrochloride, to a patient in need of treatment, or

(3) treating Alzheimer's disease, comprising administering an effective amount of a compound Claim 1 , in combination with an effective amount of one or more cholinesterase, to a patient in need of treatment, or

(4) treating Alzheimer's disease, comprising administering an effective amount of a compound of Cfairn 1, in combination with an effective amount of donepezif hydrochloride, to a patient in need of treatment, or (5) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of (rivasttgmine, to a patient in need of such treatment, or

(6) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of tacrine, to a patient in need of such treatment, or (7) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of a Tau kinase inhibitor, to a patient in need of such treatment, or

(8) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Ciaim 1 , in combination with an effective amount of one or more Tau kinase inhibitors selected from the group consisting of: GSK3beta inhibitors, cdk5 inhibitors, ERK inhibitors, to a patient in need of such treatment, or

(9) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Ciaim 1 , in combination with an effective amount of one anti-Abeta vaccination, to a patient in need of such treatment, or

(10) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Ciaim 1 , in combination with an effective amount of one or more APP ligands, to a patient in need of such treatment, or (11 ) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more agents that upregulate insulin degrading enzyme and/or neprifysin, to a patient In need of such treatment, or

(12) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more cholesterol lowering agents, to a patient in need of such treatment, or

(13) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Ciaim 1 , in combination with an effective amount of one or more cholesterol towering agents selected from the group consisting of: Atorvastatin, Ffuvastatin, Lovastatin, Mevastatin, Pravastatin, Pravastatin, Rosuvastatin, Simvastatin, and Ezetimibe, to a patient in need of such treatment, or

(14) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1, in combination with an effective amount of one or more fibrates, to a patient in need of such treatment, or

(15) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more fibrates selected from the group consisting of, clofibrate, Clofibride, Etofibrate, Aluminium Clofibrate, to a patient in need of such treatment, or

(16) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more LXR agonists, to a patient in need of such treatment, or (17) treating Alzheimer's disease, comprising administering an effective amount o1 one or more compounds of Claim 1 , in combination with an effective amount of one or more LRP mimics, to a patient in need of such treatment, or

(18) treating Alzheimer^'s disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more 5-HT6 receptor antagonists, to a patient in need of such treatment, or

(19) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more nicotinic receptor agonists, to a patient in need of such treatment, or

(20) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more H3 receptor antagonists, to a patient in need of such treatment, or

(21) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more histone deacetylase inhibitors, to a patient in need of such treatment, or (22) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more hsp90 inhibitors, to a patient in need of such treatment, or

(23) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more ml muscarinic receptor agonists, to a patient in need of such treatment, or

(24) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more 5-HT6 receptor antagonists mGiuRI or mG!uR5 positive aliosteric modulators or agonists, to a patient in need of such treatment, or

(25) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more mGluR2/3 antagonists, to a patient in need of such treatment, or (26) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more anti-inflammatory agents that can reduce neuroinflammatϊon, to a patient in need of such treatment, or (27) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more Prostaglandin EP2 receptor antagonists, to a patient in need of such treatment, or (28) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more PAI-1 inhibitors, to a patient in need of such treatment, or

(29) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more agents that can induce Abeta efflux, to a patient in need of such treatment, or

(30) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of gelsolin, to a patient in need of such treatment,or (31 ) treating Downs syndrome, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or

(32) treating Downs syndrome, comprising administering an effective amount of a compound of Claim 1 to a patient in need of treatment, or

(33) treating Downs syndrome, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of one or more cholinesterase inhibitors, to a patient in need of treatment.

(34) treating Downs syndrome, comprising administering an effective amount of one or more compounds of Claim 1 , in combination with an effective amount of donepezii hydrochloride, to a patient in need of treatment, or (35) treating Downs syndrome, comprising administering an effective amount of acompound of Claim 1 , in combination with an effective amount of one or more cholinesterase inhibitors, to a patient in need of treatment.

(37) treating Downs syndrome, comprising administering an effective amount of a compound of Claim 1 , in combination with an effective amount of donepezii hydrochloride, to a patient in need of treatment, or

(38) treating mild cognitive impairment, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or

(39) treating glaucoma, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or

(40) treating cerebral amyloid angiopathy, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or (41) treating stroke, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or

(42) This invention also provides a method of treating dementia, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or

(43) treating microgliosis, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or

(44) treating brain inflammation, comprising administering an effective amount of one or more compounds of Claim 1 to a patient in need of treatment, or (45) treating olfactory function loss, comprising administering an effective amount of one or more compounds of Cfaim 1 to a patient in need of treatment,

62. A kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of Claim 1 in a pharmaceutically acceptable carrier, and another container comprises an effective amount of another pharmaceutically active ingredient, the combined quantities of the compound of claim 1 and the other pharmaceutically active ingredient being effective to: (a) treat Alzheimer's disease, or (b) inhibit the deposition of amyloid protein in, on or around neurological tissue, or (c) treat neurodegenerative diseases, or (d) modulate the activity of gamma-secretase.